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Abbreviations 
% percent 
3’UTR 3 Prime Untranslated Region 
AVP arginine vasopressin gene 
BDNF Brain-Derived Neurotrophic Factor 
CpG cytosine-guanine dinucleotide 
CRH Corticotrophin Releasing Hormone 
CTQ Childhood Trauma Questionnaire 
Delta-Age Epigenetic age acceleration, the difference between 
DNA methylation-predicted and chronological age 
DEX Dexamethasone 
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferase 
FKBP5 FK506 binding protein 5 (gene and protein name) 
FKBP51 FK506 binding protein 51 kDa (protein name) 
GR Glucocorticoid Receptor (protein name) 
GRE Glucocorticoid Response Element 
HDAC Histone deacetylase 
HPA-axis Hypothalamus-Pituitary-Adrenal axis 
Hsp90 Heat shock protein 90 
IKK-α Nuclear factor Kappa-B Kinase subunit alpha 
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kb kilobase 
MDD Major Depressive Disorder or Major Depression 
MeCP2 MEthyl CpG binding Protein 2 
miRNA micro RNA 
mRNA messenger RNA 
n Number 
NF-κB nuclear factor kappa-light-chain-enhancer of 
activated B cells 
NFAT Nuclear Factor of Activated T-cells 
NIK NF-κB-Inducing Kinase 
p p-value 
PBMC Peripheral Blood MonoCytes 
PTSD Post-Traumatic Stress Disorder 
RNA Ribonucleic acid 
SNP Single Nucleotide Polymorphism 
TET Ten-Eleven Translocation enzymes 
TSS Transcription start site 
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Summary 
Psychological stress has been associated with accelerated cellular aging and increased disease 
risk, but the underlying molecular mechanisms remain elusive. The overarching goal of this 
thesis is to examine epigenetic regulation as a novel mechanism linking stress-related phenotypes 
with aging-related diseases. To achieve this goal, the thesis examines large human cohorts, 
where genome-wide DNA methylation and gene expression have been measured in peripheral 
blood, and which have detailed information on stress-related phenotypes, including childhood 
and lifetime stress, major depression, and posttraumatic stress disorder. The epigenetic effects of 
stress-related phenotypes are examined both 1) at the systems level, using a genome-wide 
measure of epigenetic aging, and 2) selectively at the stress-responsive FKBP5 gene. The results 
presented here show that stress-related phenotypes accelerate both epigenetic aging and aging-
related demethylation of the FKBP5 gene. By examining subjects exposed to glucocorticoid 
agonists, this work further illustrates that age-related DNA methylation sites may be susceptible 
to stress-induced dysregulation of glucocorticoid signaling. Furthermore, mechanistic dissection 
of these effects shows that the age- and stress-related epigenetic upregulation of FKBP5 may be 
associated with functional effects on gene expression, alterations in biological pathways critical 
for immune function and epigenetic regulation, and heightened risk for aging-related disease. 
Overall, these findings provide molecular insights into the mechanisms through which stress-
related phenotypes may contribute to disease risk. 
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Aims of the thesis 
The first aim of this thesis is to investigate whether stress-related phenotypes accelerate 
epigenetic changes as life progresses both at the genome-wide level and at stress-responsive 
genetic loci in peripheral blood. As a genome-wide marker of epigenetic aging, this work 
examines the DNA methylation-based age predictor, “epigenetic clock.” As a stress-responsive 
locus, it examines the gene encoding FK506 binding protein 51 (FKBP5), a co-chaperone and 
modulator of the glucocorticoid receptor complex.  
The second aim of the thesis is to mechanistically dissect the functional consequences of age- 
and stress-related epigenetic changes, by examining how these changes influence genome-wide 
and FKBP5 expression levels, and how changes in FKBP5 expression impacts downstream 
biological pathways. This aim is achieved by combining genome-wide gene expression data 
from humans with experiments in relevant cellular models.  
The third aim is to examine the relevance of these genomic effects on disease risk. This is 
achieved by examining how epigenetic and gene expression changes are associated with 
peripheral inflammation and cardiovascular disease phenotypes.  
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Overarching introduction 
Psychological stress and aging-related disease 
The increase in life expectancy over the last decades constitutes a major accomplishment of 
modern medicine, but it also results in an exponential rise in the number of older adults ―which 
is predicted to more than double over the next two decades (Prevention, 2013; Statistics, 2012)― 
and a concomitant explosion in the prevalence of aging-related diseases, including 
cardiovascular disease, cancer, and dementia. Because these conditions are worldwide the 
leading causes of morbidity and mortality (Niccoli and Partridge, 2012), it is important to gain 
understanding into how modifiable factors may impact healthy aging and shape risk for aging-
related diseases.  
A well-documented risk factor for aging-related disease is psychological stress. Increased 
risk for aging-related diseases has been observed in individuals exposed to excessive and chronic 
stress (Chandola et al, 2006; Peavy et al, 2009; Powell et al, 2011; Powell et al, 2013; Rozanski 
et al, 1999; Zannas et al, 2012), in individuals experiencing traumatic events during sensitive 
developmental periods, such as during childhood (Danese and McEwen, 2012; Danese et al, 
2008; Felitti et al, 1998), and in patients with stress-related psychiatric disorders, including 
major depression and posttraumatic stress disorder (Danese et al, 2008; Vaccarino et al, 2013). 
At the molecular level, studies show that stress can induce cellular aging as measured with 
telomere length. In particular, telomere shortening has been observed with a wide-range of 
stressors, including chronic caregiver stress (Epel et al, 2004; Litzelman et al, 2014), stress in 
utero and early life (Entringer et al, 2011; Entringer et al, 2013; Kananen et al, 2010; Savolainen 
et al, 2014), work stress (Ahola et al, 2012), and perceived stress (Parks et al, 2009; Puterman et 
al, 2010).  
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How could stress-related phenotypes increase risk for aging-related disease? A plausible 
mediator of this relationship could be the impact of stress on immune function and peripheral 
inflammation. This hypothesis is supported by studies showing heightened peripheral 
inflammation in association with childhood trauma (Danese et al, 2008; Danese et al, 2007), 
acculturative stress (Fang et al, 2014), and depressive syndromes (Danese et al, 2009; Danese et 
al, 2008). Because inflammation is a key process implicated in the pathogenesis of several aging-
related diseases (Franceschi and Campisi, 2014; Howcroft et al, 2013) and immune functions are 
influenced by stress responses (Danese et al, 2012), these studies overall suggest that 
psychological stressors of certain type, timing, and duration could contribute to accelerated aging 
and aging-related disease phenotypes, potentially through their effects on immune function and 
peripheral inflammation. However, the underlying mechanisms and the cascade of molecular 
events linking stress and aging are poorly understood. 
 
Epigenetic regulation through DNA methylation: a plausible mechanism linking stress and aging 
Among plausible molecular processes that could mediate the impact of stress on complex 
phenotypes, it is relevant to consider epigenetic regulation. Epigenetics is a composite term 
derived from the Greek prefix “epi-,” which means “over”, and “genetics.” In its modern use, 
epigenetics denotes the set of biological processes that regulate gene expression without 
influencing the underlying nucleotide sequence. The constantly growing repertoire of epigenetic 
processes includes various types of DNA methylation, posttranslational histone modifications, 
noncoding RNAs, and higher-order changes in chromatin conformation (Telese et al, 2013). 
Beyond their central role in mammalian development and cell differentiation, these processes 
collectively constitute a molecular interface, which can be shaped by environmental factors 
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(Telese et al, 2013), including stress exposure (Zannas and West, 2014), and can in turn 
contribute to regulation of genomic function and the expression of complex phenotypes, 
including diseases of the aging (Brunet and Berger, 2014). Consequently, epigenetic regulation 
represents a plausible mechanism to consider when examining the impact of stress exposure on 
aging-related disease phenotypes. 
Despite the epigenome’s ability to respond dynamically to environmental changes, a 
body of evidence in both humans and rodents shows that stress exposure across different life 
stages can result in lasting epigenetic modifications. More specifically, exposure to stress as 
early as in utero can induce profound changes in DNA methylation (Boersma et al, 2014; Cao-
Lei et al, 2014; Dong et al, 2015; Mychasiuk et al, 2011; Palacios-Garcia et al, 2015; Palma-
Gudiel et al, 2015; Schraut et al, 2014; Xu et al, 2014), histone modifications (Benoit et al, 
2015; Winston et al, 2014), and changes in the expression of miRNAs (Monteleone et al, 2014; 
Zucchi et al, 2013). Likewise, stressors occurring during childhood and adolescence can induce 
lasting changes in DNA methylation (Anier et al, 2014; Doherty et al, 2016; Houtepen et al, 
2016; Klengel et al, 2013; McGowan et al, 2009; Murgatroyd et al, 2009; Niwa et al, 2013; 
Ouellet-Morin et al, 2013; Perroud et al, 2011; Roth et al, 2009; Tyrka et al, 2012; Tyrka et al, 
2015; Unternaehrer et al, 2012; van der Knaap et al, 2014, 2015; Weaver et al, 2004; Weaver et 
al, 2006), histone modifications (Kao et al, 2012), miRNA changes (Zhang et al, 2015), and 
alterations in DNA-binding of the methyl CpG binding protein 2 (MeCP2) (Murgatroyd et al, 
2009). Lasting epigenetic changes have also been observed following stress exposure during 
adulthood, including DNA methylation changes (Alasaari et al, 2012; Elliott et al, 2010; Lam et 
al, 2012; Le Francois et al, 2015; Roth et al, 2011; Tran et al, 2013; Uchida et al, 2011; Ursini et 
al, 2011; Witzmann et al, 2012), histone modifications (Erburu et al, 2015; Nasca et al, 2015; 
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Renthal et al, 2007; Uchida et al, 2011), miRNA changes (Volk et al, 2016; Volk et al, 2014; 
Zhang et al, 2015), higher-order changes in chromatin conformation (Sun et al, 2015), and 
alterations in MeCP2 binding to DNA (Uchida et al, 2011). Notably, the epigenetic 
modifications associated with stress can, in many cases, last long after stressor exposure, 
potentially persisting throughout life and even across generations. This has been observed for 
several epigenetic modifications, including changes in DNA methylation, histone modifications, 
and miRNA changes (Dias and Ressler, 2014; Montagud-Romero et al, 2016; Rodgers et al, 
2013; Rodgers et al, 2015; Yehuda et al, 2015). 
Among epigenetic modifications associated with stress exposure, this thesis focuses on 
the role of DNA methylation that occurs at the 5’ cytosine of cytosine-guanine dinucleotides 
(CpG), for simplicity denoted hereafter as DNA methylation. Following the advent of genome-
wide methylation arrays, DNA methylation has become the most widely studied epigenetic 
modification in human cohorts. DNA methylation was initially considered a stable epigenetic 
change, but was subsequently shown to be a reversible process that responds dynamically to 
environmental factors. Increases in DNA methylation are mediated by DNA methyltransferases 
(DNMTs), whereas DNA methylation decreases are effected by enzymes involved in active 
demethylation, such as the TET family of 5-methylcytosine dioxygenases (Telese et al, 2013). 
Despite the dynamic nature of DNA methylation signatures, certain methylation markers can be 
stabilized during life and even across generations (Dias et al, 2014; Gassen et al, 2016; Yehuda 
et al, 2015), thereby exerting long-term influence on genomic function and potentially 
contributing to the development of complex phenotypes.  
While these observations suggest that DNA methylation holds promise as biomarker of 
stress-related disease, an inherent limitation is that, like all epigenetic processes, DNA 
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methylation shows considerable cell and tissue specificity. Therefore, although some epigenetic 
signatures may show similar patterns across multiple tissues (Capra, 2015; Hannon et al, 2015; 
Horvath, 2013), changes in DNA methylation modifications should be examined, when feasible, 
in the tissue implicated in the disease phenotype under study. In the present thesis, this limitation 
is partly overcome by assessing DNA methylation changes in peripheral blood monocytes 
(PBMC), a tissue that plays central role in orchestrating immune responses and is highly relevant 
for examining the impact of stress on peripheral inflammation and aging-related disease 
phenotypes.  
 
DNA methylation as biomarker of aging-related disease phenotypes 
Aging is associated with widespread changes in DNA methylation (Bjornsson et al, 2008; 
Christensen et al, 2009; Hernandez et al, 2011; Heyn et al, 2012; Horvath, 2013; Horvath et al, 
2012; Rakyan et al, 2010). The pattern of these changes shows substantial variability along the 
human lifespan. Advancing age is generally associated with increasing inter-individual 
variability in DNA methylation levels, and there is an overall increase in DNA methylation 
levels in early life with subsequent decline later in life (Hannum et al, 2013; Herbstman et al, 
2013; Heyn et al, 2012; Li et al, 2010; Talens et al, 2012; Weidner et al, 2014). Despite these 
age-related changes in global methylation, the pattern of DNA methylation changes also varies 
across distinct sites. For example, methylation sites that are not located in CpG islands and those 
with high methylation levels tend to decrease with increasing age (Christensen et al, 2009; Heyn 
et al, 2012; Weidner et al, 2014), whereas methylation sites located in CpG islands and with low 
methylation levels tend to increase with advancing age (Heyn et al, 2012; Rakyan et al, 2010; 
Weidner et al, 2014). Age-related changes in DNA methylation have in most cases been 
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examined in peripheral blood (Bjornsson et al, 2008; Christensen et al, 2009; Florath et al, 2014; 
Heyn et al, 2012; Horvath, 2013; Horvath et al, 2012; Rakyan et al, 2010; Talens et al, 2012; 
Weidner et al, 2014), and studies suggest that they hold promise as biomarkers for aging 
research (Bell et al, 2012; Issa, 2014; Langevin et al, 2014; Poulsen et al, 2007). Furthermore, 
the role of DNA methylation as biomarker has been supported by studies showing that the DNA 
methylation changes observed in tissues implicated in aging-related diseases, such as cancer 
tissues and atherosclerotic arteries, show striking similarities with age-related methylation 
changes, including global decreases in methylation and CpG-island hypermethylation (Castillo-
Diaz et al, 2010; Jones and Baylin, 2007). Beyond their potential role as biomarkers, age-related 
epigenetic changes have been further proposed to represent a hallmark of the aging process 
(Benayoun et al, 2015; Lopez-Otin et al, 2013). 
Among potential DNA methylation-based biomarkers of aging, promise has been shown 
for the composite predictors of chronological age, which are calculated by integrating the 
methylation status of multiple CpGs across the genome that strongly correlate with age 
(Bocklandt et al, 2011; Florath et al, 2014; Hannum et al, 2013; Horvath, 2013; Koch and 
Wagner, 2011; Weidner et al, 2014). Among these DNA methylation-based age predictors, 
particular promise has been shown for the so-called “epigenetic clock,” a predictor comprised of 
353 CpGs (Horvath, 2013), which robustly correlates with chronological age across multiple 
human tissues. Despite the strong correlations between the DNA methylation (epigenetic clock)-
predicted age and chronological age, some individuals show substantial differences between the 
two, and this difference (Delta-Age) has been proposed as a measure of accelerated epigenetic or 
biological aging (Horvath, 2013). Notably, since the introduction of this measure in aging 
research, accumulating evidence shows that accelerated epigenetic aging is associated with a 
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host of aging-related phenotypes, including physical and cognitive decline (Levine et al, 2015b; 
Marioni et al, 2015b; Wolf et al, 2015), cancer incidence and outcomes (Levine et al, 2015a; 
Perna et al, 2016; Zheng et al, 2016), frailty in the elderly (Breitling et al, 2016), osteoarthritis 
(Vidal-Bralo et al, 2016), Parkinson’s disease (Horvath and Ritz, 2015), menopause (Levine et 
al, 2016), obesity (Horvath et al, 2014), cardiovascular disease (Perna et al, 2016), and all-cause 
mortality (Chen et al, 2016; Marioni et al, 2016; Marioni et al, 2015a; Perna et al, 2016). 
Although these observations show that age-related DNA methylation changes are 
associated with disease phenotypes, the exact cascade of molecular events that drives these 
changes is elusive. Because age-related DNA methylation changes may result from a complex 
interplay among genetic and environmental factors (Fraga et al, 2005; Gronniger et al, 2010; 
Hannum et al, 2013; Horvath, 2013; Lu et al, 2016), stress exposure and stress-related 
phenotypes could contribute to these changes, accounting to an extent for the inter-individual 
variability in disease risk. The molecular mechanisms driving these changes may be distinct 
across different methylation sites; for example, senescence-associated transcription factors may 
be involved in sites where methylation rises (Hanzelmann et al, 2015), whereas downregulation 
of DNMT1 appears to play central role in sites where methylation declines with advancing age 
(Li et al, 2010). The following section discusses potential mechanisms through which 
psychological stress may drive epigenetic changes and, in particular, lasting changes in DNA 
methylation. 
 
HPA axis and glucocorticoid signaling as molecular effectors of stress 
Psychological stress triggers a set of behavioral, hormonal, neural, and molecular responses that 
can have profound effects on body tissues. A primary effector of the stress response, and the 
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focus of this thesis is the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is set into 
motion by the hypothalamus, a brain region that secretes corticotropin-releasing hormone and 
arginine vasopressin, thereby signaling the anterior pituitary to secrete adrenocorticotropic 
hormone (ACTH) (Chrousos and Gold, 1992). ACTH in turn triggers adrenal release of 
glucocorticoids, cortisol in humans, in the periphery. Homeostatic regulation of the HPA axis is 
essential, and HPA dysregulation has been linked with increased risk for behavioral and somatic 
disease phenotypes in both humans and rodents (Barha et al, 2011; Bourke and Neigh, 2011; de 
Kloet et al, 2006; Heim et al, 2008; Jankord et al, 2011). Such dysregulation can occur upon 
exposure to stressors of certain duration, intensity, type, and timing (Tsigos and Chrousos, 
2002); for example, chronic stress deregulates the circadian and ultradian rhythmicity of 
glucocorticoid secretion (Lightman, 2008). Consequently, dysregulated HPA axis and 
glucocorticoid secretion represent a prime mechanism for examining the molecular effects of 
stress on body tissues. 
While glucocorticoids can have both genomic and nongenomic effects on target tissues 
(Uchoa et al, 2014), their genomic effects are to a large extent mediated by the glucocorticoid 
receptor (GR). The GR primarily functions as a ligand-dependent transcription factor that 
regulates gene transcription either through direct binding to conserved DNA sequences called 
glucocorticoid response elements (GRE) or through interactions with other transcription factors 
that can be GRE-dependent or -independent (Vockley et al, 2016). Beyond the rapid regulation 
of gene transcription, however, the genomic actions of glucocorticoids can also result in lasting 
epigenetic modifications. The most widely described epigenetic effect of glucocorticoids is the 
rapid demethylation, which can result in global methylation decreases (Bose et al, 2010; Bose et 
al, 2015), but most strikingly occurs within or near GREs (Klengel et al, 2013; Thomassin et al, 
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2001; Wiench et al, 2011a; Wiench et al, 2011b). Glucocorticoid-induced hypermethylation has 
also been observed, most notably in promoter CpGs (Niwa et al, 2013). The mechanisms 
underlying these effects are largely unknown; however, glucocorticoids have been shown to 
upregulate the Tet family of 5-methylcytosine dioxygenases (TET) (Bose et al, 2015; Sawamura 
et al, 2015), which actively demethylate DNA, and to downregulate the maintenance 
methyltransferase DNMT1 (Yang et al, 2012) and the methyltransferase DNMT3a (Bose et al, 
2015). Besides changes in DNA methylation, glucocorticoids can also induce changes in histone 
methylation and acetylation, which can occur at sites of direct GR binding (Vockley et al, 2016), 
or through the interactions of the GR with other transcription factors and the consequent 
recruitment of histone modifiers to target genomic sites (Di Stefano et al, 2015; Zannas and 
Chrousos, 2015b). Glucocorticoids can also regulate several miRNAs (Dwivedi et al, 2015; Ko 
et al, 2015), and can induce chromatin remodeling, thereby changing accessibility of GR-binding 
sites to transcription factors (Vockley et al, 2016). Despite these observations, the mechanisms 
through which glucocorticoids modulate the epigenetic machinery are poorly understood. 
An important conclusion drawn from studies to date is the potential of time-limited 
glucocorticoid exposure to exert long-lasting effects on the epigenome. This is supported by 
work in both cell lines and rodents showing that changes in DNA methylation can last long after 
cessation of glucocorticoid exposure (Bose et al, 2010; Bose et al, 2015; Lee et al, 2010; Niwa et 
al, 2013). These lasting effects are thought to represent a “molecular memory” that can influence 
subsequent responses to glucocorticoids, ultimately shaping genomic function and phenotypic 
expression (Klengel et al, 2013; Thomassin et al, 2001; Wiench et al, 2011a; Wiench et al, 
2011b; Zannas et al, 2014). As discussed above, these principles parallel the observation that 
psychological stress, which dysregulates glucocorticoid secretion, can induce long-lasting 
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epigenetic modifications that can persist throughout life and even across generations (Dias et al, 
2014; Gassen et al, 2016; Yehuda et al, 2015). Because epigenetic changes can influence 
genomic function and phenotypic expression, this work highlights that DNA methylation is an 
important mechanism that may underlie the pathogenesis of stress-related disease phenotypes.  
 
FKBP5: a stress- and glucocorticoid-responsive immunophilin  
As highlighted above, the lasting effects of stress on the epigenome are likely to occur at 
genomic sites that are targeted by the GR. Therefore, beyond examining the association of stress-
related disease phenotypes with epigenetic markers derived from genome-wide approaches, such 
as the epigenetic clock, it is also relevant to determine how stress throughout life epigenetically 
regulates selective glucocorticoid-responsive loci. One such locus is the gene encoding FK506 
binding protein 51 (FKBP5/FKBP51), which is the most robustly induced gene upon 
glucocorticoid exposure in peripheral blood (Menke et al, 2012). As suggested by its 
responsivity to glucocorticoids, upregulation of FKBP5 can result from stress-induced DNA 
demethylation that occurs at CpGs within or near FKBP5 GREs (Klengel et al, 2013; Lee et al, 
2010; Lee et al, 2011). Consequently, a plausible hypothesis is that persistent stress or multiple 
stressors accumulating throughout life could lead to sustained epigenetic upregulation of FKBP5. 
Furthermore, it is plausible that FKBP5 could itself influence downstream components of the 
epigenetic machinery, mediating some of the effects of stress on the epigenome. 
FKBP5 is a 51-kDa immunophilin that was originally named after its ability to bind the 
immunosuppressant drug FK506 (Wiederrecht et al, 1992), but it is best known for its ability to 
function as a co-chaperone and modulator of the glucocorticoid receptor complex (Zannas et al, 
2016).  More specifically, FKBP5 has been shown to exert intracellular negative feedback on GR 
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function, by delaying nuclear translocation and decreasing transcriptional activity of the GR 
(Wochnik et al, 2005). The ability of FKBP5 to modulate the GR complex stems from its 
function as a co-chaperone that interacts with and influences the folding of other members of the 
steroid receptor complex, most notably the heat shock protein 90 (Hsp90) and the P23 protein 
(Schiene-Fischer and Yu, 2001). The result of these molecular effects is that changes in FKBP5 
levels can lead to altered GR sensitivity, an effect that in turn could have important implications 
for stress-related disease phenotypes. 
 In particular, a body of evidence shows that FKBP5 upregulation may be associated with 
a number of aberrant phenotypes, including aging-related disease phenotypes (Binder et al, 2008; 
Blair et al, 2013; Kim et al, 2012; Klengel et al, 2013; Pereira et al, 2014; Romano et al, 2004; 
Romano et al, 2010; Sinclair et al, 2013). The potential of FKBP5 upregulation to contribute to 
aberrant phenotypes could result from its downstream effects on diverse biological pathways 
(Zannas et al, 2016). Among processes influenced by FKBP5, studies in cells and mice have 
shown that it can influence immune pathways, including the NF-κB  (nuclear factor kappa-light-
chain-enhancer of activated B cells) and the calcineurin/NFAT (nuclear factor of activated T-
cells) signaling pathways (Avellino et al, 2005; Baughman et al, 1995; Bouwmeester et al, 2004; 
Daudt and Yorio, 2011; Erlejman et al, 2014; Giordano et al, 2006; Kim et al, 2012; Li et al, 
2002; Maiaru et al, 2016; Park et al, 2007; Romano et al, 2004; Romano et al, 2010; Romano et 
al, 2015; Srivastava et al, 2015; Weiwad et al, 2006).  Because immune dysregulation is a 
potential process linking stress and disease risk, together these studies suggest that the impact of 
FKBP5 on immune pathways could be one molecular mechanism through which stress 
contributes to somatic phenotypes along the lifespan. However, this hypothesis has not been 
examined in living humans. 
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Lifetime stress accelerates epigenetic aging
in an urban, African American cohort:
relevance of glucocorticoid signaling
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Abstract
Background: Chronic psychological stress is associated with accelerated aging and increased risk for aging-related
diseases, but the underlying molecular mechanisms are unclear.
Results: We examined the effect of lifetime stressors on a DNA methylation-based age predictor, epigenetic clock.
After controlling for blood cell-type composition and lifestyle parameters, cumulative lifetime stress, but not
childhood maltreatment or current stress alone, predicted accelerated epigenetic aging in an urban, African
American cohort (n = 392). This effect was primarily driven by personal life stressors, was more pronounced with
advancing age, and was blunted in individuals with higher childhood abuse exposure. Hypothesizing that these
epigenetic effects could be mediated by glucocorticoid signaling, we found that a high number (n = 85) of
epigenetic clock CpG sites were located within glucocorticoid response elements. We further examined the
functional effects of glucocorticoids on epigenetic clock CpGs in an independent sample with genome-wide DNA
methylation (n = 124) and gene expression data (n = 297) before and after exposure to the glucocorticoid receptor
agonist dexamethasone. Dexamethasone induced dynamic changes in methylation in 31.2 % (110/353) of these
CpGs and transcription in 81.7 % (139/170) of genes neighboring epigenetic clock CpGs. Disease enrichment
analysis of these dexamethasone-regulated genes showed enriched association for aging-related diseases, including
coronary artery disease, arteriosclerosis, and leukemias.
Conclusions: Cumulative lifetime stress may accelerate epigenetic aging, an effect that could be driven by
glucocorticoid-induced epigenetic changes. These findings contribute to our understanding of mechanisms linking
chronic stress with accelerated aging and heightened disease risk.
Keywords: Aging, Aging-related disease, DNA methylation, Epigenetics, Gene expression, Glucocorticoids,
Psychological stress
Background
The last decades have witnessed a dramatic increase in
life expectancy. As a result, the number of older adults
is predicted to more than double over the next two
decades [1, 2]. While this increase in life expectancy
is undoubtedly one of the biggest achievements of
modern medicine, population aging also brings forth
an unprecedented increase in aging-related diseases,
including cardiovascular disease, cancer, and dementia
[3]. Given that these conditions are currently the
leading causes of morbidity and mortality, it is im-
perative to gain insights into factors that impact healthy
aging and contribute to aging-related diseases.
An important risk factor for accelerated aging and
aging-related diseases is psychological stress. Although
stressors are ubiquitous in nature and necessary for
survival [4], excessive and chronic stress has been associ-
ated with accelerated cellular aging [5, 6] and increased
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risk for aging-related disease phenotypes, including car-
diovascular disease, immune dysregulation, and late-life
neuropsychiatric disorders [7–12]. Furthermore, stressors
occurring during sensitive developmental periods, such as
childhood maltreatment, have been linked with later
development of aging-related diseases [13–15]. Lastly,
stress-related psychiatric disorders, including major de-
pression and post-traumatic stress disorder (PTSD), are
themselves risk factors for such diseases [15, 16]. Despite
these observations, the molecular mechanisms linking
psychological stress with accelerated aging and aging-
related diseases remain largely unknown.
One plausible mechanism that may mediate the ad-
verse effects of stress on the aging process is epigenetic
regulation. Long-term epigenetic changes can be in-
duced by environmental stimuli, including psychological
stressors, and can shape complex phenotypes [17]. The
most studied epigenetic modification in this context is
DNA methylation. Stressors can induce lasting changes
in DNA methylation [18, 19], an effect that is in part
mediated by the genomic effects of glucocorticoids, a
primary molecular effector of the stress response [20].
Glucocorticoids exert actions in essentially every body
organ via activation of the glucocorticoid receptor (GR),
a transcription factor that regulates gene expression by
the binding of its homodimer to glucocorticoid response
elements (GREs) in regulatory regions of target genes
[21]. Beyond regulating gene transcription, GRE binding
can locally induce lasting changes in DNA methylation,
a form of molecular memory that shapes subsequent re-
sponses to glucocorticoids and stressors [17, 18, 22–24].
Therefore, it is plausible that stress and glucocorticoid
exposure throughout the lifetime could impact cellular
aging via cumulative effects on aging-related DNA
methylation sites.
Aging and aging-related diseases are associated with
profound changes in DNA methylation [25–31]. Rec-
ognizing the importance of DNA methylation in the
aging process has led to recent development of several
DNA methylation-based predictors of aging [27, 32–34].
Among these, a composite predictor comprised of 353
Cytosine-phosphate-Guanosine sites (CpGs) across the
genome (‘epigenetic clock’) was shown to strongly correl-
ate with chronological age across multiple tissues in
humans [27], suggesting its usefulness as a biomarker in
aging-related research. Using this predictor, accelerated
epigenetic aging (Δ-age), defined as the difference be-
tween DNA methylation-predicted age (DNAM-age)
and chronological age, has been associated with
aging-related and other phenotypes, including cancer,
obesity, cytomegalovirus infection, Down’s syndrome,
PTSD, physical and cognitive decline, all-cause mortality,
and the presence of higher self-control and lower socio-
economic status [27, 35–41]. However, no studies have
examined the relationship between this predictor and cu-
mulative lifetime stress nor the potential molecular mech-
anisms underlying this relationship.
In the present study, we first show that cumulative
lifetime stress, but not childhood or current stress alone,
is associated with accelerated epigenetic aging in a
cohort of highly traumatized African American individ-
uals. Examining GR signaling as a potential mechanism
underlying this effect, we identify that a high number of
epigenetic clock CpGs are located within functional
GREs and show dynamic methylation changes following
GR activation by exposure to the GR agonist dexametha-
sone (DEX). Lastly, we show that genes neighboring
these CpGs are dynamically regulated by DEX and that
these DEX-regulated genes show enriched association
for aging-related diseases. Taken together, our findings
support a model of stress-induced acceleration of epi-
genetic aging, overall contributing to our understanding
of mechanisms linking chronic stress with accelerated
aging and heightened disease risk.
Results
Prediction of chronological age using the epigenetic clock
DNAM-age was calculated from peripheral blood from
two independent samples, derived from the Grady
Trauma Project (GTP) and the Max Planck Institute of
Psychiatry (MPIP) cohorts using genome-wide Illumina
HumanMethylation450 BeadChips (450 K), as previously
described [27]. Given that the GTP primarily comprises
(>90 %) African American participants, we excluded
other ethnicities to minimize confounders. This resulted
in a total of 393 participants with DNAM-age data. In
contrast, the MPIP cohort consists only of Caucasian
participants with a total of 124 participants with base-
line DNAM-age data. The mean (SD, range) age was
41.33 years (12.85, range 18 to 77 years) for the GTP
and 39.5 years (14.14, range 21 to 71 years) for the
MPIP. The n (%) of female participants was 278
(70.7 %) for the GTP and 44 (35.5 %) for the MPIP.
To validate the epigenetic clock predictor in our co-
horts, we correlated DNAM-age with chronological
age as previously described [27]. This correlation was
strong for both the GTP (r = 0.90, P <2.2 × 10−16)
(Fig. 1a) and MPIP (r = 0.94, P <2.2 × 10−16) cohorts
(Fig. 1b) and proved robust and similar for both gen-
ders (r = 0.89 for male vs. r = 0.90 for female in the
GTP; r = 0.95 for male vs. r = 0.94 for female in the
MPIP).
Epigenetic age acceleration is associated with cumulative
lifetime stress, but not childhood or current stress alone,
in an urban, African American cohort
We then hypothesized that epigenetic age acceleration
(Δ-age), calculated by subtracting the actual chronological
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age from DNAM-age [27], would be positively associated
with exposure to life stress. This hypothesis was tested in
the highly traumatized GTP cohort. The mean (SD, range)
Δ-age in the GTP was –0.13 years (5.69, range –17.31 to
43.98 years). A total of 304 GTP participants had data
on lifetime stressors assessed by the Stressful Events
Questionnaire (SEQ) and 386 participants had data
on childhood maltreatment assessed by the Childhood
Trauma Questionnaire (CTQ). The individual items
from the SEQ were summed to yield a total score of
lifetime stress exposure (Life Stress), and a similar
total score was generated for the CTQ (Child Stress).
The SEQ additionally assesses stressor exposure over
the last year, and these items were summed to yield a
score of more recent stress exposure (Current Stress).
Linear regression models controlling for sex and age
showed that Life Stress was positively associated with
Δ-age (β = 0.24, SE = 0.08, P = 2.8 × 10−3), and this ef-
fect remained significant after further controlling for
Houseman blood cell counts and technical batch ef-
fects (β = 0.18, SE = 0.08, P = 1.8 × 10−2) (Fig. 2a), life-
style parameters, including body mass index, smoking,
alcohol, cocaine, marijuana, and heroin use (β = 0.31,
SE = 0.11, P = 7.4 × 10−3), as well depressive symptom-
atology, psychiatric treatments, and genome-wide
SNP-based principal components (β = 0.28, SE = 0.13,
P = 2.7 × 10−2).
In secondary analyses, we examined whether the effect
of lifetime stress on age acceleration depends on the
type of stressor and other moderating variables. Based
on previous work distinguishing between life events that
affect the individual directly vs. life events that affect
one’s social network [42], we separately summed SEQ
items assessing personal life events (Personal Life
Stress) and items assessing network events (Network
Life Stress). Δ-age showed a positive and significant
association with Personal Life Stress (β = 0.26, SE = 0.10,
P = 8.7 × 10−3) (Fig. 2b) and a positive but not significant
association with Network Life Stress (P = 1.1 × 10−1)
(Fig. 2c). No significant interactions were noted between
Life Stress or Personal Life Stress and either sex or age.
However, stratification of the GTP by a median split of
age showed that the effect of Personal Life Stress on Δ-age
was marginally stronger in older (β = 0.33, SE = 0.17,
P = 5.3 × 10−2) (Fig. 2d) as compared to younger par-
ticipants (β = 0.15, SE = 0.14, P = 2.8 × 10−1) (Fig. 2e).
On the other hand, Δ-age was not associated with ei-
ther CTQ score (P = 4 × 10−1) or Current Stress alone
(P = 1.3 × 10−1). However, when participants were
stratified based on the severity of childhood maltreat-
ment, only individuals exposed to lower levels (none
or mild) of sexual and physical childhood abuse
(based on respective CTQ subscale scores) showed
significant effects of Life Stress on Δ-age (Fig. 2f ).
This was not a consequence of differential stress
exposure burden between the two groups, since, as
expected, individuals exposed to higher levels of
childhood abuse also had higher levels of Life Stress
with a mean (SD) Life Stress of 12.32 (3.64) as com-
pared to 10.01 (3.76) in individuals with lower levels
of childhood abuse (t299 = 5.38, P = 1.5 × 10
−7). Fur-
thermore, the two strata showed similar correlations
between DNAM-age and chronological age (r = 0.91
for higher vs. 0.92 for lower abuse, Fisher z score = 0.6, P =
5.5 × 10−1). Lastly, we found no association between Δ-age
and current stress-related psychiatric phenotypes, including
depressive (P = 3.4 × 10−1) and PTSD symptomatology (P =
7.9 × 10−1) in the GTP. In line with this finding, depression
diagnosis was not associated with Δ-age in the MPIP co-
hort (P = 2.3 × 10−1, n = 72 controls vs. 52 depressed).
Taken together, these findings show that cumulative life-
time stress, but not childhood trauma or current stress
alone, is associated with accelerated epigenetic aging, an
effect that is primarily driven by personal life events, may
be more evident in advancing ages, and is blunted in par-
ticipants exposed to high levels of childhood abuse.
Fig. 1 Correlation between chronological age and age predicted by
DNA methylation-based predicted age in two independent cohorts.
a GTP cohort (n = 393). b MPIP cohort (n = 124)
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Epigenetic clock CpGs and neighboring genes are
regulated by GR activation and show enriched association
with aging-related diseases
The effect of lifetime stress on epigenetic aging prompted
us to examine susceptibility of individual epigenetic clock
CpGs to glucocorticoids, a primary molecular effector of
stress responses, as a potential mechanism underlying this
association. To address this hypothesis, we first examined
whether epigenetic clock CpGs show DNA methylation
changes 3 h after oral exposure to a GR agonist (1.5 mg of
DEX) in the independent MPIP cohort (n = 124). After
correcting for multiple testing, 110 of the 353 CpGs
showed statistically significant methylation changes (false
discovery rate (FDR)-adjusted P <5 × 10−2). Among the
DEX-regulated CpGs, 98 (89 %) showed decrease in
methylation, whereas 12 (11 %) showed increase in
methylation (Additional file 1: Table S1). We next ex-
amined the effect of acute DEX exposure on the epi-
genetic clock by comparing DNAM-age at baseline vs.
3 h after DEX exposure (n = 124). There was no effect
of DEX on DNA methylation-predicted age (baseline
mean DNAM-age = 45.24 vs. post-DEX mean DNAM-
age = 45.15, paired t123 = 0.31, P = 7.6 × 10
−1).
Given that GR binding to GREs can exert changes in
DNA methylation, we then examined whether epigenetic
clock CpGs co-localize with GREs. Among the 353 epi-
genetic clock CpGs, 85 CpGs were located within GREs
as defined by CHIP-Seq peaks in a lymphoblastoid cell
line (LCL) (Additional file 1: Table S1). This CpG-GRE
co-localization significantly differed from the one ex-
pected by chance as determined by randomly drawing
1,000 sets (n = 353 CpGs) of CpG sites from all CpGs
present on the 450 K array (expected mean 48.8, SD 6.1,
range 31 to 68, pperm <1 × 10
−3) (Fig. 3a). Proximity to
GREs was particularly observed for DEX-regulated CpGs
(Fig. 3b), with 17 of these sites located right within GREs
and 35 within 1 kb distance from GREs. Because the 353
CpGs were originally derived from the 21,369 (21 K)
CpGs that overlap the 27 K and 450 K Illumina arrays
[27], we next examined whether the epigenetic clock
Fig. 2 Cumulative lifetime stress is associated with epigenetic age acceleration in a highly traumatized human cohort derived from the Grady
Trauma Project. Epigenetic age acceleration (Δ-age) was calculated by subtracting chronological age from DNA methylation predicted age. Δ-age
was regressed on cumulative lifetime stress (Life Stress) after adjusting for covariates (fitted stress measures are shown). a Life Stress was positively
associated with epigenetic age acceleration (β = 0.18, SE = 0.08, P = 1.8 × 10−2), and this association remained significant after further controlling for
lifestyle parameters, including body mass index, smoking, alcohol, cocaine, marijuana, and heroin use (β = 0.31, SE = 0.11, P = 7.4 × 10-3), as well
depressive symptomatology, psychiatric treatments, and genome-wide SNP-based principal components (β = 0.28, SE = 0.13, P = 2.7 × 10−2).
Statistically significant association was found for Personal Life Stress (β = 0. 26, SE = 0.10, P = 8.7 × 10−3) (b), whereas the effect of Network
Life Stress was not significant (P= 1.1 × 10−1) (c). Age stratification by a median split showed that the effect of Personal Life Stress on Δ-age was stronger in
older (β = 0.33, SE = 0.17, P = 5.3 × 10−2) (d), as compared to younger participants (β = 0.15, SE = 0.14, P = 2.8 × 10−1) (e). Stratification of the
effect of cumulative life stress on epigenetic age acceleration based on the presence or not of moderate to severe physical or sexual
child abuse showed that Life Stress was positively associated with Δ-age in participants with no or mild physical and sexual child abuse
(β = 0.34, SE = 0.11, P = 2.5 × 10−3, n = 212) but not in those with moderate to extreme child abuse (P = 3.9 × 10−1, n = 174) (f)
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CpG-GRE co-localization differs from the one present in
the 21 K background. Epigenetic clock CpG-GRE co-
localization did not differ from the one expected by
chance when randomly drawing 1,000 CpG sets (n = 353
CpGs) from the 21 K CpG sites (expected mean 3,094,
SD 50.7, range 2,927–3,270, pperm = 9.7 × 10
−1). Given
that this lack of enrichment could be the result of high
CpG-GRE co-localization already present in the 21 K, as
a last step we compared the co-localization present in
the 21 K with the 450 K background and we noted sig-
nificantly higher CpG-GRE co-localization in the 21 K
as compared to the 450 K background (pperm <1 × 10
−3).
These findings suggest that the increased epigenetic
clock CpG-GRE co-localization is a more general
property of the 21 K CpGs used to develop the epigen-
etic clock. Yet the presence of a high number of epigen-
etic clock CpGs within functional GREs is in line with
our hypothesis that these sites may be highly susceptible
to GR activation.
We then assessed whether genes that have transcrip-
tion start sites (TSS) in the proximity of epigenetic clock
CpGs are also dynamically regulated by GR activation.
For this purpose, we used peripheral blood genome-wide
gene expression array data in the MPIP cohort to exam-
ine the DEX-induced changes in the expression of genes
with transcription start sites (TSS) close to epigenetic
clock CpGs based on the 450 K annotation from [43].
Using these criteria, we annotated 344 unique genes. Of
these, 333 genes were present on the gene expression
microarray and a total of 170 genes, corresponding to
220 epigenetic clock CpGs, were expressed above back-
ground in the MPIP cohort (Additional file 2: Table S2).
Transcription of these genes was detected by 216 unique
gene expression array probes. After FDR-based correc-
tion for multiple testing, 167 out of the 216 detected
probes, corresponding to 139 unique genes (81.7 %),
showed significant changes in gene expression following
DEX exposure (FDR-adjusted P values <0.05) (Fig. 4).
Fig. 3 Epigenetic clock CpGs co-localize with functional glucocorticoid
response elements (GREs) and show methylation changes following
GR activation. a Epigenetic clock CpGs co-localize with functional GREs.
GRE peaks were derived from ENCODE NR3C1 ChIP-seq data
from lymphoblastoid cell lines. Among the 353 epigenetic clock
CpGs, 85 CpG sites were noted to be located within GR ChIP-Seq peaks
in a lymphoblastoid cell line (shown with the red dotted line)
(Additional file 1: Table S1). This number significantly differed
(pperm <0.001) from the CpG-GRE overlap predicted by 1,000 randomly
selected sets of CpGs covered by the 450 K array (mean 48.8, SD 6.14,
range 31 to 68). b Epigenetic clock CpGs that are significantly
regulated by DEX exposure are in proximity to GREs. GRE peaks
were derived from ENCODE NR3C1 ChIP-seq data from lymphoblastoid
cell lines. Volcano plot was zoomed for +/− 10 kb distance around the
GRE peaks. The dotted red line in the volcano plot represents the level
of statistical significance (P = 5 × 10−2) after FDR correction for multiple
comparisons. Further details on DEX-regulated CpGs are given in
Additional file 1: Table S1
Fig. 4 Glucocorticoid receptor activation regulates the expression of
genes with transcription start sites (TSS) near epigenetic clock CpGs.
Gene TSS near epigenetic clock CpGs were identified based on the
annotation from [43]. The volcano plot shows DEX-induced fold change
in gene expression plotted against their corrected P values (q values).
The dotted red line represents the corrected level of statistical
significance (q = 5 × 10−2) after FDR correction for multiple comparisons.
Among the 216 unique array probes, 167 probes, corresponding to 139
unique genes, showed significant changes in gene expression following
DEX. Fifty-eight per cent of these probes (n = 97) showed upregulation
and 42 % (n = 70) showed downregulation. The mean (SD, range)
distance of each regulated gene TSS to the corresponding epigenetic
clock CpGs was ±419.3 bp (336.65 bp, range 1 to 1,423 bp). Marked in
red are the probes showing fold changes in gene expression >1.1.
Further details are provided in Additional file 2: Table S2
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Fifty-eight per cent of these probes (n = 97) showed up-
regulation and 42 % (n = 70) showed downregulation.
The mean (SD, range) distance of each regulated gene
TSS to the corresponding epigenetic clock CpGs was
±419.3 bp (336.65 bp, range 1 to 1,423 bp). To rule out
potential bias derived from the 21 K background, we
then asked whether genes neighboring epigenetic clock
CpGs are more responsive to GR activation compared to
genes neighboring the 21 K CpGs. A total of 5,443
unique genes, corresponding to 21,015 21 K CpGs,
showed significant DEX-induced mRNA expression
changes (FDR-adjusted P values <5 × 10−2). The number
of DEX-regulated genes was significantly higher for the
genes with TSS close to epigenetic clock CpGs as com-
pared to 21 K CpGs (Fisher’s exact test P = 6.3 × 10−5).
Taken together, these data demonstrate enhanced
responsivity of genes neighboring epigenetic clock CpGs
to GR activation.
Lastly, we performed disease enrichment analysis in
WebGestalt using the set of unique DEX-regulated genes
(n = 139) as the input for the analysis and the genes
expressed above background in our peripheral blood
gene expression arrays as the reference set of genes.
After FDR correction for multiple testing, this resulted
in enriched association for aging-related diseases, includ-
ing coronary artery disease, arteriosclerosis, and leuke-
mias (FDR-adjusted P <5 × 10−2 each) (Additional file 3:
Table S3).
Discussion
The present study sought to determine the effect of life
stressors on epigenetic aging, as measured with the epi-
genetic clock [27] in peripheral blood samples. While
previous studies found associations of the epigenetic
clock with several phenotypes [27, 35–41], this is the
first study to use this predictor in a highly traumatized
cohort. As hypothesized, accelerated epigenetic aging
was associated with cumulative lifetime stress burden.
Given that epigenetic effects of the stress response can
be mediated by GR signaling, we further examined the
molecular basis of this association by annotating epigen-
etic clock CpG sites in relation to GREs and examining
the impact of GR activation on these sites. We found
that GREs co-localize with epigenetic clock CpGs and
that glucocorticoid activation can induce dynamic
methylation changes of these sites as well as changes in
the expression of genes neighboring epigenetic clock
CpGs. Taken together, these converging findings support
a model of stress-induced accelerated epigenetic aging,
plausibly mediated by the lasting effects of cumulative
stressor exposure and aberrant glucocorticoid signaling
on the epigenome.
Further examination of the relationship between life
stress and epigenetic aging led us to several interesting
observations. First, this relationship was apparent for
cumulative stress exposure throughout the lifetime,
whereas no significant association was found with child-
hood maltreatment or current stress alone. This finding
is in accordance with a recent study observing no effect
of childhood trauma on epigenetic aging in combat vet-
erans [35] and suggests that cumulative stressors over
the lifetime, rather than time-limited stressors either
during childhood or adulthood, have a stronger or more
lasting effect on epigenetic aging. Nonetheless, it is also
possible that these null findings may be due to lack of
power, the timing of DNA methylation assessments, or
reversibility of epigenetic aging, possibilities that could
be addressed by future longitudinal studies. Second, the
effect of lifetime stress was driven by personal stressors
– affecting the participant directly – rather than network
stressors that occur to someone within the participant’s
network. This is congruent with previous studies show-
ing that personal life events are more strongly correlated
with genetic factors as compared to network events [44].
In line with the effects of lifetime vs. current stress,
these effects were more pronounced in older individuals,
suggesting cumulative epigenetic vulnerability in older
individuals. Lastly, the epigenetic effects of lifetime stress
were blunted in individuals with higher levels of child-
hood abuse. This finding could not be attributed to dif-
ferences in the levels of lifetime stress, since individuals
exposed to higher levels of childhood abuse also had
higher levels of cumulative lifetime stress burden. Thus,
it is possible that early trauma exposure triggers add-
itional mechanisms of risk and resilience that may inter-
fere with subsequent effects of stressors on epigenetic
aging, a hypothesis that remains to be tested by future
studies.
The effects of lifetime stress on epigenetic aging in
peripheral blood are likely mediated by persistent
neuroendocrine alterations induced by cumulative stress
exposure. Stressors and glucocorticoids can drive persist-
ent changes in the expression of glucocorticoid-responsive
genes and concomitant changes in DNA methylation at
CpGs located at or near GREs [17, 18, 22, 45]. Supporting
this hypothesis, we noted that a high number of epigenetic
clock CpG sites are located within functional GREs and
show dynamic methylation changes following DEX ex-
posure. Notably, most of these CpGs show DEX-
induced decrease in methylation, whereas far fewer
sites show increased methylation (98 vs. 12). This is in
accordance with previous studies showing that activa-
tion of the GR results in local demethylation of CpGs
in the proximity of a GRE [18, 22, 23] and that site-
specific decreases in methylation have been implicated
in aging-related phenotypes [46]. CpG demethylation
has been proposed to be potentially mediated by at
least two enzymatic processes, base excision repair and
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oxidation [47, 48]. Examining the role of these pro-
cesses may provide further insights into mechanisms of
stress-induced epigenetic aging. Furthermore, an open
question concerns the sequence of molecular events
that determine whether some stress-induced DNA
methylation changes become embedded and longlast-
ing, while other changes are dynamic and reversible.
Given the low dose and acute exposure to glucocorticoids
in our study, additional experiments with different doses
and more chronic in vitro or in vivo GR activation will be
necessary to better elucidate this mechanism.
An important implication of our findings is the poten-
tial role of stress-induced epigenetic aging in health and
disease. Increasing age and aging-related diseases have
been associated with global and site-specific changes in
DNA methylation [25–30, 39]. The age-related epigenetic
clock CpGs co-localize with genes that show enrichment
for cell growth and survival, organismal development, and
cancer [27]. Furthermore, we show that DEX-regulated
genes neighboring epigenetic clock CpGs show enriched
association for aging-related diseases, including coronary
artery disease, arteriosclerosis, and leukemias. These find-
ings raise the possibility that lifetime stress may contribute
to these diseases via its cumulative impact on epigenetic
regulation of genes implicated in aging-related diseases.
The findings of the present study should be viewed in
the context of its limitations. Although we observe an
association between epigenetic age acceleration and
lifetime stressors in the GTP cohort, the cross-sectional
design of the study limits conclusions regarding the dir-
ection of causality. As discussed above, it is plausible
that epigenetic aging of peripheral blood cells results
from persistent alterations of the neuroendocrine but
also immune milieu induced by repetitive stressor expos-
ure. However, accelerated epigenetic aging might alterna-
tively represent a vulnerability marker that predisposes
individuals to expose themselves to stressful environ-
ments. It is also important to acknowledge that, while
the high levels of traumatic events in the GTP make
this cohort highly suitable for examining the effects
of lifetime stress on the epigenome, they may also
limit generalizability of these findings to other less
traumatized cohorts. Moreover, the present study ex-
amined epigenetic aging in peripheral blood only.
While this tissue is easily accessible and relevant for
biomarker research, other tissues may be more sus-
ceptible to psychological stress and should be exam-
ined in the context of specific diseases. For example,
disease-specific effects on the epigenetic clock have
been demonstrated for liver tissue in the context of
obesity [39]. Another limitation is the use of Chip-Seq
data from lymphoblastoid cell lines to examine epigenetic
clock CpG-GRE co-localization. This cell line represents
the best available proxy for peripheral blood, the source
tissue for our methylation data, but this approach may
also be limited by the tissue specificity of functional GREs
and the altered epigenetic landscapes of immortalized cell
lines. Lastly, although we corrected for several con-
founders that might influence DNA methylation, such as
sex, age, smoking, body mass index, substance abuse,
current psychiatric symptoms and treatments, other fac-
tors not captured by our methods may have confounded
the observed relationships. These limitations may be over-
come in future studies by employing detailed prospective
measurements of lifestyle factors, stressor exposure, DNA
methylation, and incidence of stress-related phenotypes at
different time points throughout the lifetime.
Conclusions
The present study provides evidence that cumulative life
stress exposure is associated with accelerated epigenetic
aging and that these effects may be mediated by gluco-
corticoid signaling. Our findings further suggest that DNA
methylation-based age prediction in peripheral blood may
be a useful molecular marker to incorporate in future stud-
ies examining the effects of life stress exposure. These find-
ings offer novel insights into the molecular mechanisms
linking psychological stress with diseases of the aging.
Methods
Clinical samples
The effect of lifetime stress on epigenetic aging was ex-
amined in the Grady Trauma Project (GTP), a large
study conducted in Atlanta, Georgia, that investigates
the role of genetic and environmental factors in shaping
responses to stressful life events. The GTP includes
more than 7,000 participants from a predominantly
African American, urban population of low socioeco-
nomic status [49, 50]. This population is characterized
by high prevalence and severity of trauma over the life-
time and is thus particularly relevant for examining the
effects of stressors on epigenetic markers. For this pur-
pose, we used a subsample of GTP participants with
genome-wide DNA methylation data. All participants
provided written informed consent and all procedures
were approved by the Institutional Review Boards of
the Emory University School of Medicine and Grady
Memorial Hospital (IRB00002114).
We examined glucocorticoid-induced methylation
changes of epigenetic clock CpGs and responsivity of
genes closest to these CpGs in 297 Caucasian participants
recruited at the Max Planck Institute of Psychiatry
(MPIP). Recruitment strategies and characterization of
participants have been previously described [51, 52].
These consisted of 200 male (83 healthy probands and
117 inpatients with depressive disorders) and 97 female
(48 healthy probands and 49 depressed) individuals. Base-
line whole blood samples were obtained at 18:00 after 2 h
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of fasting and abstention from coffee and physical activity
(baseline). Participants then received 1.5 mg oral dexa-
methasone (DEX) and a second blood draw was
performed at 21:00, 3 h after DEX ingestion (post-DEX).
The study was approved by the local ethics committee
(approval number: 318/00) and all individuals gave written
informed consent. All experimental methods comply with
the Helsinki Declaration.
Psychometric instruments
Childhood trauma was measured in the GTP with the
Childhood Trauma Questionnaire (CTQ), a validated
self-report questionnaire that assesses five types of mal-
treatment during childhood: sexual, physical, and emo-
tional abuse, as well as emotional and physical neglect
[53]. Scores for each type of maltreatment were derived
from participant responses to questionnaire items and
scores from all types were summed to yield a total CTQ
score reflecting overall burden of childhood maltreat-
ment. Moderate to extreme sexual abuse was defined by
a cutoff score of 8 or above in the CTQ sexual abuse
subscale, and moderate to extreme physical abuse was
defined by a cutoff score of 10 or above in the physical
abuse subscale as previously described [54].
Stressful lifetime events in the GTP were assessed with
the Stressful Events Questionnaire (SEQ), a 39-item self-
report instrument that has been described in detail [55].
The SEQ covers a wide range of stressor exposure, ranging
from personal life events, such as divorce, unemployment,
crime, and financial stressors, to network life events,
such as knowing someone who was murdered. Partici-
pants report whether they have experienced these
events either in the past year or at any time in their
life. Although the SEQ assesses life event exposure
throughout the lifetime, it does not include questions
specific for childhood maltreatment. Life events are
summed to yield a total score that reflects the number of
stressors experienced over the last year (Current Stress) or
cumulative number of stressors experienced throughout
one’s lifetime (Life Stress).
Participants underwent the Structured Clinical Inter-
views for DSM-IV defined psychiatric diagnoses. Given
the observed relation between stress-related psychiatric
disorders and accelerated cellular aging, we also exam-
ined major depression and PTSD as variables of interest.
In the GTP, current depressive symptomatology was
assessed with the 21-item validated Beck Depression In-
ventory (BDI) [56, 57] and current PTSD symptomatol-
ogy was assessed with the validated 17-item PTSD
Symptom Scale (PSS) [49, 58].
DNA methylation
Genomic DNA from the GTP cohort (n = 393) and the
MPIP (n = 124) was extracted from whole blood using
the Gentra Puregene Blood Kit (QIAGEN). DNA quality
and quantity was assessed by NanoDrop 2000 Spectro-
photometer (Thermo Scientific) and Quant-iT Picogreen
(Invitrogen). Genomic DNA was bisulfite converted
using the Zymo EZ-96 DNA Methylation Kit (Zymo
Research) and DNA methylation levels were assessed
for >480,000 CpG sites using the Illumina Human-
Methylation450 BeadChip array. Hybridization and
processing was performed according to manufacturer’s
instructions as previously described [59]. Quality
control of methylation data, including intensity read
outs, filtering (detection P value >0.01 in at least
75 % of the samples), cellular composition estima-
tion, as well as beta and M-value calculation was
done using the minfi Bioconductor R package version
1.10.2 [60].
For the GTP cohort, X chromosome, Y chromosome,
and non-specific binding probes were removed [61]. We
also excluded probes if single nucleotide polymorphisms
(SNPs) were documented in the interval for which the
Illumina probe is designed to hybridize. Given that the
GTP cohort includes individuals from different ethnici-
ties, we also removed probes if they were located close
(10 bp from query site) to a SNP which had Minor Allele
Frequency of ≥0.05, as reported in the 1,000 Genomes
Project, for any of the populations represented in the
samples. Technical batch effects were identified by
inspecting the association of the first principal compo-
nents of the methylation levels with plate, sentrix array,
and position (row) and by further visual inspection of
principal component plots using the shinyMethyl
Bioconductor R package version 0.99.3 [62]. This
procedure identified row and slide as technical
batches. The raw methylation data and all related
phenotypes for the GTP cohort have been deposited
into NCBI GEO (GSE72680).
For the MPIP cohort, filtered beta values were reduced
by eliminating any CpG sites/probes on sex chromo-
somes, as well as probes found to have SNPs at the CpG
site itself or in the single-base extension site with a MAF
≥1 % in the 1,000 Genomes Project European population
and/or non-specific binding probes according to [61].
Additionally, we performed a re-alignment of the array
probe sequences using Bismark (doi: 10.1093/bioinfor-
matics/btr167). This yielded a total of 425,883 CpG sites
for further analysis. Using the same procedure for batch
identification as above, we identified processing (experi-
ment) date as technical batch in the MPIP. The data
were then normalized with functional normalization
[63], an extension of quantile normalization included in
the minfi R package and batch-corrected using ComBat.
The raw methylation data and all related phenotypes for
the MPIP cohort have been deposited into NCBI GEO
(GSE74414).
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Gene expression
In the DEX-treated (MPIP) cohort (n = 297, including
the 124 individuals used for the MPIP methylation
analysis), both baseline and post-DEX whole blood
RNA was collected using PAXgene Blood RNA Tubes
(PreAnalytiX), processed as described previously [51, 52].
Samples had a mean RNA integrity number (RIN) of
8 ± 0.51 SD. Blood RNA was hybridized to Illumina
HumanHT-12 v3 and v4 Expression BeadChips (Illumina,
San Diego, CA, USA). Raw probe intensities were
exported using Illumina’s GenomeStudio and further stat-
istical processing was carried out using R. All 29,075
probes present on both microarrays, excluding X and Y
chromosomes as well as cross-hybridizing probes identi-
fied by using the Re-Annotator pipeline (http://dx.doi.org/
10.1101/019596) were first filtered with an Illumina detec-
tion P value of 0.05 in at least 50 % of the samples, leaving
11,994 expressed probes for further analysis. Subse-
quently, each transcript was transformed and normalized
through variance stabilization and normalization (VSN)
[64]. Using the same procedure for batch identification as
for the methylation data, we identified slide, amplification
round, array version, and amplification plate column as
technical batches. The data were then adjusted using
ComBat [65] and have been deposited into NCBI GEO
(GSE64930).
Statistical analyses
All statistical analyses were conducted in R version 3.1.0
(http://www.r-project.org/) [66]. Unless indicated other-
wise, P values are nominal and two-tailed. All correc-
tions for multiple testing were performed using the FDR
method of Benjamini and Hochberg. The level of statis-
tical significance was set a priori at 0.05 (5 × 10−2).
DNA methylation-based age prediction was performed
using the R code and statistical pipeline developed by
Horvath [27]. This predictor was developed using 82
Illumina DNA methylation array datasets (n = 7,844)
involving 51 healthy tissues and cell types [27]. The
raw data were normalized using BMIQ normalization
method [67] implemented in the Horvath DNA
methylation-based age predictor R script [27]. Robust-
ness and reproducibility of the epigenetic age pre-
dictor was tested using 40× technical replicates of an
individual control sample, randomized across microarray
chips and batches used to measure DNA methylation in
the GTP cohort. The average epigenetic age (DNAM-age)
of the control sample (true age = 32 years) was 32.64 (SD:
0.23) years with an average correlation r = 0.97 (0.001).
Age acceleration (Δ-age) was defined (as previously)
as the average difference between DNAM-age and
chronological age. One GTP participant had extreme
Δ-age (43.98 years), and using the Grubbs’ test (http://
graphpad.com/quickcalcs/grubbs2/) was noted to be the
only outlier (Z = 3.80, P <5 × 10−2). Although primary ana-
lyses were conducted without this outlier, inclusion of this
individual did not substantially alter the reported results.
Generalized linear regression models tested the relation-
ship of Δ-age with stressors and stress-related phenotypes
(GTP cohort). Because DNAM-age is calculated from raw
beta values (before Combat correction for batches), tech-
nical batches identified for the GTP (row and slide) and
the MPIP cohort (processing date) were tested as potential
confounders in the respective regression models. In the
GTP, models were further adjusted for age, sex, House-
man cell counts, body mass index, smoking, alcohol,
current substance abuse, and the principal components
from population stratification checks. In the MPIP, models
were adjusted for gender, age, body mass index, and
Houseman cell counts.
To determine if methylation signals or gene expression
levels are significantly different before and after DEX
stimulation in the MPIP cohort, likelihood ratio tests
accounting for gender, age, body mass index, disease
status, and estimated cell-type counts were applied to
each CpG site (n = 353) and expression array probe
(n = 11,994), respectively. DNA methylation and gene
expression changes were corrected for multiple com-
parisons using FDR. The 353 epigenetic clock CpGs
were annotated to a total of 344 genes. Among these,
170 genes were detected in peripheral blood by 216
gene expression array probes (163 genes were expressed
below background and 11 genes were not covered by the
gene expression arrays).
To account for population stratification due to dis-
crepancies between self-reported and actual race in the
GTP, we used genome-wide SNP data that were available
for 382 participants. Of the 700 k SNPs present on the
Omni Quad and Omni express arrays, 645,8315 auto-
somal SNPs were left after filtering with the following
criteria: minor allele frequency of >1 %; Hardy-Weinberg
equilibrium of 0.000001; and genotyping rate of >98 %.
The samples were clustered to calculate rates of identity
by descent (IBD). We then ran multidimensional scaling
analysis on the IBD matrix using PLINK2 (https://
www.cog-genomics.org/plink2) and plotted the first ten
axes of variation against each other. No outliers were de-
tected. The first two principal components were used as
covariates in regression models to adjust for population
stratification.
To identify whether epigenetic clock CpG sites are
co-localized with GREs, we used ENCODE NR3C1
ChIP-Seq data from lymphoblastoid cell lines (acces-
sion: ENCSR904YPP) for which no aligned tracks are
currently available. Initial filtering was performed using
FASTX Toolkit (v. 0.0.14, http://hannonlab.cshl.edu/
fastx_toolkit/index.html) and Prinseq (v. 0.20.3) [68] to
eliminate artefacts and low quality reads. Alignment on
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hg19 was performed using BWA (v. 0.7.10) [69] allowing
only uniquely mappable alignments with an alignment
quality of above 20. Reads from both ChIP-Seq and both
control libraries were pooled leading to 46,453,650 and
68,227,580 used reads, respectively. Peak-calling was car-
ried out by MACS14 (v. 1.4.2) [70] using default settings,
resulting in approximately 23,000 annotated signals. The
average length of ChIP-Seq signal as defined by the peak
calling was 746.3 bps (SD: 370.6). We generated 1,000 sets
(n = 353 CpGs) of randomly drawn CpG sites (without re-
placement) from the set of all CpGs present on the 450 K
BeadChip array (excluding X and Y chromosomes). For
every set we counted the percentage of CpG sites within a
GRE ChIP-Seq signal (+/− 0 bp). On this basis we
constructed the null distribution and compared it to the
observed percentage of clock CpG sites within a GRE
ChIP-Seq signal to measure the enrichment statistics.
Disease enrichment analysis was performed using the
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt;
http://bioinfo.vanderbilt.edu/webgestalt/) [71, 72]. This
was performed by using as input the set of unique DEX-
regulated genes neighboring epigenetic clock CpGs
(n = 139) and as reference the set of genes expressed
above background in our peripheral blood gene ex-
pression arrays. The minimum number of genes for
the enrichment analysis was set at 5, the statistic
performed was hypergeometric test, and results were
corrected for multiple testing using FDR.
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Chaperoning epigenetics: FKBP51 decreases the
activity of DNMT1 and mediates epigenetic effects
of the antidepressant paroxetine
Nils C. Gassen,1*† Gabriel R. Fries,1,2† Anthony S. Zannas,1,3 Jakob Hartmann,4
Jürgen Zschocke,1 Kathrin Hafner,1 Tania Carrillo-Roa,1 Jessica Steinbacher,5
S. Nicole Preißinger,1 Lianne Hoeijmakers,4 Matthias Knop,6 Frank Weber,6 Stefan Kloiber,6
Susanne Lucae,6 George P. Chrousos,7 Thomas Carell,5 Marcus Ising,6
Elisabeth B. Binder,1,8 Mathias V. Schmidt,4 Joëlle Rüegg,9 Theo Rein1*
Epigenetic processes, such as DNA methylation, and molecular chaperones, including FK506-binding
protein 51 (FKBP51), are independently implicated in stress-related mental disorders and antidepressant
drug action. FKBP51 associates with cyclin-dependent kinase 5 (CDK5), which is one of several kinases
that phosphorylates and activates DNA methyltransferase 1 (DNMT1). We searched for a functional link
between FKBP51 (encoded by FKBP5) and DNMT1 in cells from mice and humans, including those from
depressed patients, and found that FKBP51 competedwith its close homolog FKBP52 for associationwith
CDK5. In human embryonic kidney (HEK) 293 cells, expression of FKBP51 displaced FKBP52 from CDK5,
decreased the interaction of CDK5 with DNMT1, reduced the phosphorylation and enzymatic activity of
DNMT1, and diminished global DNA methylation. In mouse embryonic fibroblasts and primary mouse as-
trocytes, FKBP51mediatedseveral effectsof paroxetine, namely, decreased theprotein-protein interactions
of DNMT1with CDK5 and FKBP52, reduced phosphorylation of DNMT1, and decreased themethylation and
increased the expression of the gene encoding brain-derived neurotrophic factor (Bdnf ). In human periph-
eral blood cells, FKBP5 expression inversely correlated with both global andBDNFmethylation. Peripheral
blood cells isolated fromdepressed patients that were then treated ex vivowith paroxetine revealed that the
abundance of BDNF positively correlated and phosphorylated DNMT1 inversely correlated with that of
FKBP51 in cells and with clinical treatment success in patients, supporting the relevance of this FKBP51-
directed pathway that prevents epigenetic suppression of gene expression.
INTRODUCTION
Environmental factors and their influence on gene expression are recog-
nized as key players in several psychiatric diseases, including major de-
pressive disorder (MDD) (1–3). Although yet unclear, it is proposed that
these environmental effects are mediated by epigenetic changes, such as
methylation and demethylation of DNA and posttranslational modifica-
tions of histones. Such epigenetic marks control the accessibility of tran-
scriptional machinery to the DNA and are responsive to both environmental
stressors and togenetic variations.Whereas histonemodifications occur at
various sites and involve the action of various enzymes, DNAmethylation
is largely confined to CpG dinucleotides in the mammalian genome and is
executed byDNAmethyltransferases (DNMTs) (4), which comprise a family
of proteins with three subtypes that exhibit different specificities and func-
tions: DNMT1, DNMT3a, and DNMT3b (5).
Epigenetic mechanisms are considered not only crucial in shaping the
phenotype of complex psychiatric disorders but also important for the re-
sponse to certain medications (6–9). For instance, some antidepressants
can reduce DNMT1 activity (10), the major DNMTensuring the mainte-
nance DNA methylation during S phase that has also been implicated in
de novo methylation (11, 12); this effect of antidepressants appears to be
partly due to the reduction of the amounts of the histone methyltransferase
G9a (13). Furthermore, DNMT inhibitors applied either systemically or
locally in the hippocampus induce antidepressant-like effects inmice,which
are accompanied by increased expression of the gene encoding brain-
derived neurotrophic factor (BDNF) (14). Epigenetic regulation of BDNF
is implicated in the development and treatment of psychiatric diseases in
several studies (9, 15–17).
The activity of DNMT1 is modulated by several interacting proteins
and by posttranslational modifications (18, 19), including phosphorylation
(20–22). Among the phosphorylated sites of DNMT1 is Ser154, which is
targeted by cyclin-dependent kinases (CDKs), such as CDK5, and increases
DNMT1 activity (23). Thus, several mechanisms might be considered for
the antidepressant-induced effects on DNMT1.
Psychological stress and trauma are consistently associated with MDD
(1). The glucocorticoid receptor (GR) is integral to the stress response and
is controlled by a complex of chaperones and cochaperones (24). The
1Department of Translational Research in Psychiatry, Max Planck Institute of
Psychiatry, 80804 Munich, Germany. 2Department of Psychiatry and Behav-
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imilians University, 81377 Munich, Germany. 6Department of Clinical Research,
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Pediatrics, University of AthensMedical School, Athens 11527,Greece. 8Depart-
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cochaperones FK506-binding protein 51
(FKBP51) and FKBP52 are major determi-
nants ofGRactivity by competingwith each
other for access to the GR-chaperone hetero-
complex and by exerting opposing effects
on GR function with FKBP52-promoting
and FKBP51-inhibiting GR activity (25–27).
Conversely, FKBP51 abundance increases
afterGRactivation (28–30).Notably, FKBP51
has been linked genetically to the response
to antidepressants, and enhanced abundance
ofFKBP51 is associatedwith improved treat-
ment response (31–36). In addition, FKBP51
andFKBP52 interactwith several proteins in-
cluding CDK5 (36, 37). Therefore, we aimed
to explore potential mechanisms by which
the stress-related cochaperones FKBP51 and
FKBP52 modulate DNMT1 phosphorylation
and activity and whether this might contrib-
ute to the clinical response to antidepressant
treatment in patients with MDD.
RESULTS
FKBP51 and FKBP52 were
differentially associated with
DNMT1 and modulate its
phosphorylation and activity
Previously, we found that CDK5 formed a
protein complex with FKBP51 or FKBP52
(36). Because CDK5 has been reported to
regulate DNMT1 by phosphorylation at
Ser154 (23), we investigated whether FKBP51
and FKBP52 modulate CDK5’s action on
DNMT1.We initially tested for associations
between CDK5 and DNMT1 with ectopic
FLAG-taggedFKBP51orFKBP52 in human
embryonic kidney (HEK) 293 cells by co-
immunoprecipitation. Both FKBP51 and
FKBP52 were associated with CDK5 (Fig.
1A), consistent with our previous results
(36); however, only FKBP52was associated
with DNMT1 (Fig. 1B). Coexpressing both
FKBPs revealed that they compete with
each other for binding to CDK5 (Fig. 1C).
Notably, coexpression of FKBP51 also re-
duced the interaction between FKBP52
and DNMT1 (Fig. 1C).
Because FKBP51 and FKBP52 are co-
chaperones of heat shock protein 90 (Hsp90)
(25) and Hsp90 interacts with both CDK5
and DNMT1 (38, 39), we explored the pos-
sibility that Hsp90 function might be im-
portant for complex assembly. We exposed
HEK293 cells to increasing concentrations
of 17-AAG, an Hsp90 inhibitor and geldana-
mycin derivative, immunoprecipitatedCDK5,
and probed for the interaction with Hsp90
andDNMT1. Therewas no significant effect
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Fig. 1. FKBP51 and FKBP52 differentially affect CDK5-dependent phosphorylation and activity of DNMT1. (A)
Immunoprecipitation (IP) for CDK5 followed by Western blotting in lysates from HEK293 cells transfected with
FKBP51 or FKBP52. Control: without primary antibody [immunoglobulin G (IgG) control in fig. S1A]. (B and C)
Immunoprecipitation for the FLAG tag (B) or FKBP51 or FKBP52 (C) followedbyWestern blotting in lysates from
HEK293 cells transfected with FLAG-tagged FKBP51, FKBP52, or both, as indicated. C, control [vector-
transfectedcells (B) orwithout primary antibody (C) (IgGcontrol in fig. S1A)]. Blots are representative of three
independent experiments. Ect., ectopic expression. Graph (C) displays the association of FKBP51 (51-IP) or
FKBP52 (52-IP) to CDK5 or DNMT1 in the dual transfected samples relative to the singly transfected samples.
Dataaremeans+SEMof three independentexperiments. (D)Westernblotting forDNMT1andphosphorylated
(p)DNMT1 (at Ser154) in primary rat astrocytes transfectedwith FKBP51or FKBP52.Amount of phosphorylated
DNMT1 was calculated relative to that of total DNMT1; this was then calculated relative to that in the control
vector sample (−), arbitrarily set to 1. Data aremean+SEMof three to six independent experiments. (E) Quan-
tification ofWestern blotting analysis of the phosphorylation of DNMT1 (corrected for total DNMT1) in wild-type
(WT), Fkbp51 knockout (51KO), or Fkbp52 knockout (52KO) MEFs transfected with CDK5 relative to vector-
transfectedcells.Dataaremeans+SEMof three independent experiments.Representativeblot is shown in fig.
S2B; full blots for (D) and (E) are shown in data file S1. (F and G) DNMT1 enzymatic activity in total nuclear
lysates from primary astrocytes (F) and cytosine methylation (percent of total cytosine) assessed by mass
spectrometry in isolated total DNA fromprimary rat astrocytes transfectedwith FKBP51 or FKBP52 or a control
vector. 5mC, 5-methylcytosine.Data aremeans+SEMof three independent experiments eachperformedwith
two (F) or three (G) technical replicates. *P < 0.05, **P < 0.01. Statistical details in tables S2 and S3.
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of Hsp90 inhibition on complex assembly of CDK5 andDNMT1 (fig. S1, A
to D, and data file S1).
In addition to DNMT1, which typically maintains DNAmethylation,
DNMT3a and DNMT3b also shape the methylome as de novo methyl-
transferases (5). Coimmunoprecipitation revealed an association between
FKBP52 and DNMT3a but not DNMT3b, whereas FKBP51 associated
with none (fig. S1, E and F).
Considering the reported effects of CDK5 on DNMT1, we analyzed
the phosphorylation of DNMT1 at Ser154 upon overexpression of FKBP51
or FKBP52 in HEK293 cells or primary rat astrocytes. Overexpressing
FKBP51 significantly lowered the phosphorylation of DNMT1, whereas
overexpressing FKBP52 increased it (Fig. 1D, data file S1, and fig. S2A).
Because phosphorylation of Ser154 is important for DNMT1 activity (23),
this suggests that FKBP52 promotes whereas FKBP51 inhibits DNMT1
activity. To check for the relevance of the FKBPs onCDK5-inducedDNMT1
Ser154 phosphorylation, we overexpressed CDK5 in wild-type, 51KO, and
52KOmouse embryonic fibroblasts (MEFs) and monitored DNMT1 phos-
phorylation. CDK5 overexpression did not change the phosphorylation of
DNMT1 in 52KOMEFs (as opposed towild-type cells), whereas a marked
increase in phosphorylation of DNMT1was evident inwild-type and 51KO
MEFs (Fig. 1E, data file S1, and fig. S2B).
To determine whether the FKBP51/52-dependent changes in phospho-
rylation of DNMT1 go along with changes in DNMT1 activity, we trans-
fected primary rat astrocyteswith plasmids expressing FKBP51 or FKBP52
and determined the enzymaticDNAmethylation activity in total cell lysates.
There was a trend toward lower methylase activity in FKBP51-transfected
cells than in FKBP52-transfected cells (Fig. 1F). Analysis of the content of
total methylated cytosines in genomic DNA revealed significantly lower
DNAmethylation in FKBP51-transfected than in FKBP52-transfected cells
(Fig. 1G). There was no difference in hydroxymethylation (fig. S2C).
To further shed light on the possible mechanism involved in the FKBP-
directed regulation of DNMT1 activity by CDK5, we analyzed the associa-
tion of the CDK5 regulatory proteins p25, p35, and p39 (40) in the human
neuroblastoma cell line SKNMC. Although all three proteins were detected
in protein lysates, only the CDK5 activator p35 associated with DNMT1
(Fig. 2A), indicating that active CDK5 is recruited toDNMT1. Ectopic expres-
sion of FKBP52 enhanced the association of p35 with DNMT1, whereas ec-
topic expression of FKBP51 did not (Fig. 2, A and B, and data file S2). There
was no significant change in the association of DNMT1with CDK5 (Fig. 2C).
FKBP51 has been suggested to facilitate the dephosphorylation of
tau, depending on its peptidylprolylisomerase (PPIase) activity (41). To test
the relevance of PPIase activity in the regulation of DNMT1 phosphoryl-
ation, we expressed increasing amounts of a PPIase-deficient mutant of
FKBP51 (25, 42) in HEK293 cells. PPIase-deficient FKBP51 exerted sim-
ilar effects on phosphorylation ofDNMT1as the nonmutated FKBP51 (Fig.
2D and data file S2).
Modulation of DNMT1 phosphorylation and activity by
paroxetine depend on FKBP51
On the basis of previous evidence of an inhibitory effect of paroxetine on
DNMT1 (13), we sought to assess whether the antidepressant action on
DNMT1 involves DNMT1 phosphorylation or its association with CDK5,
FKBP51, and FKBP52. First, we tested whether paroxetine affects the
association between the FKBPs and CDK5 in HEK293 cells. We found
that treatment with paroxetine increased the association between FKBP51
and CDK5 and reduced the interaction between FKBP52 and CDK5
(Fig. 3A, fig. S3, and data file S1). There was no significant effect on the
interaction between FKBP52 and DNMT1.
We next checked for the effects of paroxetine on phosphorylation of
DNMT1 in primary astrocytes and found that it decreased phosphoryl-
ation of DNMT1 in a dose-dependent manner (Fig. 3B). Furthermore, we
found evidence that the antidepressant-induced reduction in phospho-
rylation of DNMT1 requires the presence of FKBP51 because paroxetine
decreased phosphorylation of DNMT1 in primary astrocytes from wild-
typemice but not in primary astrocytes from 51KOmice (Fig. 3C and data
file S3). Similar results were obtained in wild-type and 51KOMEFs (Fig.
3D, fig. S4A, and data file S3). Likewise, paroxetine reduced DNMT1
enzymatic activity in wild-type but not in 51KOMEFs (Fig. 3E and data
file S3). To test whether these results can be translated to the action of
paroxetine in an established animal model, we determined phosphoryl-
ation of DNMT1 in mice that were acutely or chronically treated with
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Fig. 2. FKBP51 does not change the interaction of DNMT1 with the CDK5
activator proteinp35andacts independently of itsPPIaseactivity on thephos-
phorylation of DNMT1. (A to C) Immunoprecipitation for DNMT1 followed by
Western blotting as indicated (A) and quantification of DNMT1-p35 (B) and
DNMT1-CDK5 (C) interaction in SKNMCcells transfectedwith FLAG-tagged
FKBP51or FKBP52or vector control (indicatedby “-” in both lanes). IgGcon-
trol in fig. S1A. (D) Western blotting as indicated in HEK293 cells transfected
with PPIase-deficient mutant FKBP51 (F67D/D68V: 51 PPImut). Phosphoryl-
ated DNMT1 was calculated against total DNMT1, relative to that in the con-
trol vector sample (−), arbitrarily set to 1. Data are means ± SEM from three
independent experiments.*P < 0.05. Statistical details in table S2. Full blots
for (B) and (D) are shown in data file S2.
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paroxetine (45-min or 21-days treatment duration, respectively). Tissue
was available from previous experiments that documented that the be-
havioral effect of paroxetine was absent in mice lacking FKBP51 (33).
Acute and chronic treatment with paroxetine led to reduced phosphoryl-
ation of DNMT1, both in the hippocampus and in the prefrontal cortex,
only in the presence of FKBP51 (Fig. 3, F to H; fig. S4, B to D; and data
file S3).
We also investigated the effects of the tricyclic antidepressant ami-
triptyline on phosphorylation of DNMT1. InMEFs, therewas no signifi-
cant effect of amitriptyline (fig. S5A). In wild-type mice previously treated
with amitriptyline (33), a reduction in phosphorylation of DNMT1 was ob-
served in the prefrontal cortex but not in the hippocampus (fig. S5,B andC).
This effect of amitriptyline was abolished in 51KOmice (fig. S5C). To also
test another neuropharmacologically active substance, we analyzed protein
extracts from mice that had been treated with the neuroleptic haloperidol
(33). Haloperidol displayed no significant effect on phosphorylation of
DNMT1 in the hippocampus and slightly enhanced phosphorylation of
DNMT1 in the prefrontal cortex (fig. S5, D to G), contrasting the effects
of the antidepressants paroxetine and amitriptyline.
FKBP51- and paroxetine-modulated DNMT1 activity
correlates with Bdnf promoter methylation and
expression in mice
In addition to the effects of FKBP51 and paroxetine on global DNA
methylation through their action on DNMT1, we analyzed possible local
consequences at Bdnf, the gene encoding BDNF, as a locus relevant to
neuropsychiatry. Bdnf features different epigenetically controlled pro-
moters that give rise to multiple isoforms at the mRNA level with differ-
ent untranslated exons at the 5′ end spliced to a common protein-coding
exon at the 3′ end (43, 44). To date, the Bdnf promoter of exon IV (called
promoter IV) is one of the best characterized (9, 45, 46). The expression
of promoter IV is representative of Bdnf expression in the brain and also
reflects the changes induced by neuronal activity and antidepressants
(16, 17, 47, 48). Therefore, we analyzed the methylation of promoter
IV in the brain of wild-type and 51KO mice that had been treated with
paroxetine for 45 min (33). In these animals, paroxetine induced the de-
methylation of Bdnf at promoter IV in the prefrontal cortex of wild-type
but not 51KO mice (Fig. 4A and table S1). The extent of demethylation
varied between 10 and 40 percentage points, depending on the CpG site.
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Fig. 3. The effect of paroxetine on DNMT1 is linked to FKBP51. (A) Im-
munoprecipitation for the FLAG tag followed by Western blotting for
CDK5 in HEK cells transfected with FLAG-tagged FKBP51 or FKBP52
and treatedwithparoxetine (PAR, 10mM)or vehicle for 72hours.Data fromparoxetine-treated
samples are presented relative to that in vehicle-treated samples, set to 1. IgG control in fig.
S1A. (B) Western blotting for phosphorylated DNMT1 relative to total DNMT1 in primary cor-
tical rat astrocytes treated with increasing concentrations of paroxetine or vehicle (−). Data
aremeans±SEM from three experiments. (C)Western blotting in lysates fromWT (gray bars)
or 51KO (white bars) primary murine astrocytes treated with paroxetine or vehicle (−). Data
aremeans±SEMof threeexperiments, eachperformed induplicate. (DandE)Quantification
of the abundance of phosphorylated DNMT1 relative to total DNMT determined by Western
blotting (D) and enzymatic DNMT1 activity (E) in WT (gray bars) or 51KO (white bars) MEFs treated with paroxetine or vehicle (−). Data are means + SEM of
three (D) or four (E) independent experiments performed in technical duplicates. (F to H) Abundance of phosphorylated relative to total DNMT1 in the pre-
frontal cortex (PFC) and hippocampus (HIP) of 51KOmice (white bars) andWTmice (gray bars) treatedwith paroxetine or vehicle in an acute (45min) (F and
G)or chronic (21days) (H) regimen (33). Data aremeans+SEMof 8 to 10animals. *P<0.05, **P<0.01. Statistical details are in tablesS2andS3. Full blots for
(C) and (F) to (H) are shown in data file S3.
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In 51KO mice, there was some increase in DNA methylation upon par-
oxetine treatment, but this change was not statistically significant (Fig. 4A
and table S1). There was no significant genotype effect in the absence of
paroxetine (table S1). Less pro-
nounced effects were observed
in the hippocampus, but there
was still a significant genotype
effect (Fig. 4B and table S1). In
addition, we analyzed the pro-
moter of exon I, but no significant
changes inDNAmethylationwere
observed (table S1).We also ana-
lyzed the effect of amitriptyline
on the methylation of Bdnf at
the exon IV promoter in the hip-
pocampus and in the prefrontal
cortex of wild-type and 51KO
mice, but therewas no significant
change in methylation (fig. S6).
To assess changes in the tran-
scription of Bdnf, we performed
in situ hybridization in brain
slices from wild-type and 51KO
mice that had previously been
treated with paroxetine or ve-
hicle for 21 days (33). In all sub-
regions of the hippocampal
formation, we observed a similar
pattern: the amount of Bdnf
mRNAwas significantly higher
in wild-type mice treated with
paroxetine than it was in 51KO
mice treated with paroxetine
(Fig. 4, C and D).
These data are in line with
the hypothesis that FKBP51-
dependent reduction of DNMT1
activity by paroxetine, also indi-
cated by the decrease of phos-
phorylation of DNMT1 (Fig. 3,
F toH, and fig. S4, B toD), leads
to demethylation and activation
of the Bdnf gene. To evaluate
whether FKBP51 mediates the
effects of paroxetine on CDK5
and FKBP52 complexes inmice,
weperformedCDK5andFKBP52
immunoprecipitation in brain ex-
tracts from wild-type and 51KO
mice that had been treated with
paroxetine for 45 min (33). Par-
oxetine changed the association
of CDK5with FKBP52 andwith
DNMT1 in wild-type but not
51KOmice (Fig. 4, E to G). This
is consistent with the inhibitory
effect of paroxetine on FKBP52-
CDK5 association we observed
in cells (Fig. 3A). When we pre-
cipitated FKBP52, the associa-
tion with CDK5 or DNMT1 in the presence of paroxetine was greater in
51KO than in wild-type mice (Fig. 4, G to I). Thus, FKBP51 mediates
the impact of paroxetine on protein associations.
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Fig. 4. FKBP51-dependent effects of
paroxetine on Bdnf promoter methyla-
tion and expression and on CDK5 pro-
tein associations. (A andB) Change in
thepercentageofCpGs inpromoter IV
of Bdnf that were methylated in DNA from the prefrontal
cortex and hippocampus from WT mice (gray bars) and
Fkbp51−/− mice (51KO, white bars) previously treated with
paroxetine relative to those treated with vehicle for 45 min
(33). Data are means + SEM from × mice each. Table S1
contains complete methylation information. *** indicate sig-
nificant overall genotype effects. (C and D) Bdnf expression assessed by in situ hybridization shown in the dorsal hip-
pocampus (C) and quantified in hippocampal sections from WT and 51KO mice treated with paroxetine for 21 days
(chronic) or vehicle (−) (33). Scale bar, 500 mm. a.u., arbitrary units;DG, dentate gyrus. (E to I) Protein binding toCDK5
(E and F) or FKBP52 (H and I) in brain extracts fromWTand 51KOmice that had been treatedwith paroxetine for 45min
(33).Western blot representing three animals for eachcondition and treatment shown in (G). IgGcontrol in fig. S1A.Data
are means + SEM from 9 to 10 animals for each condition or treatment. Data fromWTmice treated with vehicle were set
to 1. *P < 0.05, **P < 0.01, ***P < 0.001. Statistical details in tables S2 and S3.
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Cellular and clinical treatment responses support the
physiological relevance of FKBP51-dependent effects of
paroxetine on DNMT1 and BDNF
To translate the findings obtained from cellular and animal studies to
humans, we made use of the whole-blood DNA methylation and RNA
data available from the Grady Trauma Project, an ongoing study examining
the role of genetic and environmental factors that predict stress responses
(49, 50). The expression of FKBP5 (the gene encoding FKBP51) was neg-
atively correlatedwith the average globalDNAmethylation, asmeasured by
450K arrays (r = −0.127, P = 0.015, n = 365), and with the average amount
ofBDNFmethylation found over the entireBDNF locus (total of 79 CpGs),
as well as with the average methylation of CpGs located near the transcrip-
tion start sites of exon I (33 CpGs) and exon IV (31 CpGs) of the gene
(Fig. 5, A and B, and fig. S7).
To test protein correlations, we first analyzed the phosphorylation of
DNMT1 and FKBP51 in peripheral blood mononuclear cells (PBMCs)
from healthy individuals. We observed that the amounts of FKBP51 and
phosphorylated DNMT1 were inversely correlated, in line with a negative
effect of FKBP51 on the phosphorylation of DNMT1 (Fig. 5C). We also
checked for the effects of paroxetine on the same cells by treating PBMCs
ex vivo with paroxetine or vehicle for 48 hours. In PBMCs, the concen-
tration used for paroxetinewas chosen tomatch therapeutic concentrations
in the serum according to the consensus guidelines for therapeutic drug
monitoring in psychiatry (51). We found that higher amounts of FKBP51
were significantly associated with smaller paroxetine-induced changes in
phosphorylation of DNMT1 (Fig. 5D), further corroborating the notion that
FKBP51 modulates the effects of paroxetine on DNMT1 phosphorylation.
Because FKBP51 abundance is increased upon stress (28–30), we ex-
plored the possibility that stress-induced glucocorticoids change pDNMT
through increasing the amount of FKBP51. PBMCs were isolated from
21 healthy individuals before and after oral intake of dexamethasone, a syn-
thetic corticosteroid that selectively activates GR. In response to dexa-
methasone, we observed a negative correlation between the change in
the phosphorylation of DNMT1 and the change in FKBP51 abundance: af-
ter dexamethasone treatment, increased abundance of FKBP51 was cor-
related with decreased phosphorylation of DNMT1 (Fig. 5E), consistent
with the role of FKBP51 as mediator of stress-induced dephosphorylation
of DNMT1.
Because higher protein amounts of FKBP51 in PBMCswere associated
with better clinical treatment outcome in depressed patients (33), we hy-
pothesized that phosphorylation of DNMT1might also be linked to treat-
ment response. Therefore, we determined the level of phosphorylation of
DNMT1 in PBMCs from 40 patients of the Munich Antidepressant Re-
sponse Signature (MARS) (52) project before and after 6 weeks of psy-
chopharmacological treatment (with various antidepressants by doctor’s
choice). The change of phosphorylation of DNMT1 showed a negative
correlationwith the clinical treatment response [presented as the reduction
in theHamiltonDepressionRating Scale (HDRS) from beginning of treat-
ment to 6 weeks later] (Fig. 6A). Similarly, when we collected PBMCs
from the patients at the time of admission to the clinic and treated the cells
with paroxetine ex vivo, the cellular response (a decrease) in the phospho-
rylation of DNMT1 also negatively correlated with patients’ (increased)
reduction in HDRS (Fig. 6B). The change in the phosphorylation of
DNMT1 observed in PBMCs in response to paroxetine ex vivo and the
change in the phosphorylation of DNMT1 observed in patients after clin-
ical treatment were well correlated (Fig. 6C). Overall, nonresponders
tended to exhibit an increase in the phosphorylation of DNMT1 after 6 weeks
of clinical treatment or after paroxetine treatment of their PBMCs ex vivo
(fig. S8, A and B). When determining BDNF abundance, we found that
the increase in BDNF secreted from PBMCs cultured and treated with
paroxetine ex vivo significantly correlated with the abundance of FKBP51
(Fig. 6D). Likewise, the change in BDNF concentration in the serum of pa-
tients 6weeks after clinical treat-
ment also positively correlated
with the abundance of FKBP51
in their blood cells collected at
the beginning of treatment (Fig.
6E). Furthermore, the BDNF re-
sponse in PBMCs cultured with
paroxetine ex vivo positively cor-
relatedwith the clinical treatment
outcome observed in patients
(Fig. 6F).A trend towardpositive
correlationwas also observed for
the change ofBDNF in the serum
and the clinical treatment out-
come after 6 weeks (Fig. 6G).
Together, these results support
the physiological and clinical rel-
evance of FKBP51 in inhibiting
DNMT1 activation and promot-
ingBDNFexpression inmodulat-
ing the action of antidepressants.
DISCUSSION
Adaptation to stressful life events
is a fundamental physiological
process that involves severalmech-
anisms, including epigenetic pro-
gramming (24, 53, 54). Gene
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Fig. 5. Correlation of BDNF meth-
ylation, DNMT1 phosphorylation,
and pharmacological effects with
FKBP51 in humans. (AandB) Cor-
relation between BDNF methyla-
tion at promoter I (A) or IV (B) and
FKBP5 expression in PBMCs from
365subjects fromtheGradyTrauma
Project. (C) Correlation of the abun-
dance of FKBP51 with that of phos-
phorylated DNMT1 (corrected by
total DNMT1) in PBMCs from
healthy individuals (n= 21). (D) Correlation of FKBP51 abundance with the change in pDNMT1 abundance after ex vivo
paroxetine exposure (48 hours, relative to vehicle) in PBMCs from healthy individuals (n = 20). (E) Correlation of the
change in the phosphorylation of DNMT1 with that of FKBP51 in PBMCS isolated from healthy individuals that received
dexamethasone (DEX, 1.5 mg, 6 hours; n = 21). Data were analyzed by Pearson correlation (A and B) or partial corre-
lation corrected for age and gender (C to E).
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programming through the GR is evident from several reports (55). The
established paradigm is that GR binds to chromatin targets and interacts with
the epigenetic machinery at these sites, thereby changing local epigenetic
marks.Our study adds another twist toGR-mediated epigenet-
ic programming by delineating a new route: we found that the
GR-enhanced cochaperoneFKBP51 suppresses the activity of
the epigenetic enzyme DNMT1 by impairing its formation of
a heterocomplex with CDK5. Our data suggest that FKBP51
displaces FKBP52 from CDK5, thereby preventing the sub-
sequent interaction with and phosphorylation of DNMT1 at
Ser154, causing reduced activity of DNMT1 and decreased
DNA methylation in the genome, including at the Bdnf gene.
This displacement favoring FKBP51 chaperoning is promoted
by paroxetine and possibly other antidepressants (Fig. 7).
Part of the translational aspect of this study uses PBMCs
cultivated and treated ex vivo. Although signal transduction
in peripheral cells ex vivo may not reliably replicate molec-
ular activity in brain cells, the proteins involved in this study
are present in multiple cell types and appear to have similar
functional interactions in human PBMCs as they did in
mouse brain tissue and astrocytes. Furthermore, our correla-
tion analyses indicated that examining the effects on the ac-
tivation of DNMT1 in patient PBMCs ex vivomay serve as a
biomarker to predict the clinical response to antidepressants.
The data reported here support the notion that the role
of chaperones in the management of stress reactivity extends
beyond protein homeostasis to the genome and epigenome.
For example, several landmark studies from the Lindquist
laboratory document the role of Hsp90 in the evolution of
heritable new traits in several organisms (56–60). The new
traits shaped not only the phenotype but also the responsive-
ness to diverse drugs.
Our finding of the association of the chaperone FKBP51
withCDK5 in the regulation ofDNMT1 adds insight into the
molecular and physiological functions of FKBP51, which
appears to be a versatile protein. In addition to its role as a
potent inhibitor of GR (25–27), FKBP51 regulates other
steroid receptors and associates with and regulates the kinase
AKT through the recruitment of PH domain and leucine-rich
repeat protein phosphatases (PHLPPs), with implications for
cancer treatment (61). FKBP51 also forms protein complexes
with Beclin1, AKT, and PHLPPs in the regulation of auto-
phagy and affects tau stability, microtubule polymerization,
neurite outgrowth, glycogen synthase kinase 3b (GSK3b) sig-
naling, aging, and nuclear factor kB (NFkB) signaling in im-
mune processes (26,33,36,41,62–64). Similar to the divergent
effects of FKBP51 and FKBP52 on CDK5, the two highly
homologous FKBPs are reported to exert opposite effects on
several other cellular processes (64). Even though both FKBPs
feature a well-described enzymatic activity [peptidylprolyl
isomerization (65)], it appears that they rather function as
protein scaffolds to promote various and at least partially dif-
fering protein complexes, such as what we observed regard-
ing their interaction with CDK5.
Several functions of FKBP51 appear to contribute to its
role in the cellular and organismal response to antidepressants
(31–35). Originally, because of its effect onGR signaling (25),
FKBP51 was included as candidate in the first gene associa-
tion study in depression (31). Since then, cellular, animal, and
clinical data suggest that the role of FKBP51 in regulating
GSK3b, AKT, and autophagy signaling mediate antidepressant effects
(33, 36). GSK3b and AKT decrease or increase, respectively, DNMT1 pro-
tein abundance (66). In our data set, we found no evidence that the presence
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Fig. 6. Changes in BDNF and phosphoryl-
ated DNMT1 in response to ex vivo paroxe-
tine or clinical treatment: Correlations with
FKBP51 and clinical treatment response.
(A) Correlation in the clinical success of anti-
depressants (reducedHDRS)with thechange
in abundance of phosphorylated DNMT1 in
PBMCscollected fromMARSprojectpatients
after 6 weeks’ antidepressant therapy. (B)
Correlation of clinical therapy success with
the change in the phosphorylation of DNMT1
in respective patients’ PBMCs isolated before therapy and treated ex vivo with paroxetine.
(C) Correlation of the change in the phosphorylation of DNMT1 in PBMCs isolated from pa-
tients after clinical therapy [as described in (A)] with that in respective patients’ PBMCs
isolatedbefore therapy and treated ex vivowith paroxetine. (D andE) Correlation of the abun-
dance of FKBP51 with that of BDNF in PBMCs either (D) isolated before therapy and treated
ex vivo with paroxetine or (E) isolated after clinical therapy [as described in (A)]. (F and G)
Correlation of the clinical success of antidepressants (reduced HDRS) with that of BDNF in
PBMCs either (F) isolated before therapy and treated ex vivo with paroxetine or (G) isolated
after clinical therapy [as described in (A)]. Protein abundance was assessed in cell extracts
by Western blotting. The abundance of phosphorylated DNMT1 was normalized to total
DNMT1.DatawereanalyzedbyPearsoncorrelationcoefficient corrected for ageandgender.
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of FKBP51 alters the overall abundance of DNMT1, possibly because
FKBP51 inhibits both AKTand GSK3b (33, 36, 61). Although we suggest
that the specific suppression of DNMT1 phosphorylation is mediated
through the interaction of FKBP51 with CDK5, given the potential for
multiple kinases being affected by FKBP51 (37), we cannot yet exclude
the possibility that kinases other than CDK5 contribute to this mechanism.
The present and several additional studies portray FKBP51 as “reactivity
protein” in the sense that it shapes the responsiveness to stress and drug
treatment (33, 36, 61, 67, 68). Part of this conclusion extends from ex-
periments with 51KO mice. Deletion of genes often goes along with com-
pensatory mechanisms that are evoked by the organism throughout
development. The effect of FKBP5 deletion is not always detectable in
the absence of a stimulus (33, 36, 67, 68); in our study, a difference in phos-
phorylation of DNMT1 between brains from wild-type and those from
51KO animals was only evident after treatment with paroxetine. Thus, it
appears that possible compensatory changes in response to gene deletion
do not compromise the effects evoked by challenges later in life.
It is tempting to speculate about the possibility to target (enhance)
FKBP51 or downstream processes for the treatment of depression or other
stress-related diseases. However, we would like to point out that due to the
multifactorial actions of FKBP51, more studies are necessary to dissect
which functions of FKBP51 are important and how it might be possible
to specifically affect a subset of these functions when targeting FKBP51
directly rather than by targeting downstream processes. A promising
FKBP51-targeting compound has been presented recently (69). This com-
pound is designed as inhibitor of the peptidylprolyl isomerase activity but
because this activity appears dispensable for many functions of FKBP51,
it is not clear yet which of themolecular actions of FKBP51 are influenced
in which direction. Because the gene encoding FKBP51 has also been
suggested as a risk factor for psychiatric disorders (31, 49, 70), timing
of pharmacological FKBP51 targeting will likely be important. Moreover,
if one limits the ability of FKBP51 to reduce GR function, more FKBP51
might be produced because of an ultrashort feedback loop (28, 30, 71).
Alternatively, our study also supports the consideration of DNMT1 inhi-
bitors for drug development in depression (14, 48).
MATERIALS AND METHODS
Cells
HEK293 cells [American Type Culture Collection (ATCC), CRL-1573],
SKNMCcells (gift fromC.Behl, University ofMainz, Germany), andMEFs
(gift from M. Cox, University of Texas at El Paso) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented
with 10% fetal calf serum (FCS) and 100 U/ml penicillin and streptomycin,
respectively. Enriched astroglial cultures were prepared from postnatal
day–1 Sprague-Dawley rat pups (Charles River) or wild-type and 51KO
mice and were handled as described previously (72).
Transfection of astrocytes and MEF cells
DetachedMEFs or cortical astrocytes (2 × 106) were resuspended in 100 ml
of transfection buffer [50 mM Hepes (pH 7.3), 90 mM NaCl, 5 mM KCl,
and 0.15 mM CaCl2] (73). Up to 5 mg of plasmid DNA expressing the
respective construct was added to the cell suspension, and electroporation
was carried out using the AmaxaNucleofactor system (Lonza). Cells were
replated at a density of 105 × cm−2 and further processed for Western blot
analysis or assessment of DNMT1 activity.
Plasmids
The constructs expressing FLAG-tagged FKBP51, PPIase-deficient
FKBP51 (F67D/D68V) or FKBP52, and hemagglutinin-tagged CDK5 have
been described previously (25, 74). The plasmids pcDNA3/Myc-DNMT3A
and pcDNA3/Myc-DNMT3B1 were from Addgene (#35521 and #35522).
Coimmunoprecipitation
Coimmunoprecipitations (CoIPs) of FLAG-tagged FKBP51/52 or en-
dogenous CDK5, FKBP51, and FKBP52 were performed in HEK293 cells
essentially as described previously (26). Briefly, 5 × 106 cells were electro-
porated with 5 mg of the respective expression plasmids using a GenePulser
(Bio-Rad) at 350 V/700 mF in 400 ml of electroporation buffer [50 mM
K2HPO4/KH2PO4, 20 mM KAc (pH 7.35), and 25 mM MgSO4]. After
3 days of cultivation in DMEM/10% FCS, cells were lysed in CoIP buffer
[20 mM tris-HCl (pH 8.0), 100 mMNaCl, 1 mMEDTA, and 0.5% Igepal
complemented with protease inhibitor cocktail (Sigma)] for 20min at 4°C
with constant mixing. In the case of precipitating endogenous proteins
from brain lysates, the tissue was homogenized and lysed in the same
buffer. The lysates were cleared by centrifugation, and the protein concen-
tration was determined and adjusted (brain lysates, 1 mg × ml−1; cell lysates,
1.2 mg × ml−1); 1ml of lysatewas incubatedwith 2.5 mg of FLAG, FKBP51,
FKBP52, or CDK5 antibody overnight at 4°C with constant mixing. Sub-
sequently, 20 ml of bovine serum albumin–blocked protein G Dynabeads
(Invitrogen, 100-03D) were added to the lysate-antibody mix followed by
BDNFBDNF
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CDK5
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FKBP51
DNMT1
DNMT1F
KB
P5
2
FK
BP
52 CDK5
p35
CDK5
p35
PDNMT1
StressAntidepressants
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Fig. 7. Model of antidepressant effects on global and local epigeneticmarks
mediated throughFKBP51-regulated suppression of DNMT1activity.Sche-
matic summarizing of our findings. FKBP51 competes with FKBP52 for bind-
ing toCDK5 and its activator p35. BecauseDNMT1preferentially associates
with FKBP52-CDK5-p35 complexes, DNMT1 displays higher phosphoryl-
ation and activity in the presence of high FKBP52 abundance but not when
FKBP51 dominates the CDK5-p35 complexes. This causes differences in
global DNA methylation and BDNF promoter methylation and expression.
The stress-enhanced protein FKBP51may thusmediate the impact of stress
on epigenetic programming. Furthermore, this pathway is targeted by par-
oxetine and possibly other antidepressants to swap chaperone binding to
CDK5, whichmaymediate the clinical response in patients with depression.
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a 3-hour incubation at 4°C. Beads were washed three times with PBS, and
bound proteins were eluted with 100 ml of 1 × FLAG peptide solution (100
to 200 mg × ml−1, Sigma F3290) in PBS for 30 min at 4°C. In case of
precipitation of endogenous proteins, elution was performed by adding
60 ml of Laemmli sample buffer and by incubation at 95 °C for 5 min. Five
to fifteen micrograms of the input lysates or 2.5 to 5 ml of the immunopre-
cipitates were separated by SDS–polyacrylamide gel electrophoresis
(PAGE) and analyzed byWestern blotting. When quantifying coimmuno-
precipitated proteins, their signals were normalized to input protein and to
precipitated interactor protein.
Western blot analysis
Western blot analysis was conducted as previously described (13). Briefly,
protein extracts were obtained by lysing cells in 62.5 mM tris, 2% SDS, and
10% sucrose, supplemented with protease (Sigma, P2714) and phospha-
tase (Roche, 04906837001) inhibitor cocktail, followed by sonication of
samples and heating at 95°C for 5 min. Proteins were separated by SDS-
PAGE and electrotransferred onto nitrocellulose membranes. Blots were
placed in tris-buffered saline (TBS) supplemented with 0.05% Tween
(Sigma, P2287) and 5% nonfat milk for 1 hour at room temperature, fol-
lowed by an incubation with the primary antibody (diluted in TBS/0.05%
Tween) overnight at 4°C. Primary antibodies recognizing the following
epitopes or proteins were used: FLAG (1:7000; Rockland, 600-401-383),
FKBP51 (1:1000; Bethyl, A301-430A), FKBP52 (1:2000; Bethyl, A301-
427A), actin (1:5000; Santa Cruz Biotechnology, sc-1616), DNMT1
(1:1000; Imgenex, IMG-261A), CDK5 (1:1000; Cell Signaling Technol-
ogy, #2506), p25 and p35 (1:1000; Cell Signaling Technology, #2680),
p39 (1:1000; Cell Signaling Technology, #3275), myc (1:1000; Sigma-
Aldrich, C3956), and Hsc70 (heat-shock cognate 70; 1:2000; Santa Cruz
Biotechnology, sc-7298). Subsequently, blots were washed and probed
with the respective horseradish peroxidase–conjugated secondary anti-
body for 1 hour at room temperature. Enhanced chemiluminesence detec-
tion reagent (Millipore) was applied to visualize the immunoreactive
bands at ChemiDoc MP (Millipore). In the figures, bands corresponding
to the respective proteins are displayed. Full lane blots corresponding to
Figs. 1 to 3 and figs. S1 and S3 are shown in data files S1 to S3.
In situ hybridization
Mouse tissue was available from experiments described previously (33).
Frozen brains were coronally sectioned in a cryostat microtome at 18 mm
and kept at −80°C. In situ hybridization using a 35S uridine triphosphate–
labeled ribonucleotide probe for BDNF (forward primer: 5′-GCGGCAGA-
TAAAAAGACTGC and reverse primer: 5′-AAGTTGTGCGCAAATG-
ACTG; size, 495 bp) was performed as described previously (75). The
slides were exposed to Kodak BioMax magnetic resonance films (Eastman
Kodak Co.) and developed. Autoradiographs were digitized, and expression
was determined by optical densitometry using the freely available National
Institutes of Health (NIH) ImageJ software. The mean of two unilateral mea-
surements (dorsal hippocampal subregions: CA1, CA2, CA3, and dentate
gyrus) was calculated for each animal, subtracting the background signal of
a nearby structure not expressing the gene of interest from the measurements.
Determination of BDNF
BDNF was quantified in the serum using the commercially available
enzyme-linked immunosorbent assay (ELISA) kit human BDNF DuoSet,
(R&D Systems, #DY248).
Subjects and preparation of human PBMCs
Human PBMCs were collected from 21 healthy male volunteers (average
age was 25.8 ± 2.7 years) for analysis of protein-protein correlations
(Fig. 5C). The same volunteers received 1.5 mg of dexamethasone (orally),
and protein expression changes in PBMCs were determined 6 hours later
(Fig. 5E). PBMCs fromanother group of volunteers (20men, average age of
34.8 ± 6.9 years) were collected for ex vivo cultivation and determination of
paroxetine effects (Fig. 5D). In addition, PBMCs were collected before and
after antidepressant treatment from 40 patients participating in the MARS
study (52) and diagnosed with depression according to the diagnostic crite-
ria of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
(DSM-IV; 23 women and 17 men, average age of 48.85 ± 14.7 years).
MARS is an open-label trial investigating outcome predictors for
antidepressant treatment. The type of treatment was chosen according
to the attending doctor’s choice and in agreement with the patients. Dos-
age was adjusted and monitored according to plasma medication con-
centrations. Treatment outcome was weekly evaluated with the 21 items
version of the HDRS. Fasting venous blood sampleswere collected through
venipuncture on admission and after 6 weeks of antidepressant treat-
ment. Samples were diluted with PBS, carefully loaded on Biocoll solu-
tion (BioChrom AG, L6113) and centrifuged at 800g for 20 min. PBMCs
were enriched by selecting the interphase of the Biocoll gradient, followed
by washing two times with ice-cold PBS. Cells were then resuspended in
RPMI and plated at 4 × 105/cm2. After recovery for 6 hours, cells were
treated with either 365 nM paroxetine or vehicle. This concentration has
been chosen to match therapeutic concentrations in the serum according
to the consensus guidelines for therapeutic drug monitoring in psychiatry
(51). Patients and healthy subjects gave informed written consent, and the
study was approved by the ethics committee of the Ludwig Maximilians
University in Munich, Germany.
Global methylation analysis
Total cytosine methylation and hydroxymethylation in genomic DNA from
rat astrocytes was determined by quantitative LC/UV-ESI-MS/MS analysis
of digested DNA samples as described previously (76).
Gene expression and DNA methylation profiling in
subjects from the Grady Trauma Project
Whole-blood samples were obtained from 365 subjects from the Grady
Trauma Project. The Grady Trauma Project is an ongoing study that in-
cludesmore than 6000 subjects from a highly traumatized, urban population
of low socioeconomic status and examines the role of genetic and
environmental factors on stress responses (49, 50). All subjects provided
written informed consent, and all procedures were approved by the Insti-
tutional Review Boards of the Emory University School of Medicine and
Grady Memorial Hospital.
To assess DNA methylation, whole-blood genomic DNA was
extracted using the Gentra Puregene Blood Kit (Qiagen). DNA quantity
and quality were assessed by Quant-iT PicoGreen (Invitrogen) and Nano-
Drop 2000 Spectrophotometer (Thermo Scientific). Subsequently, DNA
was bisulfite-convertedwith the ZymoEZ-96DNAMethylationKit (Zymo
Research), and DNA methylation was assessed with Illumina Human-
Methylation450 BeadChip (450K) arrays. Hybridization and processing
was performed as previously described (77). Quality control of methylation
data, including intensity readouts, normalization, and cellular composition
estimation, was carried out using the minfi Bioconductor R package ver-
sion 1.10.2 (78). Failed probeswere excluded on the basis of a detection of
P value greater than 0.01 in at least 75%of the samples (n=233 probes).We
also removed probes inXorYchromosome andnonspecific binding probes
(79) if single nucleotide polymorphisms (SNPs) were documented in the
interval for which the Illumina probe is designed to hybridize or if theywere
located close (10 bp fromquery site) to SNPs reported in the 1000Genomes
Project to have minor allele frequency ≥ 0.05 (80). Data were normalized
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with functional normalization included in the minfi R package (81). Batch
effects were identified after inspection of principal component analysis
using the shinyMethyl Bioconductor R package version 0.99.39 and re-
moved using COMBAT (82). As previously recommended (83), we used
M values to perform the statistical analyses involving DNA methylation
and bmethylationvalues tovisualize the relationshipswith gene expression.
To assess gene expression, whole-blood RNAwas collected with PAX-
geneBloodRNATubes (PreAnalytiX) and processed as previously described
(84). Blood RNAwas then hybridized to Illumina HumanHT-12 version
3 and version 4 Expression BeadChips (Illumina). Gene expression was
measured using the Illumina HumanHT-12 version 3 Expression BeadChip
Kit (Illumina). Raw microarray scan files were exported with the Illumina
BeadStudio program 13 and were analyzed with R (www.R-project.org).
Using Illumina internal controls, microarray data were transformed and
normalized through variance stabilizing normalization (85). Potential con-
founding as a result of batch effects was corrected using an empirical Bayes
method (82). Data reproducibility was confirmedwith six pairs of technical
replicates (average Pearson correlation = 0.996). The raw array data for the
Grady study have been deposited toGene ExpressionOmnibus (GEO) both
for gene expression (GSE58137) and DNA methylation (GSE72680).
DNMT1 activity assay
DNMT1 activity was measured as previously described (13), with the mod-
ification that astrocytes were also transfected with FKBP51, FKBP52, or
vector plasmids 3 days before cell harvesting.
Bdnf promoter methylation analysis
The methylation status of Bdnf promoters I and IV in mouse brain was
analyzed by bisulfite pyrosequencing. Briefly, total DNA was isolated
from specific brain regions using NucleoSpin Tissue (Macherey-Nagel),
according to the manufacturer’s instructions. After quantification, about
300 ng ofDNAwere bisulfite-converted using theEZDNAMethylationKit
(Zymo Research), and bisulfite-converted DNA samples were used as tem-
plates for polymerase chain reactions (PCRs) amplifying promoters I and
IVof theBdnf gene. Primers used for the bisulfite PCR and pyrosequencing
are provided in table S4. Pyrosequencing primers were designed with the
MethMarker software and carried out on a PSQ96 (Pyrosequencing) using
PyroMark Gold Q96 reagents (Qiagen) according to the manufacturer’s
recommendations.
Statistical analysis
Statistical analyses were performed with SigmaPlot 13.0 and SPSS 18.
Student’s t tests or Mann-Whitney tests were applied to compare two
groups, whereas one- or two-way analysis of variance (ANOVA)were per-
formed for comparisons between three or more groups, followed by
Bonferroni, Tukey’s, or Duncan’s post hoc test, as appropriate. Correla-
tions between variables were analyzed using the Pearson correlation co-
efficient. Treatment outcome in the patient sample was determined as
percent reduction of the HDRS rating scores between admission and after
6 weeks of antidepressant treatment. In case of an early discharge from the
hospital (after at least 2 weeks of antidepressant treatment), missing HDRS
scores were estimated using nonlinear regression with sex, age, and previ-
ous HDRS scores as predictor variables. P values lower than 0.05 were
considered statistically significant.
Ethics statement
All experiments were carried out in the animal facilities of the Max Planck
Institute of Psychiatry in Munich, Germany. The experiments were carried
out in accordance with the European Communities’ Council Directive
86/609/EEC. All efforts were made to minimize animal suffering during
the experiments. The protocols were approved by the committee for the
Care and Use of Laboratory Animals of the Government of Upper Bavaria,
Germany. Approval for theMARS project was received by the ethics com-
mittee in charge (submission no. 318/00, ethics committee of the Medical
Faculty at the Ludwig Maximilians University, Munich, Germany), and
participants gave oral and written consent before study inclusion.
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Fig. S1. DNMT protein interaction analysis.
Fig. S2. FKBP51 and FKBP52 differentially affect the phosphorylation and activity of
DNMT1.
Fig. S3. Paroxetine promotes FKBP51 binding to CDK5.
Fig. S4. FKBP51 shapes the effect of paroxetine on DNMT1.
Fig. S5. The effect of amitriptyline and haloperidol on the phosphorylation of DNMT1.
Fig. S6. The effect of amitriptyline on Bdnf promoter IV methylation.
Fig. S7. DNA methylation of Bdnf inversely correlates with the abundance of FKBP5 mRNA.
Fig. S8. Cellular and clinical change in the abundance of phosphorylated DNMT1 in
PBMCs in response to antidepressants.
Table S1. Pyrosequencing results of Bdnf promoter methylation analyses in wild-type and
51KO mice.
Table S2. Statistical details of ANOVA analysis by figure panel.
Table S3. Statistical details of Student’s t test or Mann-Whitney analysis by figure panel.
Table S4. Primers for bisulfite PCR and pyrosequencing.
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ABSTRACT 
Aging and stress-related phenotypes are associated with heightened inflammation and disease 
risk, but the underlying molecular mechanisms are unknown. We examined the role in these 
relations of the stress-responsive immunophilin FKBP5. In four independent human cohorts 
(total n=2,818), increasing age consistently decreased FKBP5 methylation at select CpGs, and 
this age-related demethylation was accelerated by depressive symptoms and childhood trauma 
and was associated with FKBP5 upregulation in human peripheral blood. FKBP5 
upregulation was associated with proinflammatory cellular and gene expression profiles and 
with extensive changes in NF-κB-related genes. In accordance, FKBP5 overexpression in 
immune cells promoted chemokine secretion, and it strengthened the interactions of 
regulatory kinases of NF-κB, but not in the presence of FKBP5 antagonists. Notably, the 
same age-and stress-related CpGs associated with FKBP5 upregulation were also 
demethylated in subjects with myocardial infarction. These findings identify FKBP5 as 
mediator of stress-driven peripheral inflammation and potential contributor to stress-related 
cardiovascular risk. 
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INTRODUCTION 
Aging is characterized by a progressive decline in functioning and a gradual increase in 
disease risk
1
, yet individuals of the same age exhibit substantial variability in their risk for 
developing age-related diseases. Among prevalent risk factors for disease risk, studies support 
the role of psychosocial stress and stress-related phenotypes, most notably chronic stress and 
childhood trauma
2-7
, as well as major depressive disorder (MDD) and posttraumatic stress 
disorder (PTSD)
8-10
. Studies further suggest that aging and stress-related phenotypes may 
synergistically influence disease risk by contributing to peripheral inflammation
8,11-15
, but the 
underlying molecular mechanisms are not well understood. 
The effects of stress on inflammation and disease risk could be mediated by stress-
responsive molecules able to modulate immune function. A relevant molecule to examine in 
this context is the immunophilin FK506-binding protein 51 (FKBP51/FKBP5), a co-
chaperone that is acutely induced by stress and glucocorticoid exposure and influences several 
biological pathways, including immune pathways in both cells and mice
16-31
. Interestingly, 
FKBP5 is not only upregulated by stress, but also in the aging brain
32,33
 and in a number of 
age-related disease phenotypes
24,26,27,32,34
. However, whether age also regulates FKBP5 in 
peripheral blood remains unknown. Moreover, given that FKBP5 can be regulated by stress-
induced epigenetic effects
35-38
, a plausible hypothesis is that stressors accumulating along the 
lifespan could lead to a lasting epigenetic upregulation of FKBP5 that may contribute to 
peripheral inflammation and disease risk.  
Here we address these questions using both human cohorts and cellular models. In 
living humans, increasing age and stress-related phenotypes interact to epigenetically 
upregulate FKBP5 in peripheral blood, an effect that contributes to a proinflammatory blood 
cell composition and gene expression profile and altered NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells) expression network. In immune cells, FKBP5 
overexpression promotes chemokine secretion through physical interactions with key 
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regulators of the NF- κB pathway, whereas these effects can be prevented by concomitant 
treatment with FKBP5 antagonists. Notably, the same age-and stress-related epigenetic 
signatures associated with FKBP5 upregulation are also observed in subjects with history of 
myocardial infarction, a condition associated with inflammatory states. These findings 
provide molecular insights into the mechanisms through which stress-related phenotypes 
contribute to peripheral inflammation and cardiovascular risk. 
 
RESULTS 
FKBP5 methylation decreases along the lifespan at select CpGs 
Epigenetic changes occur at susceptible genomic sites throughout life largely as a result of 
environmental factors
39
. This so-called “epigenetic drift” may account for interindividual 
variability in genomic function and disease risk
40
. To identify FKBP5 sites that may be 
particularly susceptible to environmental factors, including stress exposure along the lifespan, 
we first examined how FKBP5 methylation changes with increasing age using Illumina 
HumanMethylation450 BeadChip array (450K) data from the Grady Trauma Project (GTP; 
n=393), the Cooperative Health Research in the Region of Augsburg (KORA; n=1,727), and 
the Max Planck Institute of Psychiatry cohort (MPIP; n=538) (for demographics see 
Supplementary Table 1). These analyses included all available cytosine-guanine 
dinucleotides (CpGs) covered by the 450K that are located within or in close proximity (10kb 
upstream or downstream) to the FKBP5 locus. After controlling for confounders (see 
Methods) and FDR correction for multiple comparisons, two CpGs (cg20813374 and 
cg00130530) were consistently and robustly demethylated with age across all cohorts (FDR 
q<0.05; Supplementary Table 2). Based on previous annotation of the 450K array
41
, the two 
age-regulated sites are located in close proximity to each other within non-island genomic 
regions close to the FKBP5 transcription start site (TSS) (-461bp for cg20813374 and -483bp 
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for cg00130530; Supplementary Table 2). The two CpGs showed significant pairwise 
correlations across cohorts (GTP: r = 0.83, p<2.2 x 10
-16
; KORA: r = 0.61, p<2.2 x 10
-16
; 
MPIP r = 0.37, p<2.2 x 10
-16
). The adjusted effect of age on average methylation of the two 
age-regulated CpGs for all cohorts is depicted on Fig. 1a.  
 
Childhood trauma and depressive phenotypes accelerate demethylation of the age-
regulated FKBP5 CpGs 
Given that stress exposure can induce demethylation of FKBP5
30,35
, it is plausible that higher 
burden of stress or psychopathology across the lifespan could accelerate demethylation of the 
age-regulated FKBP5 CpGs. To address this hypothesis, we examined the interactive effects 
between age and stress-related phenotypes on the age-regulated CpGs. After adjusting for all 
covariates (see Methods), depressive symptoms significantly accelerated age-related 
demethylation of FKBP5 in the GTP, KORA, and MPIP (total n=2,250, meta-analysis 
interaction p=3 x 10
-2
; Fig. 1b) In contrast, we observed no significant acceleration by 
childhood maltreatment, lifetime stress, or PTSD in the GTP, where these phenotypes were 
available. Because MDD has been shown to influence disease profiles by interacting with 
childhood trauma
8
, we further examined whether the effect of depression on age-related 
FKBP5 demethylation is moderated by childhood trauma severity as measured with the 
childhood trauma questionnaire (CTQ) in the GTP. This stratified analysis yielded a 
significant age-depression interaction in the higher-CTQ (interaction p=4.6 x 10
-2
) but not the 
lower-CTQ group (interaction p=3.3 x 10
-1
). Lastly, to examine whether exposure to a severe 
and prolonged childhood stressor is sufficient to induce lasting demethylation of the age-
regulated CpGs, we compared subjects that underwent prolonged early childhood separation 
from their parents with sex- and age-matched nonseparated controls in the Helsinki Birth 
Cohort Study (HBCS; n=160, for demographics see Supplementary Table 1). Separation 
was associated with demethylation of the age-regulated CpGs (p=7.4 x 10
-3
; Fig. 1c). 
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Together, these findings suggest that childhood trauma and depressive phenotypes synergize 
to accelerate age-related demethylation of FKBP5.  
 
Aging and stress-related phenotypes epigenetically upregulate FKBP5 in peripheral 
blood 
Changes in DNA methylation can shape gene expression, eventually contributing to cellular 
function and phenotypic expression
42-44
. To examine whether age-related changes in FKBP5 
methylation influence FKBP5 expression levels, we used FKBP5 mRNA data measured in the 
GTP cohort with Illumina HumanHT-12 v3 and v4 Expression BeadChip arrays (n=355). 
After controlling for confounders (see Methods), FKBP5 expression negatively correlated 
with methylation of the age-regulated sites (p=1.6 x 10
-2
; Fig. 2a). Given that FKBP5 mRNA 
is robustly induced by glucocorticoids
30,45
, we next examined whether age-related FKBP5 
demethylation moderates the effect of cortisol on FKBP5 expression. After confirming a 
strong positive association between cortisol and FKBP5 levels (p=2.3 x 10
-9
), we found that 
the cortisol-FKBP5 relationship was stronger at lower as compared to higher methylation 
levels (interaction p=1.4 x 10
-3
), as well as in older as compared to younger subjects 
(interaction p=2.4 x 10
-5
) (Fig. 2b). Furthermore, depressive symptoms strengthened the 
cortisol-FKBP5 relationship but only in the high-CTQ group (interaction p = 7.3 x 10
-5
) 
(Figure 2c). Overall, these findings indicate that increasing age interacts with stress-related 
phenotypes to epigenetically upregulate FKBP5. 
 
FKBP5 upregulation promotes NF-κB-driven peripheral inflammation and chemotaxis 
FKBP5 upregulation has been previously linked with the development of aberrant 
phenotypes, an effect that may be driven by alterations in distinct biological pathways
24-
27,32,34,46,47
. To examine the genome-wide functional implications of FKBP5 in peripheral 
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blood, we correlated the FKBP5 expression levels with all genes in the GTP (n=355). After 
FDR correction for multiple comparisons, FKBP5 showed significant correlation (FDR-
adjusted p<0.05) with a total of 3,275 genes (Supplementary Table 3). Using these genes as 
input and the unique array genes expressed above background (except FKBP5) as the 
reference set of genes (9,538 genes), we then performed disease association analysis in 
WebGestalt. By far the strongest enrichment was observed for inflammation and was 
conferred by a total of 123 inflammation-related genes (FDR-adjusted p=9.2 x 10
-6
; Fig. 3a; 
Supplementary Table 3). Notably, FKBP5 showed strong positive associations with a host 
of proinflammatory genes, such as interleukin and toll-like receptors. To examine whether 
this proinflammatory profile may be explained by changes in peripheral blood composition, 
we correlated FKBP5 expression levels with blood cell proportions. Higher FKBP5 levels 
correlated with increased granulocyte to lymphocyte (G/L) ratio (p=8.3 x 10
-9
; 
(Supplementary Fig. 1), suggesting that FKBP5 upregulation is associated with enhanced 
chemotaxis of proinflammatory cells. To test this hypothesis, we overexpressed FKBP5 in 
Jurkat T cells (≈3.2-fold induction; Fig. 3b) and tested their potential to secrete interleukin-8 
(IL-8), a major chemokine that promotes granulocyte chemotaxis and peripheral 
inflammation. FKBP5 overexpression nearly doubled secretion of IL-8 upon immune 
stimulation (p=4.4 x 10
-7
; Fig. 3c). 
To examine whether the proinflammatory effect of FKBP5 may be driven by distinct 
transcription factors, we then performed transcription factor target analysis in the GTP using 
the same input and reference gene sets (3,275/9,538). The strongest enrichment was observed 
for NF-κB (FDR-adjusted adjusted p=4.8 x 10
-3
; Figure 3a; Supplementary Table 3), a 
master immune regulator that can be influenced by FKBP5
20,26
. To experimentally confirm 
that FKBP5 upregulation promotes NF-κB signaling in immune cells, we performed dual-
luciferase reporter assays comparing NF-κB activity between Jurkat cells overexpressing 
FKBP5 and cells expressing control vector. FKBP5 overexpression resulted in increased NF-
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κB activity following immune stimulation (Fig. 3d). Taken together, these findings indicate 
that FKBP5 upregulation in peripheral blood promotes peripheral inflammation through 
effects on NF-κB signaling. Therefore, our further analyses sought to better characterize the 
mechanisms via which FKBP5 impacts the NF-κB pathway. 
 
FKBP5 expression changes are associated with extensive alterations in the NF-κB co-
expression network 
To determine the effect of FKBP5 on NF-κB signaling, we used gene expression data in the 
GTP (n=355) to calculate the pairwise correlations between genes encoding molecules that 
directly interact along the NF-κB pathway, and we adjusted each pairwise correlation for the 
expression levels of all other partners in the pathway. These partial pairwise correlations were 
then compared between subjects with higher and those with lower FKBP5 expression levels 
(see Methods). As shown arithmetically in Supplementary Table 4 and schematically in Fig. 
3e, several partial pairwise correlations significantly differed between the two groups. The 
strongest effect was noted for the MAP3K14-CHUK pair (rlow FKBP5 = 0.13 vs. rhigh FKBP5 = -
0.28, p = 1.9 x 10
-3
), and this effect remained robust after controlling for sex, age, cortisol, 
and blood cell proportions (p=7.1 x 10
-3
), indicating that the effects of FKBP5 on NF-κB 
signaling are independent of changes in cortisol levels or blood cell composition. 
 
FKBP5 upregulation promotes NF-κB signaling by strengthening the interaction of key 
regulatory kinases, whereas these effects are prevented by FKBP5 antagonists 
Because FKBP5 acts as a molecular co-chaperone, its effects on NF-κB signaling could result 
from physical interactions of this co-chaperone with regulators of the NF-κB pathway. 
Intriguingly, MAP3K14 and CHUK, the gene pair most profoundly influenced by changes in 
FKBP5 levels (Fig. 3e), encode respectively the NF-kappa-B-inducing kinase (NIK) and the 
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antagonist of nuclear factor kappa-B kinase subunit alpha (IKK-α), two key regulatory 
kinases of the non-canonical NF-κB pathway. Specifically, NIK interacts with and 
phosphorylates IKKα at serine 176 (pIKKα
S176
), and this phosphorylation event activates 
IKKα and facilitates NF-κB signaling
48,49
.  
 To examine whether FKBP5 modulates the NIK-IKKα interaction complex, we 
performed a series of co-immunoprecipitation experiments in human Jurkat cell lines and 
peripheral blood monocytes (PBMC). These experiments showed an interaction of FKBP5 
with both NIK and IKKα and an interaction between NIK and IKKα (Fig. 4a). We then 
examined whether FKBP5 upregulation can strengthen the FKBP5-NIK-IKKα interaction, by 
stimulating both cell types with the glucocorticoid receptor agonist (DEX), which robustly 
induces FKBP5 expression
45,47,50
. After confirming the induction (≈2.2-fold) of FKBP5 by 
DEX (Fig. 4a), we found that DEX treatment significantly increased the physical interaction 
among FKBP5, NIK, and IKKα in both Jurkat cells and PBMC, whereas this enhancement 
was abolished by concomitant treatment with the recently developed, selective FKBP5 
antagonist SAFit1
51
 in both cell types (Fig. 4a,b). These effects were accompanied by an 
increase in the functional phosphorylation of IKKα at serine 176 (pIKKα
S176
), whereas 
pIKKα
S176 
induction was abolished by treatment with SAFit1 (Fig. 4c). The effect on 
pIKKα
S176 
was recapitulated by FKBP5 overexpression in Jurkat cells (Fig. 4d). Furthermore, 
FKBP5 overexpression nearly doubled NF-κB activity in Jurkat cells, whereas this effect was 
again prevented by concomitant treatment with SAFit1 (Fig. 4e). These findings support a 
model whereby FKBP5 upregulation promotes NIK-IKKα interaction, pIKKα
S176
, and NF-κB 
signaling, whereas these effects are prevented by concomitant treatment with selective 
FKBP5 antagonists (Fig. 4f). 
 
Age-related FKBP5 demethylation is associated with history of myocardial infarction 
Epigenetics of stress and aging   56 
  
 
Besides the potential role of DNA methylation in the causality of disease states, recent studies 
suggest that methylation signatures, including those at stress-responsive loci, may hold 
promise as biomarkers for disease phenotypes
40,52,53
. Specifically, the converging findings 
presented above ―indicating that demethylation of the age-regulated CpGs upregulates 
FKBP5, which in turn promotes peripheral inflammation― prompted us to ask whether 
demethylation of the same CpGs is also associated with inflammation-related disease. 
Inflammatory markers in peripheral blood, and in particular, IL-8 secretion and the G/L ratio 
shown here to increase with FKBP5 upregulation, have been linked with increased risk for 
cardiovascular disease, most notably acute coronary syndromes
54-57
. To examine whether 
lower methylation of the age-regulated FKBP5 CpGs is associated with acute cardiovascular 
risk, we used data on self-reported history of myocardial infarction (MI) that were available in 
the KORA and the MPIP. After controlling for potential confounders (see Methods), 
methylation of the age-regulated sites was significantly lower in individuals with positive 
history for MI in both cohorts (KORA: p = 4.4 x 10
-2
; MPIP: p = 3.1 x 10
-2
; Fig. 5).  
 
DISCUSSION 
Psychosocial stress and related phenotypes are prevalent throughout life and may confer risk 
for several disease phenotypes, including cardiovascular disease. While the underlying 
molecular mechanisms are not well understood, stress-related phenotypes have been 
associated with peripheral inflammation
8,11-13,15
, a process that contributes to vascular 
pathology and disease risk
54-57
. Among potential mediators of stress-driven inflammation, the 
present study examined the role of the stress-responsive immunophilin FKBP5. Our findings 
support a model whereby aging and stress-related phenotypes interact to epigenetically 
upregulate FKBP5, an effect that promotes NF-κB-driven peripheral inflammation (Fig. 6). 
Mechanistically, the effects of FKBP5 upregulation on immune function may be in part 
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mediated by its physical interactions with key regulatory kinases of the NF-κB pathway that 
are amenable to treatment with FKBP5 antagonists. Importantly, the same age-and stress-
related epigenetic signatures associated with FKBP5 upregulation are also observed in 
subjects with history of myocardial infarction, suggesting their relevance for heightened 
cardiovascular risk.  
The present study shows that FKBP5 methylation is influenced by a complex interplay 
among increasing age, childhood trauma, and depressive symptoms (Fig. 1). Focusing on age-
regulated FKBP5 CpGs as potential sites of stress-induced epigenetic drift, we found that 
depressive symptoms accelerate demethylation of the age-regulated sites. By contrast, 
childhood trauma exerted both direct effects, as observed in subjects with prolonged early life 
separation, and indirect effects, as seen by its ability to moderate the effect of depression on 
age-regulated CpGs. While the cross-sectional nature of these analyses does not allow safe 
causal inferences, our findings extend previous studies supporting the cumulative impact of 
lifetime stress on the methylome and the potential of childhood trauma to moderate the 
epigenetic effects of subsequent adult stressors
52,58
. Notably, both childhood trauma and 
depressive symptoms led to decreases in FKBP5 methylation; this is consistent with studies 
showing that FKBP5 and other stress-responsive sites undergo demethylation upon stress and 
glucocorticoid exposure
35,38,52,59
. Together these findings provide novel insights, but also raise 
intriguing questions, into the mechanisms through which stressful experiences of different 
types, timing, and duration may interact to induce and stabilize changes in methylation of 
stress-responsive CpGs along the lifespan. 
The effect of aging and stress-related phenotypes on FKBP5 methylation is in turn 
associated with a modest increase in FKBP5 expression and robust strengthening of the 
cortisol-FKBP5 relationship in peripheral blood (Fig. 2). These findings suggest that older 
individuals with higher stress burden are likely to show exaggerated FKBP5 levels in 
peripheral blood both at baseline and, most notably, upon stress exposure, when blood cortisol 
Epigenetics of stress and aging   58 
  
 
rises. While in many cases dynamic FKBP5 responses favor adaptations to organismal and 
cellular stress
60-63
, FKBP5 upregulation has also been linked with the development of aberrant 
phenotypes
24-27,32,34,46,47
. The phenotypic outcome may depend on the context of stress 
exposure and the pleiotropic effects of FKBP5 on downstream biological pathways
30,62,64,65
.  
In the present study, converging evidence in both living humans and immune cells 
shows that FKBP5 upregulation contributes to peripheral inflammation by promoting NF-κB 
signaling and secretion of the NF-κB target IL-8
66
 (Fig. 3). The FKBP5-driven secretion of 
IL-8 in Jurkat T cells extends a previous study showing that FKBP5 downregulation 
suppresses NF-κB-mediated production of IL-8 in melanoma cells
29
. In turn, the 
proinflammatory effect of FKBP5 we observe in peripheral blood may in part be explained by 
the IL-8-mediated recruitment of granulocytes in peripheral blood
67
, a possibility supported 
by the positive association we observe between FKBP5 levels and the G/L ratio 
(Supplementary Fig. 3). Higher G/L ratio and IL-8 levels are associated with heightened 
cardiovascular risk and mortality
54-56
, and because FKBP5 is the most robustly induced gene 
by glucocorticoids in human blood
45
, older inidividuals with higher levels of stress exposure 
―who have epigenetic upregulation of FKBP5― may be more prone to stress-induced 
peripheral inflammation and vascular pathology. This pathogenic cascade could explain the 
association we observe between FKBP5 demethylation and history of MI (Fig. 5) and 
provides molecular insights into previous associations of stress-related phenotypes with 
heightened inflammation and cardiovascular risk
2,3,6,7,9,10
. 
Although FKBP5 has been previously shown to influence various players of the NF-
κB pathway, to our knowledge this is the first study to uncover the interaction of FKBP5 with 
NIK and the functional modulation of the NIK-IKKα interaction upon FKBP5 upregulation 
and glucocorticoid exposure (Fig. 4). The FKBP5-mediated induction of NF-κB activity, 
which we observe here, is in accordance with the majority of previous studies showing that 
downregulation of FKBP5 inhibits NF-κB signaling
19-21,23,24,26-29,31
, though opposite effects 
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have been reported in select cell lines
22
. We also show for the first time the effect of FKBP5 
on NF-κB signaling in Jurkat T cells and PBMC, both relevant cellular models of peripheral 
inflammation. Strikingly, the FKBP5-driven induction of NF-κB can be prevented with 
concomitant use of FKBP5 antagonists (SAFit1). By contrast, as shown both here and in a 
previous study
51
, SAFit1 has no effects on immune function under baseline FKBP5 levels, 
suggesting that FKBP5 antagonists could prevent the undesirable effects of stress only if 
targeted at immune systems with upregulated FKBP5.  
In conclusion, the present study shows that the immunophilin FKBP5 mediates stress-
driven peripheral inflammation, potentially contributing to stress-related cardiovascular risk. 
While the impact of stress on disease risk is undoubtedly mediated by multiple molecules 
―each having pleitropic effects on downstream pathways― the present study exemplifies 
how examining relevant molecules, by using converging evidence from both human cohorts 
and cellular models, can provide insights into how stress-related phenotypes could shape 
disease risk at the molecular level. 
 
 
 
 
 
 
 
 
 
 
 
 
Epigenetics of stress and aging   60 
  
 
Figure 1. Childhood trauma and depressive phenotypes accelerate age-related demethylation 
of FKBP5. (a) Methylation decreases at age-regulated FKBP5 CpGs along the lifespan (GTP: 
βage = -0.0045, p = 8 x 10
-8
; KORA: βage = - 0.0055, p < 2 x 10
-16
; MPIP: βage = -0.0066, p = 
2.1 x 10
-8
; total n = 2,818). (b) Depressive phenotypes accelerate age-related FKBP5 
demethylation (GTP: βage for moderate/severe depression = -0.0075 vs. βage for no/mild 
depression = -0.0032; KORA: βage for moderate/severe depression = -0.0063 vs. βage for 
no/mild depression = -0.0047; MPIP: βage for depressed = -0.0078 vs. βage for non-depressed = 
-0.0047; total n = 2,250, meta-analysis interaction p = 3 x 10
-2
, heterogeneity p = 2.8 x 10-1). 
(c) Early life separation is associated with demethylation of the age-regulated FKBP5 CpGs in 
the HBCS (βseparation = -0.0932, mean DNA methylation difference = 1.4%, p=7.4 x 10
-3
). In 
all panels, the average methylation of the two age-regulated CpGs (cg20813374 and 
cg00130530) is depicted. The age-regulated CpGs were determined after examining all 450K-
covered CpGs within or in close proximity (10kb upstream or downstream) to the FKBP5 
locus (Supplementary Table 2). All coefficients and p values are derived from models using 
M-values for DNA methylation and after correcting for covariates (see Methods). ** p < 10
-2
. 
GTP, Grady Trauma Project; HBCS, Helsinki Birth Cohort Study; KORA, Cooperative 
Health Research in the Region of Augsburg F4 community study; MPIP, Max Planck Institute 
of Psychiatry case/control study. 
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Figure 2. Aging and stress-related phenotypes epigenetically upregulate FKBP5 in peripheral 
blood in the Grady Trauma Project (n = 355). (a) FKBP5 expression levels are negatively 
associated with average methylation of the age-regulated sites (β = -0.3835, p=1.6 x 10
-2
). (b) 
The cortisol-FKBP5 relationship is stronger at lower methylation levels of the age-regulated 
CpGs (interaction p=1.4 x 10
-3
, βcortisol for lower methylation = 0.0299 vs. βcortisol for higher 
methylation = 0.0069) and in older ages (interaction p=2.4 x 10
-5
, βcortisol for older subjects = 
0.0376 vs. βcortisol for younger subjects = 0.0075). (c) Depressive symptoms strengthen the 
cortisol-DFKBP5 relationship only in subjects with higher levels of childhood trauma (higher-
CTQ group: interaction p=7.3 x 10
-5
; lower-CTQ group: interaction p=1.4 x 10
-1
). For all 
stratified analyses, we performed median splits of the respective continuous variables. All 
coefficients and p values are derived from models using M-values for DNA methylation and 
after correcting for covariates (see Methods). CTQ, Childhood Trauma Questionnaire. 
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Figure 3. FKBP5 upregulation promotes NF-κB-driven peripheral inflammation. (a) FKBP5-
related genes in peripheral blood show enrichment for inflammation-related genes and NF-κB 
gene targets. Disease association and transcription factor target analyses were performed 
using genome-wide gene expression data in the Grady Trauma Project (GTP; n = 355). The 
number of genes for each analysis is shown in parentheses. Statistical details are provided in 
Supplementary Table 3. (b) Control experiment confirming FKBP5 overexpression in Jurkat 
T cells transfected with FKBP51-FLAG vs. cells transfected with the control vector. (c) 
FKBP5 overexpression nearly doubles IL-8 secretion by stimulated Jurkat T cells. The bar 
graph depicts IL-8 secretion in stimulated cell supernatants measured with ELISA from two 
independent experiments (n = 8 per condition). For each experiment, fold ratios of IL-8 
secretion were calculated relative to stimulated cells expressing the control vector. IL-8 was 
undetectable in non-stimulated cells (not shown). (d) FKBP5 overexpression increases NF-κB 
activity in stimulated Jurkat T cells. The bar graph depicts NF-κB reporter activity in 
stimulated cells measured with dual-luciferase reporter assays from three independent 
experiments (n = 9 per condition). For each experiment, fold ratios of NF-κB activity were 
calculated relative to non-stimulated cells expressing the control vector. (e) FKBP5 
expression changes are associated with extensive alterations in the NF-κB co-expression 
network in the GTP (n = 355). Stratification in higher- and lower-FKBP5 expression groups 
was performed by a median split of FKBP5 expression levels. The circles depict all genes 
encoding molecular partners of the NF-κB pathway. Pairwise correlations (blue lines) have 
been corrected for expression levels of all other genes in the pathway. Continuous lines show 
positive and dotted lines negative correlations. The thickness of each line corresponds to 
correlation strength for each pair. The gene pair with the most robust difference in correlation 
between the two groups (CHUK-MAP3K14) is highlighted in orange. Statistical details are 
provided in Supplementary Table 4. ** p < 10
-2
; *** p < 10
-3
. 
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Figure 4. FKBP5 upregulation promotes NF-κB signaling by strengthening the interaction of 
key regulatory kinases, whereas these effects are prevented by FKBP5 antagonists. (a) 
Immunoprecipitation (IP) for either FKBP5 or NIK followed by Western blotting in lysates 
from Jurkat T cells or peripheral blood monocytes (PBMC) treated with dexamethasone 
(DEX) and/or selective FKBP5 antagonists (SAFit1). Control: without primary antibody 
(IgG). (b) Quantifications of respective IPs, overall showing DEX-induced increase in 
FKBP5-NIK-IKKα interactions, which is prevented by concomitant treatment with SAFit1 (n 
= 3 biological replicates per condition). (c and d) Western blotting in Jurkat and PBMC 
lysates, overall showing increase in the functional phosphorylation of IKKα at serine 176 
(pIKKα) by DEX treatment (c) and FKBP5 overexpression (d), both of which are prevented 
by SAFit1 treatment (n = 3-4 per condition). (e) FKBP5 overexpression increases NF-κB 
activity in stimulated Jurkat T cells, whereas this increase is prevented by concomitant 
treatment with SAFit1. The bar graph depicts NF-κB reporter activity measured with dual-
luciferase reporter assays from three independent experiments (n = 9 per condition). For each 
experiment, fold ratios of NF-κB activity were calculated by comparison to cells expressing 
the control vector. (e) Scheme summarizing the model supported by the IP and Western data. 
FKBP5 upregulation, which can be induced by DEX, strengthens the NIK-IKKα interaction, 
thereby inducing pIKKα and NF-κB signaling. These effects on NF-κB signaling are 
prevented by concomitant treatment with SAFit. All statistical comparisons were performed 
with two-way ANOVAs, and significant two-way interactions were followed by Bonferroni-
corrected pairwise comparisons. * p < 5 x 10
-2
; ** p < 10
-2
; *** p < 10
-3
, significant pairwise 
comparisons. 
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Figure 5. Age-related FKBP5 demethylation is associated with history of myocardial 
infarction. KORA: N = 1,648 subjects without vs. 62 with history of MI, p = 4.4 x 10
-2
, mean 
DNA methylation difference = 1.8%; MPIP: N = 310 subjects without vs. 8 with history of 
MI, p = 3.1 x 10
-2
, mean DNA methylation difference = 4.8%. All p values are derived from 
models using M-values for DNA methylation and after correcting for covariates (see 
Methods). 
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Figure 6. Conceptual scheme summarizing the model supported by the study’s findings. 
Aging, childhood trauma, and depressive symptoms interact to demethylate FKBP5 at select 
CpGs located 483 bp (cg00130530) and 461bp (cg20813374) upstream from the transcription 
start site (TSS). These effects derepress FKBP5 responses in peripheral blood upon stress 
and/or cortisol exposure. FKBP5 upregulation promotes NF-κB signaling, whereas this effect 
is prevented by concomitant treatment with FKBP5 antagonists. Disinhibited FKBP5 
responses may lead to enhanced chemotaxis of proinflammatory cells and peripheral 
inflammation, potentially contributing to stress-related cardiovascular risk. 
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Supplementary Figure 1. Correlation between FKBP5 expression levels and the granulocyte 
to lymphocyte ratio, a marker of proinflammation that predicts heightened cardiovascular 
risk
54
. The reported p value is after controlling for covariates (see Methods). 
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Supplementary Table 1. Demographics and characteristics of study cohorts 
 Grady 
(n=411) 
KORA 
(n=1,727) 
MPIP 
(n=538) 
HBCS 
(n=160) 
Age, mean, range (SD) 41.4, 18-77 
(13) 
61, 32-81 
(8.9) 
47.7, 18-87 
(13.4) 
63.5, 58-69 
(2.8) 
Sex, n (%) 
        Male 
        Female 
 
119 (29) 
292 (71) 
 
845 (48.9) 
882 (51.1) 
 
229 (42.6) 
309 (57.4) 
 
160 (100) 
NA 
Race, n (%) 
        AA 
        Caucasian 
        Other 
 
411 (100) 
NA 
NA 
 
NA 
1,727 (100) 
NA 
 
NA 
538 (100) 
NA 
 
NA 
160 (100) 
NA 
CTQ, mean (SD) 42.6 (18.3) NA NA NA 
Severity of depressive 
symptoms (BDI), n (%) 
          Low 
          High 
 
 
250 (64.6) 
137 (35.4) 
 
 
NA 
NA 
 
 
NA 
NA 
 
 
NA 
NA 
Depressed mood/exhaustion 
(DEEX), n (%) 
          Low 
          High 
 
 
NA 
NA 
 
 
957 (65.2) 
510 (34.8) 
 
 
NA 
NA 
 
 
NA 
NA 
Depressed cases/controls, n 
(%) 
          Nondepressed 
          Depressed 
 
 
NA 
NA 
 
 
NA 
NA 
 
 
209 (39.1) 
325 (60.9) 
 
 
NA 
NA 
Early separation, n (%) 
Separated 
Nonseparated 
 
NA 
NA 
 
NA 
NA 
 
NA 
NA 
 
80 (50) 
80 (50) 
Available 450K data, n 393 1,727 538 160 
Available gene expression 
data, n 
355 NA NA NA 
 
Supplementary Table 2
name #bin chrom chromStart chromEnd score strand thickStart
cg20813374 857 chr6 35657180 35657181 120 - 35657180
cg00130530 857 chr6 35657202 35657203 114 - 35657202
cg18357736 857 chr6 35705548 35705549 134 + 35705548
cg23873288 857 chr6 35705850 35705851 477 + 35705850
cg25114611 857 chr6 35696870 35696871 521 - 35696870
cg13719443 857 chr6 35700381 35700382 142 + 35700381
cg19014730 856 chr6 35635984 35635985 648 + 35635984
cg25994725 857 chr6 35703435 35703436 572 - 35703435
cg14642437 857 chr6 35652521 35652522 920 - 35652521
cg03591753 857 chr6 35659140 35659141 736 + 35659140
cg07944278 857 chr6 35699424 35699425 51 + 35699424
cg14284211 856 chr6 35570223 35570224 332 + 35570223
cg17085721 856 chr6 35645341 35645342 910 - 35645341
cg05741161 857 chr6 35699498 35699499 71 + 35699498
cg07061368 856 chr6 35631735 35631736 847 + 35631735
cg21626086 857 chr6 35704928 35704929 764 - 35704928
cg00610228 857 chr6 35695933 35695934 79 + 35695933
cg07485685 857 chr6 35696060 35696061 32 + 35696060
cg00862770 857 chr6 35655763 35655764 41 + 35655763
cg06937024 857 chr6 35695489 35695490 33 - 35695489
cg08915438 857 chr6 35697759 35697760 741 - 35697759
cg10913456 857 chr6 35656589 35656590 15 + 35656589
cg22211300 857 chr6 35704822 35704823 795 - 35704822
cg26868354 857 chr6 35699951 35699952 52 + 35699951
cg01294490 857 chr6 35656905 35656906 93 + 35656905
cg01321308 857 chr6 35704223 35704224 64 + 35704223
cg02665568 856 chr6 35544467 35544468 846 + 35544467
cg10780318 857 chr6 35704148 35704149 77 + 35704148
cg16052510 856 chr6 35603143 35603144 812 - 35603143
cg19226017 857 chr6 35697184 35697185 839 + 35697184
cg07633853 856 chr6 35569471 35569472 433 - 35569471
cg18726036 856 chr6 35543610 35543611 937 - 35543610
cg03546163 857 chr6 35654363 35654364 724 - 35654363
cg23416081 857 chr6 35693572 35693573 621 + 35693572
cg08586216 856 chr6 35612351 35612352 908 - 35612351
cg08636224 857 chr6 35657921 35657922 881 - 35657921
cg00140191 857 chr6 35656242 35656243 37 - 35656242
cg11845071 857 chr6 35695859 35695860 17 - 35695859
cg06087101 856 chr6 35551932 35551933 85 - 35551932
cg07843056 857 chr6 35656847 35656848 11 + 35656847
cg10300814 856 chr6 35565116 35565117 897 - 35565116
cg15929276 857 chr6 35687456 35687457 112 + 35687456
cg16012111 857 chr6 35656757 35656758 63 + 35656757
cg17030679 857 chr6 35696299 35696300 92 + 35696299
cg00052684 857 chr6 35694245 35694246 665 - 35694245
Effects of age in the Grady Effects of age in the KORA
thickEnd itemRgb Coefficient t value p value q value Coefficient t value p value
35657181 0,0,205 -0.0054607 -6.11751 3.22E-09 1.42E-07 -0.00736 -12.6943 2.37E-35
35657203 0,0,205 -0.0038199 -4.08717 5.72E-05 1.26E-03 -0.00407 -6.64303 4.12E-11
35705549 0,0,205 -0.0029015 -3.60401 0.000371 0.005444 -0.00492 -5.6474 1.9E-08
35705851 128,0,128 -0.0029819 -3.05615 0.00246 0.02706 -0.00054 -0.74372 0.457148
35696871 128,0,128 -0.0021073 -2.77685 0.005862 0.051584 -0.00298 -5.43903 6.13E-08
35700382 0,0,205 -0.0024314 -2.63532 0.008878 0.065103 -0.00147 -2.56969 0.010263
35635985 255,127,0 -0.0033178 -2.5419 0.011568 0.072716 -0.00197 -1.50514 0.132473
35703436 128,0,128 -0.0021795 -2.46129 0.014451 0.079483 -0.00319 -3.01026 0.002648
35652522 255,127,0 -0.002673 -2.13716 0.033458 0.163571 -0.00154 -1.25236 0.210612
35659141 255,127,0 0.00117248 1.859871 0.06396 0.23452 0.000417 1.258235 0.208479
35699425 0,0,205 0.00307827 1.934743 0.054036 0.23452 0.006041 1.203135 0.22909
35570224 128,0,128 -0.0018162 -1.89744 0.058805 0.23452 -0.00168 -1.54423 0.122719
35645342 255,127,0 -0.001863 -1.79788 0.07328 0.248025 -0.00141 -1.00029 0.317315
35699499 0,0,205 -0.001172 -1.59164 0.112603 0.309658 -0.00017 -0.23048 0.81775
35631736 255,127,0 -0.0020621 -1.6114 0.108227 0.309658 -0.00435 -2.79372 0.005269
35704929 255,127,0 0.00129673 1.59924 0.110903 0.309658 -0.00033 -0.50164 0.615984
35695934 0,0,205 -0.0016398 -1.48257 0.139322 0.360597 0.001211 1.207049 0.22758
35696061 0,0,205 -0.0023459 -1.39365 0.164537 0.402202 -0.00331 -0.36892 0.712232
35655764 0,0,205 0.00121426 1.243536 0.214718 0.43187 0.00051 0.249271 0.803181
35695490 0,0,205 0.00320536 1.240233 0.215935 0.43187 -0.01218 -1.38721 0.165559
35697760 255,127,0 0.00186397 1.304645 0.193093 0.43187 -0.00102 -1.14243 0.253436
35656590 0,0,205 0.00271904 1.251844 0.211679 0.43187 0.004101 0.499023 0.617828
35704823 255,127,0 -0.0008445 -1.18181 0.238291 0.442686 -0.00101 -1.85953 0.063123
35699952 0,0,205 0.00084856 1.173837 0.241465 0.442686 0.0001 0.118814 0.905437
35656906 0,0,205 0.0010166 0.88074 0.37922 0.564982 0.000324 0.260912 0.794192
35704224 0,0,205 0.00061148 0.873269 0.38327 0.564982 -0.0005 -0.6469 0.51778
35544468 255,127,0 0.00110126 0.898657 0.369613 0.564982 -0.00089 -0.62598 0.531411
35704149 0,0,205 0.00077473 0.869699 0.385215 0.564982 0.000589 0.614234 0.539143
35603144 255,127,0 0.0015079 0.949422 0.343231 0.564982 -5.4E-05 -0.02958 0.976409
35697185 255,127,0 -0.0009848 -0.96894 0.333416 0.564982 0.00047 0.498083 0.61849
35569472 128,0,128 -0.0015421 -0.84451 0.399109 0.566477 0.010183 0.986322 0.324385
35543611 255,127,0 0.00100256 0.704214 0.481889 0.662597 -0.00219 -1.92149 0.054836
35654364 255,127,0 0.00124224 0.655363 0.512776 0.682124 -0.00398 -2.33511 0.019671
35693573 255,127,0 -0.0006283 -0.63324 0.527095 0.682124 -0.00169 -3.05802 0.002263
35612352 255,127,0 -0.0005937 -0.52724 0.59845 0.752337 0.00194 1.424833 0.154388
35657922 255,127,0 -0.0004224 -0.45937 0.64633 0.789958 0.0007 0.637144 0.524116
35656243 0,0,205 -0.0005857 -0.28974 0.772231 0.918329 -9.6E-05 -0.01242 0.990089
35695860 0,0,205 -0.0005065 -0.24204 0.808931 0.936657 -0.00549 -0.64994 0.515816
35551933 0,0,205 -1.65E-04 -0.07142 0.943114 0.969369 -0.00341 -2.72711 0.006454
35656848 0,0,205 -0.0001648 -0.03843 0.969369 0.969369 0.003979 0.435325 0.663383
35565117 255,127,0 -4.929E-05 -0.04863 0.961246 0.969369 -0.00152 -1.22509 0.220712
35687457 0,0,205 7.1538E-05 0.046326 0.963083 0.969369 -0.01368 -2.68774 0.007267
35656758 0,0,205 9.83E-05 0.095616 0.923894 0.969369 0.001839 1.452296 0.146603
35696300 0,0,205 1.41E-04 0.125257 0.900411 0.969369 -0.00128 -1.18822 0.234911
35694246 255,127,0 NA NA NA NA -0.00219 -1.88701 0.059334
Effects of age in the MPIP
q value Coefficient t value p value q value
1.06E-33 -0.008486326 -5.53062 5.11E-08 2.25E-06
9.28E-10 -0.005942286 -3.72754 0.000215 0.004731
2.85E-07 -0.0051099 -2.84359 0.00464 0.06435
0.709367 -0.000407146 -0.37192 0.710106 0.867907
6.9E-07 -0.003383814 -2.6931 0.007312 0.06435
0.046182 -0.003167353 -1.84487 0.065637 0.320892
0.37258 -0.001988293 -2.03017 0.042859 0.253446
0.019863 -0.001638524 -1.48727 0.137562 0.413116
0.422841 0.000207793 0.140263 0.888508 0.961746
0.422841 -0.001077513 -1.46904 0.142441 0.413116
0.422841 -7.77383E-05 -0.09972 0.920609 0.961746
0.368158 -0.003335117 -1.73301 0.0837 0.368282
0.521333 -5.4397E-05 -0.04799 0.961746 0.961746
0.87616 -0.000906078 -1.05628 0.291343 0.522004
0.033872 -0.000396566 -0.33158 0.74034 0.874458
0.752218 0.000434503 0.444536 0.656844 0.835057
0.422841 0.001132291 0.938634 0.348364 0.567704
0.821806 -0.001161764 -1.52611 0.127603 0.413116
0.87616 -0.000921469 -0.9548 0.340133 0.567704
0.392114 -0.00029627 -0.48165 0.630263 0.835057
0.438639 -0.00419694 -2.75134 0.006147 0.06435
0.752218 -0.001854449 -2.21668 0.027086 0.198633
0.202896 1.54E-04 0.178993 0.858015 0.961746
0.94755 -0.001766213 -1.99954 0.046081 0.253446
0.87616 -0.001616459 -1.37737 0.169002 0.413116
0.713572 -0.001390459 -1.31479 0.189174 0.438087
0.713572 0.001236426 1.055134 0.291865 0.522004
0.713572 -0.0018522 -1.51217 0.131112 0.413116
0.990089 0.001901819 1.044839 0.296593 0.522004
0.752218 0.001205412 0.897713 0.369763 0.57174
0.521333 0.000623096 0.437394 0.662011 0.835057
0.202896 0.001431617 1.08716 0.277481 0.522004
0.080473 7.88E-05 0.103827 0.917347 0.961746
0.019863 -0.001448144 -0.82473 0.409911 0.601203
0.38597 0.001096196 1.420029 0.156211 0.413116
0.713572 0.000743784 0.884529 0.376828 0.57174
0.990089 -5.69E-05 -0.07066 0.943699 0.961746
0.713572 0.000208683 0.311941 0.755213 0.874458
0.036306 -0.001256067 -0.79467 0.427178 0.606317
0.785585 -0.001377381 -1.42132 0.155835 0.413116
0.422841 0.001143342 1.164145 0.244911 0.515902
0.036337 -0.001611337 -1.40639 0.160219 0.413116
0.38597 0.000516412 0.434306 0.66425 0.835057
0.422841 -0.00139674 -1.1609 0.246226 0.515902
0.202896 NA NA NA NA
Disease Number of Genes
Inflammation 123
Bacterial Infections 56
Necrosis 106
Hydrops Fetalis 21
Hyperpigmentation 18
Gram-Negative Bacterial Infections 39
Common Cold 63
Respiratory Tract Infections 64
Melanosis 15
Bronchial Diseases 57
Supplementary Table 3
Statistics for significant diseases
C=235;O=123;E=80.73;R=1.52;rawP=7.57e-09;adjP=9.21e-06
C=97;O=56;E=33.32;R=1.68;rawP=1.87e-06;adjP=0.0011
C=216;O=106;E=74.20;R=1.43;rawP=4.61e-06;adjP=0.0015
C=27;O=21;E=9.28;R=2.26;rawP=4.80e-06;adjP=0.0015
C=22;O=18;E=7.56;R=2.38;rawP=6.59e-06;adjP=0.0016
C=64;O=39;E=21.99;R=1.77;rawP=1.18e-05;adjP=0.0024
C=120;O=63;E=41.22;R=1.53;rawP=3.02e-05;adjP=0.0053
C=123;O=64;E=42.26;R=1.51;rawP=3.77e-05;adjP=0.0057
C=20;O=15;E=6.87;R=2.18;rawP=0.0002;adjP=0.0221
C=112;O=57;E=38.48;R=1.48;rawP=0.0002;adjP=0.0221
Inflammation-related genes
Gene Symbol beta coefficient nominal p value fdr-adjust p value
MMP9 0.684081518 3.09E-10 2.53E-09
IL1R2 0.566654243 3.13E-27 1.28E-25
CEBPD 0.480668435 1.45E-22 3.76E-21
IL18R1 0.464453217 3.61E-28 2.22E-26
DUSP1 0.449429137 1.61E-18 2.48E-17
ORM1 0.445917893 1.73E-07 6.67E-07
NAMPT 0.435025537 1.08E-08 5.77E-08
IL13RA1 0.41581729 7.87E-18 9.68E-17
IRAK3 0.407098117 1.53E-22 3.76E-21
TLR8 0.388715476 2.17E-16 2.43E-15
TLR2 0.387400934 2.90E-29 3.56E-27
TLR4 0.384626067 4.95E-20 1.02E-18
FPR2 0.377356641 2.21E-08 1.09E-07
TLR5 0.367479198 1.16E-09 8.37E-09
CD163 0.335881522 5.67E-19 9.96E-18
FPR1 0.314000143 1.86E-08 9.51E-08
ITGAM 0.312357016 1.08E-14 1.02E-13
CXCR1 0.310259131 1.37E-07 5.43E-07
ALOX5 0.307999903 4.41E-10 3.39E-09
ALOX5AP 0.297385187 8.46E-09 4.96E-08
S100A12 0.278909351 0.001670509 0.002389217
ADM 0.260029478 0.000641148 0.001065693
TREM1 0.248663489 2.55E-06 7.83E-06
TNFAIP6 0.248610967 0.00257583 0.003481616
ENTPD1 0.245420827 1.42E-15 1.45E-14
LY96 0.239005748 1.90E-05 3.95E-05
CXCL16 0.237317236 8.65E-07 2.95E-06
CEBPB 0.230763623 3.00E-08 1.42E-07
NFKBIA 0.228992201 3.23E-09 1.98E-08
FCGR2A 0.215407732 7.19E-06 1.85E-05
CXCR2 0.211012085 0.001068554 0.001602832
RETN 0.21058321 0.01586697 0.016400314
MYD88 0.208259258 6.46E-08 2.74E-07
NLRP12 0.205071809 1.08E-08 5.77E-08
IL4R 0.20291588 8.88E-05 0.000170727
TNFRSF1A 0.202417641 4.37E-06 1.19E-05
IL1RN 0.198768135 0.00040592 0.000713259
IL6ST 0.198412828 1.40E-06 4.41E-06
IL17RA 0.197957216 3.17E-06 9.28E-06
IL10RB 0.196049234 1.44E-10 1.26E-09
SELL 0.195994519 9.25E-05 0.000175105
C5AR1 0.195238456 0.000205723 0.000377671
CASP1 0.188119209 1.14E-07 4.68E-07
ZFP36 0.183934196 2.93E-06 8.80E-06
SERPINA1 0.179503315 7.22E-06 1.85E-05
TNFSF13B 0.177445234 0.000825575 0.001288621
HSPA1B 0.176420869 5.39E-06 1.44E-05
TIMP1 0.172673927 0.000822678 0.001288621
TLR6 0.168820362 1.01E-06 3.26E-06
PLAUR 0.166612685 1.65E-05 3.55E-05
CD14 0.16611474 0.000276697 0.000493243
CHUK 0.165667344 7.70E-18 9.68E-17
MAPK14 0.164727678 2.18E-09 1.49E-08
OSM 0.164574234 1.23E-05 2.81E-05
NOD2 0.161685042 0.003678409 0.004435729
LTB4R 0.159007204 5.90E-07 2.13E-06
STAT3 0.155460508 4.60E-07 1.72E-06
SELPLG 0.149165939 0.000445034 0.000770974
BCL10 0.148776514 5.46E-08 2.40E-07
CARD8 0.144871565 1.60E-05 3.52E-05
IL6R 0.14012784 0.002147151 0.00293444
PTAFR 0.136092322 0.001921332 0.002716366
IRAK4 0.134877814 2.98E-09 1.93E-08
NFKB1 0.134014828 3.29E-06 9.43E-06
IKBKG 0.130383236 2.85E-05 5.76E-05
ANXA1 0.130203007 0.000827651 0.001288621
PECAM1 0.129501877 0.000892952 0.001372914
F2RL1 0.123314772 0.007587343 0.008407596
NFKBIZ 0.120023326 0.00470153 0.005507506
IRF1 0.11964364 0.012863897 0.013640167
CCR2 0.116629854 9.69E-06 2.29E-05
RCAN1 0.112483772 8.89E-07 2.96E-06
HPSE 0.111383491 0.000244685 0.000442593
SOCS3 0.109583073 0.004550887 0.005382299
ADIPOR2 0.109271796 8.70E-06 2.14E-05
NLRP3 0.104785425 0.000609514 0.001041253
CARD16 0.10350658 1.83E-05 3.88E-05
PIK3CD 0.090833315 0.007494019 0.008379675
PTPN2 0.088722727 0.000702432 0.001151988
TRAF3IP2 0.086542869 0.002961432 0.003695784
TNFAIP3 0.080100771 0.003144102 0.003828956
IL1RAP 0.07949029 0.002828537 0.003626765
HIF1A 0.072219718 0.005202065 0.005979944
TNFAIP8L2 0.061064562 0.002745426 0.003592419
ADORA2B 0.059095047 0.005495082 0.006258287
ADAM17 0.052399583 0.010995964 0.011969059
MAP3K7 0.044048652 0.017079787 0.017079787
TRAF6 0.032325573 0.004846396 0.005623648
MAP3K14 -0.05296715 0.00137599 0.002009456
IL23A -0.059042421 0.014300211 0.014906152
CCL3 -0.064408626 0.002912586 0.00369328
TNF -0.064552552 0.011243983 0.012131666
ALOX15 -0.067813122 0.013582075 0.014278592
MAZ -0.069654198 0.002974655 0.003695784
SFTPD -0.071748494 0.003825975 0.004568883
IL12RB1 -0.072193083 0.002006878 0.002805068
KLF2 -0.075626476 0.010628397 0.011672258
P2RX7 -0.077772639 0.002830646 0.003626765
PPARD -0.081043617 1.94E-05 3.97E-05
SIGIRR -0.082236908 0.002705693 0.003578497
ADORA2A -0.082809198 0.003124957 0.003828956
IFNG -0.084841981 0.016847177 0.016985269
BPIFA1 -0.087435574 0.001181906 0.001751499
CD40 -0.089015821 0.000813221 0.001288621
F2R -0.10420127 4.40E-05 8.58E-05
PLA2G2D -0.107836381 0.012033862 0.012871
NOD1 -0.108542087 8.53E-06 2.14E-05
TRPA1 -0.124820033 1.45E-05 3.23E-05
CCR6 -0.128247976 3.54E-08 1.61E-07
LTB -0.137537799 0.000981616 0.001490603
CCL5 -0.138819059 0.016415155 0.01668648
IL18 -0.146424229 0.001388648 0.002009456
IL10 -0.146441153 0.005654359 0.006380607
ACP5 -0.153268287 0.002616126 0.003497646
IL10RA -0.153655151 1.18E-05 2.74E-05
ICAM2 -0.16220602 7.34E-07 2.58E-06
IL2RB -0.164932166 0.002072265 0.002863917
CX3CR1 -0.175684408 0.000102118 0.00019031
PPBP -0.182534847 0.016142107 0.01654566
BDKRB1 -0.198525938 3.04E-05 6.04E-05
IL32 -0.200554941 9.41E-06 2.27E-05
TMSB4X -0.215714048 3.61E-06 1.01E-05
CLC -0.326173416 0.00062178 0.001047657
Transcription Factor Target Number of Genes
hsa_V$NFKB_C 75
hsa_GGGTGGRR_V$PAX4_03 271
hsa_V$PAX4_03 63
hsa_TGACAGNY_V$MEIS1_01 180
hsa_V$ARNT_02 80
hsa_TGANTCA_V$AP1_C 225
hsa_V$AP1FJ_Q2 65
hsa_TTGTTT_V$FOXO4_01 388
hsa_V$MEIS1_01 57
hsa_TAAYNRNNTCC_UNKNOWN 39
Statistics for significant diseases 
C=144;O=75;E=49.47;R=1.52;rawP=8.01e-06;adjP=0.0048
C=663;O=271;E=227.77;R=1.19;rawP=0.0002;adjP=0.0242
C=126;O=63;E=43.29;R=1.46;rawP=0.0002;adjP=0.0242
C=421;O=180;E=144.63;R=1.24;rawP=0.0002;adjP=0.0242
C=168;O=80;E=57.71;R=1.39;rawP=0.0002;adjP=0.0242
C=548;O=225;E=188.26;R=1.20;rawP=0.0004;adjP=0.0330
C=135;O=65;E=46.38;R=1.40;rawP=0.0006;adjP=0.0330
C=994;O=388;E=341.48;R=1.14;rawP=0.0006;adjP=0.0330
C=115;O=57;E=39.51;R=1.44;rawP=0.0005;adjP=0.0330
C=72;O=39;E=24.73;R=1.58;rawP=0.0004;adjP=0.0330
NFKB-related genes
Gene Symbol beta coefficient nominal p value fdr-adjust p value
IL18R1 0.464453217 3.61E-28 2.71E-26
XPO6 0.31937061 5.27E-12 1.97E-10
FOS 0.309348885 6.87E-10 1.29E-08
NFKBIA 0.228992201 3.23E-09 4.84E-08
IL1RN 0.198768135 0.00040592 0.000951375
RHOG 0.174148362 2.05E-05 0.000102744
BCKDK 0.164503562 2.27E-08 2.84E-07
RGL1 0.15799469 8.34E-07 7.05E-06
BCL3 0.157650167 0.000420445 0.000955556
MAP3K8 0.143443863 9.92E-06 6.20E-05
RIN2 0.140793936 1.22E-05 6.55E-05
RAB10 0.140437973 5.44E-07 5.83E-06
LIX1L 0.137800467 2.95E-11 7.37E-10
PRKCD 0.132297165 0.000213285 0.000620286
NUP153 0.122550194 3.73E-06 2.73E-05
IRF1 0.11964364 0.012863897 0.014399885
GNA13 0.116993805 0.000176122 0.00055038
ZNF217 0.114337331 0.001154151 0.00227793
FUT7 0.107951233 0.000227155 0.000630985
LASP1 0.107016238 0.000215032 0.000620286
DNAJA1 0.1011257 0.000329587 0.000852381
RHOA 0.100231568 0.001987826 0.00355243
ARPC5 0.098642419 0.016273109 0.016636982
ANKHD1 0.0966872 1.12E-05 6.49E-05
GADD45B 0.094541587 0.002246107 0.003917629
TMEM88 0.084289459 0.005124534 0.007686802
MOB3C 0.084221031 0.006517674 0.009170021
STX4 0.082604922 0.000402966 0.000951375
GPBP1 0.07356536 0.001583382 0.00296884
ALG6 0.07299218 0.003255373 0.005425621
RAP2C 0.069993847 0.012310945 0.014204937
SIN3A 0.069732275 0.006840859 0.009170021
ZNF800 0.069441522 0.008683582 0.011038451
PPP2R5E 0.069021879 0.009020497 0.011275622
C4orf32 0.065644833 0.012670533 0.014398333
PPP3CA 0.065085653 0.000616222 0.001359313
LRRFIP2 0.06373689 0.001038262 0.002104586
ANKHD1-EIF4EBP3 0.063436005 0.00338456 0.005518304
PTPRJ 0.062773732 0.016974057 0.016974057
INO80D 0.051455996 0.015256939 0.015892645
CHD4 -0.053163141 0.010308622 0.012272169
CD70 -0.055732558 0.005684573 0.008359667
SLC6A12 -0.056007442 0.008258504 0.0106791
IL23A -0.059042421 0.014300211 0.015321655
CDC37 -0.067234867 0.009917246 0.012193335
SOCS2 -0.068121343 0.006846949 0.009170021
SCAF4 -0.069577897 0.007237649 0.009523222
HOXB6 -0.071973212 0.00026763 0.000716866
PCBP4 -0.076440886 0.000350769 0.000876923
IER5 -0.076592766 0.003978347 0.006348427
PFN1 -0.077142455 0.00471044 0.007360063
HCFC1 -0.084139618 0.006316696 0.00911062
CD40 -0.089015821 0.000813221 0.001742616
TRIB2 -0.091235744 0.010177571 0.012272169
TCTA -0.096277567 4.61E-05 0.000181955
ENO3 -0.099501559 0.001989361 0.00355243
BCL11A -0.10263154 5.91E-05 0.000221766
MLLT6 -0.102666422 0.004889854 0.00748447
EIF5A -0.106031141 0.013549929 0.014728183
CD74 -0.109894237 0.013447025 0.014728183
DDR1 -0.11265689 0.006743331 0.009170021
PURG -0.113044219 6.60E-05 0.000225083
CD247 -0.117294609 0.014686657 0.015514074
SYMPK -0.121091293 4.01E-06 2.73E-05
SPTB -0.12718435 0.010716518 0.01255842
RALGDS -0.130466343 0.001254976 0.002413415
LTB -0.137537799 0.000981616 0.002045034
CCL5 -0.138819059 0.016415155 0.016636982
CXCR5 -0.140963751 3.05E-05 0.000127286
BDNF -0.167787053 0.000121264 0.000395428
GDPD5 -0.177416693 8.46E-07 7.05E-06
PTMS -0.182125073 6.35E-05 0.000225083
FAM117A -0.21360573 2.88E-05 0.000127205
RANBP10 -0.25049502 2.43E-05 0.000113672
BCL2L1 -0.272543632 0.002935254 0.005003273
Supplementary Table 4
gene1 gene2 Partial correlation in lower FKBP5 group
MAP3K14 CHUK 0.132436629
TRAF5 TAB3 -0.110467438
TNFSF14 LTBR 0.071238297
RELA PTGS2 0.179752297
TLR4 TICAM1 -0.092933208
MYD88 TAB1 -0.146650236
PRKCB CARD11 0.04715756
TRAF6 TAB1 0.177279293
IRAK4 TAB3 -0.12829314
BTK CHUK 0.137688847
MAP3K14 TAB2 -0.060587472
RIPK1 MAP3K7 0.11824212
ZAP70 LAT -0.079190985
NFKB1 BCL2 0.11910841
RELA BIRC3 -0.242890674
PRKCQ CARD11 0.044708189
CD40 TRAF6 0.174198063
RELA IL1B 0.161272883
BTK IKBKB 0.108360452
TNFRSF1A TRADD 0.070085264
TRADD TAB2 0.019197261
TRAF5 MAP3K14 0.043723895
BIRC3 RIPK1 -0.016049575
LTBR TRAF5 -0.012855229
BIRC2 RIPK1 0.022034958
LAT PLCG1 0.255379888
IRAK1 TAB1 0.070563226
IRAK1 TAB2 -0.145736375
CSNK2B NFKBIA 0.133486117
RIPK1 TAB2 0.017519098
RIPK1 TAB3 0.025294604
TRAF5 TAB1 -0.180974135
DDX58 TRAF6 0.056179678
TRADD TAB3 0.025808766
RELA BCL2 0.235036324
NFKB1 NFKBIA 0.235863281
NFKBIA NFKB1 0.235863281
NFKB1 IL1B 0.231656702
RELB TNFSF13B 0.119999885
MAP3K7 IKBKB 0.170053728
NFKB1 TRAF1 -0.062980105
CSNK2A1 NFKBIA -0.063627755
RIPK1 TAB1 0.184068978
NFKB1 GADD45B -0.129871096
NFKB1 CFLAR 0.133751003
TRIM25 DDX58 0.172814544
CHUK NFKB2 0.13045199
NFKB2 TNFSF13B 0.066157861
RELA BIRC2 -0.091272133
NFKB1 BCL2L1 0.238463855
CD14 TLR4 0.169720956
IRAK4 TAB2 -0.073391111
MYD88 TAB2 0.018096715
TRAF6 TAB3 0.065013758
NFKB1 TNFAIP3 -0.10940864
RELA TRAF1 -0.008309294
IRAK4 MAP3K7 0.160351607
NFKB1 BIRC2 0.004745478
TNFRSF1A TRAF5 0.015645208
MYD88 IRAK4 0.102080512
TNFRSF1A RIPK1 0.153632996
TRAF6 TAB2 0.009191737
LTB LTBR -0.139841382
SYK BTK 0.170704222
TNF TNFRSF1A -0.114509548
TRAF5 TAB2 0.197906574
CD40LG CD40 -0.140908404
MAP3K14 TAB1 -0.025226161
RELA NFKB2 0.09715396
TRAF5 MAP3K7 0.120597931
BTK IKBKG 0.036876583
RELA TNF -0.096476824
TRAF6 MAP3K14 0.012714424
NFKB1 BCL2A1 0.077533938
MYD88 TRAF6 0.076802967
BTK PLCG2 -0.005180287
NFKBIA RELA 0.084011194
RELA NFKBIA 0.084011194
TRAF6 MAP3K7 0.027560944
NFKB1 NFKB2 0.051904974
IRAK1 MAP3K7 0.106635656
IRAK1 TAB3 0.00525706
RELA BCL2A1 -0.009474199
NFKB1 TNF -0.106668698
RELA GADD45B 0.032493649
RELA BCL2L1 -0.067685043
RELA CXCL8 0.042867685
TRADD TAB1 0.003033641
TNFSF13B TNFRSF13C -0.105947084
RELA TNFAIP3 0.004822892
TICAM1 RIPK1 -0.078743797
CSNK2A3 NFKBIA -0.182557122
MAP3K14 MAP3K7 -0.135832519
TLR4 MYD88 0.089085064
MYD88 TAB3 -0.075184545
IKBKB NFKBIA 0.096968983
CSNK2A2 NFKBIA -0.085464184
NFKB1 CXCL8 -0.064135883
TRADD MAP3K7 -0.019213748
NFKB1 BIRC3 -0.045010747
TICAM1 TRAF6 -0.073616907
IRAK4 TAB1 -0.044424501
MYD88 IRAK1 0.029573907
LTA LTBR -0.040120183
NFKB1 PTGS2 -0.041918814
MYD88 MAP3K7 0.098745902
MAP3K14 TAB3 0.05488285
Partial correlation in higher FKBP5 group Difference in partial correlations p value
-0.275039094 0.407475723 0.0019
0.215465481 0.325932919 0.0052
-0.263448577 0.334686873 0.0087
-0.138725032 0.318477329 0.013
0.219816225 0.312749433 0.0174
0.150640471 0.297290708 0.018
-0.227360317 0.274517877 0.0288
-0.090086652 0.267365945 0.0413
0.159453376 0.287746516 0.0445
-0.179678413 0.317367259 0.0448
0.206314426 0.266901898 0.0494
-0.174900151 0.29314227 0.0742
0.150136714 0.229327699 0.0763
-0.11194658 0.231054989 0.0906
-0.030933939 0.211956735 0.101
0.257787533 0.213079344 0.112
-0.038803568 0.213001631 0.1161
-0.035543278 0.196816161 0.1162
-0.07361192 0.181972372 0.123
-0.134659342 0.204744607 0.1348
-0.176427818 0.195625079 0.1436
-0.133503135 0.177227029 0.1495
0.155588014 0.171637589 0.1689
0.148269488 0.161124717 0.1704
-0.154848979 0.176883937 0.1751
0.079319001 0.176060887 0.1752
0.249470693 0.178907466 0.1765
0.020342585 0.16607896 0.1887
-0.036126981 0.169613098 0.1991
-0.146279139 0.163798237 0.2323
0.181969645 0.156675041 0.2328
-0.039008143 0.141965992 0.2491
-0.09437496 0.150554639 0.2609
-0.128932058 0.154740823 0.2872
0.10017325 0.134863074 0.2896
0.08532022 0.150543061 0.3003
0.08532022 0.150543061 0.3003
0.102885706 0.128770996 0.3025
-0.024058581 0.144058466 0.3074
0.031594807 0.138458921 0.3264
0.067811925 0.130792031 0.327
-0.191080621 0.127452866 0.3435
0.067329816 0.116739162 0.3438
-0.006591367 0.123279729 0.3499
0.022250933 0.11150007 0.3905
0.290044984 0.117230439 0.3954
0.015204604 0.115247386 0.4148
0.181851065 0.115693204 0.4278
0.020460433 0.111732566 0.448
0.137483437 0.100980418 0.4597
0.077197478 0.092523478 0.4648
0.023978195 0.097369306 0.4696
0.107905721 0.089809006 0.4708
-0.026282954 0.091296711 0.4834
-0.196088904 0.086680264 0.4919
-0.107052161 0.098742867 0.497
0.247797795 0.087446188 0.5034
-0.088008843 0.092754321 0.5065
-0.069916498 0.085561705 0.5199
0.009217704 0.092862807 0.5204
0.232811824 0.079178828 0.5249
0.100608514 0.091416777 0.5277
-0.216819943 0.076978561 0.5507
0.253581313 0.08287709 0.5542
-0.034546864 0.079962684 0.5551
0.12036681 0.077539763 0.5553
-0.067513557 0.073394847 0.5584
0.05326085 0.07848701 0.5633
0.020799048 0.076354911 0.5695
0.049468462 0.071129469 0.5862
-0.031544552 0.068421134 0.5918
-0.036959744 0.05951708 0.6144
0.081924394 0.069209969 0.6159
0.013676504 0.063857434 0.6185
0.012109466 0.064693501 0.619
0.062166899 0.067347186 0.6226
0.012426088 0.071585106 0.6243
0.012426088 0.071585106 0.6243
0.093991947 0.066431003 0.6323
-0.007986131 0.059891104 0.6568
0.163953875 0.057318219 0.6569
-0.049217185 0.054474246 0.6731
0.038777601 0.0482518 0.703
-0.055543558 0.05112514 0.713
-0.00930505 0.041798699 0.7252
-0.112784033 0.04509899 0.7312
3.95E-05 0.042828161 0.7543
0.039041318 0.036007677 0.7701
-0.073167739 0.032779345 0.7976
0.036951641 0.032128749 0.7986
-0.044849528 0.033894269 0.8152
-0.159187905 0.023369217 0.861
-0.159003692 0.023171173 0.8635
0.109486869 0.020401804 0.8643
-0.051061591 0.024122954 0.8715
0.075885199 0.021083784 0.8788
-0.065618486 0.019845698 0.8906
-0.046133461 0.018002422 0.8907
-0.004067677 0.01514607 0.9015
-0.054324929 0.009314182 0.9505
-0.08159261 0.007975702 0.9522
-0.05021406 0.005789559 0.9632
0.023987969 0.005585939 0.9653
-0.034888229 0.005231954 0.9688
-0.046329746 0.004410933 0.9717
0.101716168 0.002970266 0.9815
0.057744665 0.002861815 0.9841
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p = 8.3 x 10-9
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METHODS 
Human cohorts and measures 
The demographics for all participating cohorts and relevant variables are provided in 
Supplementary Table 1. 
The first cohort, which served as discovery cohort for most of our analyses, was derived 
from the Grady Trauma Project (GTP), a large study conducted in Atlanta, Georgia that 
investigates the role of genetic and environmental factors in shaping stress responses. 
Participants predominantly come from an African American, urban population of low 
socioeconomic status(Binder et al, 2008; Gillespie et al, 2009). This population is characterized 
by high prevalence and severity of psychosocial stress exposure and is thereby particularly 
relevant for examining the impact of stress-related phenotypes on genomic regulation. All 
African American subjects with available FKBP5 DNA methylation and/or genome-wide gene 
expression data were included in the analyses. Stress-related phenotypes of interest included 
depressive symptoms measured by the Beck Depression Inventory (BDI)(Beck et al, 1988; Beck 
et al, 1961), post-traumatic stress disorder symptomatology assessed with the validated 17-item 
PTSD Symptom Scale(Binder et al, 2008; Coffey et al, 1998), lifetime stressful events 
determined with the Stressful Events Questionnaire(Smith et al, 2011), and childhood trauma 
measured with the Childhood Trauma Questionnaire (CTQ)(Bernstein et al, 2003). Based on a 
standard BDI cutoff score(Beck et al, 1988), subjects were categorized as having high (total BDI 
score ≥ 19) or low levels (total BDI score < 19) of depressive symptoms. Lifetime abuse of 
substances, including tobacco, alcohol, cannabis, and heroin was assessed with the Kreek-
McHugh-Schluger-Kellogg scale(Kellogg et al, 2003). Morning serum cortisol was measured as 
described previously with a commercial radioimmunoassay kit (Diagnostic Systems 
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Laboratories, Webster, TX, USA)(Kaminsky et al, 2015). All participants provided written 
informed consent and all procedures were approved by the Institutional Review Boards of the 
Emory University School of Medicine and Grady Memorial Hospital (IRB00002114). 
The second cohort was derived from the KORA (Cooperative Health Research in the 
Region of Augsburg) F4 study, a follow-up study of the fourth KORA survey (S4) conducted in 
1999—2001. Subjects were recruited from the city of Augsburg and two adjacent counties in the 
south of Germany(Holle et al, 2005), and DNA methylation was measured in a study subset. 
Depressive symptoms were assessed with the DEpression and EXhaustion subscale (DEEX 
scale) of the von Zerrssen symptom checklist(Ladwig et al, 2004). Based on a previously defined 
DEEX cutoff(Hafner et al, 2011), subjects were categorized as having high (total BDI score ≥ 
11) or low levels (total DEEX score < 11) of depressive symptoms. Smoking was defined as 
current smoker, occasional smoker, former smoker, or never smoker. History of diagnosed 
myocardial infarction (MI) was determined using a self-reported questionnaire. The study has 
been conducted according to the principles expressed in the Declaration of Helsinki. Written 
informed consent has been given by each participant. All study protocols were reviewed and 
approved by the local ethical committee (Bayerische Landesärztekammer). 
The third cohort comprised of Caucasian depressed and control subjects that were 
recruited at the Max Planck Institute of Psychiatry (MPIP). Recruitment strategies and 
characterization of case/control subjects have been previously described(Heck et al, 2009; Kohli 
et al, 2011; Lucae et al, 2006). Briefly, subjects were screened either with the Schedule for 
Clinical Assessment in Neuropsychiatry or the Composite International Diagnostic Screener, and 
diagnosis of major depression was ascertained according to the Diagnostic and Statistical Manual 
of Mental Disorders (DSM) IV criteria. Self-reported history of physician-diagnosed myocardial 
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infarction was documented upon enrollment in the study. Written informed consent was obtained 
from all subjects, and the study was approved by the ethics committee of the Ludwig-
Maximilians-University in Munich. 
The impact of severe early life stress on FKBP5 methylation was examined in a subset of 
the Helsinki Birth Cohort Study (HBCS)(Barker et al, 2005). The HBCS has detailed 
information on the separation of Finnish children from their parents, which occurred during 
World War II and was documented by the Finnish National Archives registry between 1939 and 
1946. The subset with available DNA methylation data includes separated and non-separated 
(control) males. In the separated subjects group, the mean age at separation was 4.7 years (SD, 
2.4 years) and the mean length of separation 1.7 years (SD, 1 year). Based on self-report, 
subjects were categorized as never smokers, former smokers, occasional smokers, and active 
smokers.  The HBCS was carried out in accordance with the Declaration of Helsinki, and the 
study protocol was approved by the Institutional Review Board of the National Public Health 
Institute. Written informed consent was obtained from all participants. 
 
DNA methylation arrays 
Genomic DNA from the GTP cohort, the MPIP, and the HBCS was extracted from whole blood 
using the Gentra Puregene Blood Kit (QIAGEN). DNA quality and quantity was assessed by 
NanoDrop 2000 Spectrophotometer (Thermo Scientific) and Quant-iT Picogreen (Invitrogen). 
Genomic DNA was bisulfite converted using the Zymo EZ-96 DNA Methylation Kit (Zymo 
Research) and DNA methylation levels were assessed for >480,000 CpG sites using the Illumina 
HumanMethylation450 BeadChip array. Hybridization and processing was performed according 
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to manufacturer’s instructions as previously described(Mehta et al, 2013). Quality control of 
methylation data, including intensity read outs, filtering (detection P value >0.01 in  >50% of the 
samples), cellular composition estimation, as well as beta and M-value calculation was done 
using the minfi Bioconductor R package version 1.10.2(Aryee et al, 2014). We excluded X 
chromosome, Y chromosome, and non-specific binding probes(Chen et al, 2013), as well as 
probes if single nucleotide polymorphisms (SNPs) were documented in the interval for which the 
Illumina probe is designed to hybridize. Given that the GTP cohort includes individuals from 
different ethnicities, we also removed probes if they were located close (10 bp from query site) 
to a SNP which had Minor Allele Frequency of ≥0.05, as reported in the 1,000 Genomes Project, 
for any of the populations represented in the samples. MPIP and HBCS data were normalized 
with functional normalization (FunNorm)(Fortin et al, 2014b), an extension of quantile 
normalization included in the R package minfi. Technical batch effects were identified by 
inspecting the association of the first principal components of the methylation levels with  
possible technical batches and by further visual inspection of principal component plots using the 
shinyMethyl Bioconductor R package version 0.99.3(Fortin et al, 2014a). This procedure 
identified array column in HBCS, 96-well plate and 96-well plate position in the MPIP as 
technical batches. The raw methylation data for the GTP cohort have been deposited into NCBI 
GEO (GSE72680). 
For the KORA study, genomic DNA (1 µg) from 1814 samples was bisulfite converted 
using the EZ-96 DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the 
manufacturer’s protocol, with the incubation conditions recommended for the Illumina Infinium 
Methylation Assay. Raw methylation data were generated by BeadArray Reader and extracted 
by GenomeStudio (version 2011.1) with methylation module (version 1.9.0). Data were 
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preprocessed using R version 3.0.1 (http://www.r-project.org/)(Team, 2014). Probes with signals 
from less than three functional beads and probes with a detection p-value > 0.01 were defined as 
low-confidence probes. As probe binding might be affected by single nucleotide polymorphisms 
(SNPs) in the binding area, CpG sites (CpGs) in close proximity (50bp) to SNPs with a minor 
allele frequency of at least 5% were excluded from the dataset. Color bias adjustment using 
smooth quantile normalization method as well as background level correction based on negative-
control probes present on the Infinium HumanMethylation BeadChip was performed for each 
chip using the R package lumi (version 2.12.0)(Du et al, 2008). Beta values corresponding to 
low-confidence probes were then set to missing, and samples as well as CpGs were subjected to 
a 95% detection rate threshold, where samples and CpGs with more than 5% low-confidence 
probes were removed from the analysis. Finally, beta-mixture quantile normalization (BMIQ) 
was applied to correct the shift in the distribution of the beta values of the InfI and InfII 
probes(Teschendorff et al, 2013). BMIQ was done using the R package wateRmelon (version 
1.0.3)(Pidsley et al, 2013). 
DNA methylation analyses included 45 cytosine-guanine dinucleotides (CpGs) covered 
by the 450K that are located within or in close proximity (10kb upstream or downstream) to the 
FKBP5 locus. All 45 CpGs were measured in the KORA, whereas one CpG (cg00052684) did 
not pass quality control in the other cohorts. All statistics involving DNA methylation are 
conducted and reported using M values, whereas Beta-values are used for figures and DNA 
methylation differences as a more intuitive measure of effect size. In all cohorts, DNA 
methylation data were used to calculate blood cell proportions as previously 
described(Houseman et al, 2012). 
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Gene expression arrays 
Genome-wide gene expression data were measured in 355 African American subjects from the 
GTP. Whole blood RNA was collected, processed, and hybridized to Illumina HumanHT-12 v3 
and v4 Expression BeadChips (Illumina, San Diego, CA, USA) as previously described(Mehta et 
al, 2013; Menke et al, 2012). The raw microarray scan files were exported using the Illumina 
Beadstudio program 13 and further analyzed in R (www.R-project.org). Microarray data were 
transformed and normalized via the variance stabilizing normalization with the use of Illumina 
internal controls(Huber et al, 2002). Empirical Bayes method was used to control for potential 
confounding as a result of batch effects(Johnson et al, 2007). Six pairs of technical replicates 
were used to confirm data reproducibility (average Pearson correlation 0.996). The raw gene 
expression array data for the GTP study have been deposited to GEO (GSE58137). 
 
Population stratification 
To control for potential confounding by population stratification, we used genome-wide SNP 
data. In the GTP, of the 700 k SNPs present on the Omni Quad and Omni express arrays, 
645,8315 autosomal SNPs were left after filtering with the following criteria: minor allele 
frequency of >1 %; Hardy-Weinberg equilibrium of 0.000001; and genotyping rate of >98 %. 
The MPIP cohort was genotyped using the Illumina 300k, 610k and Omni express arrays. For 
each chip array, quality control was performed separately following the same quality control 
protocol like in GTP.  After QC, we used the overlap of 168,138 SNPs across all chip types. The 
samples were clustered to calculate rates of identity by descent (IBD). We then ran 
multidimensional scaling analysis on the IBD matrix using PLINK2 (https://www.cog-
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genomics.org/plink2) and plotted the first ten axes of variation against each other. No outliers 
were detected. The first two principal components were used as covariates in regression models 
to adjust for population stratification. 
 
Pathway analyses 
FKBP5 mRNA levels were correlated with the expression of all genes detected above 
background in peripheral blood in the GTP. Using the set of FDR-corrected genes correlating 
with FKBP5 (n = 3,275) as input and the set of genes expressed above background (n = 9,538) as 
reference, we then performed disease association and transcription factor target analysis using 
the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt; 
http://bioinfo.vanderbilt.edu/webgestalt/)(Wang et al, 2013; Zhang et al, 2005). This was 
performed with a hypergeometric test, whereby the minimum number of genes for the 
enrichment analysis was set at 5. Both analyses were FDR-corrected for multiple testing. 
 For the NF-κB co-expression network analyses, the list of NF-κB-related genes was 
acquired from the KEGG Pathway Database (http://www.genome.jp/dbget-
bin/www_bget?pathway:hsa04064). Using the gene expression array data in the GTP, the 
pairwise correlation coefficients between gene pairs encoding molecules that directly interact 
along the NF-κB pathway were calculated and adjusted for the expression levels of all other 
pathway partners using the R package GeneNet(Schafer and Strimmer, 2005). These partial 
pairwise correlations were then compared between subjects with higher and those with lower 
FKBP5 expression as defined by a median split of FKBP5 mRNA levels. To test whether there is 
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a significant change of each gene pair between the two groups, the FKBP5 high/low group 
assignments for each pair were permuted 10,000 times across samples.  
 
Cell culture 
Cell culture experiments were conducted in peripheral blood monocytes (PBMC) or Jurkat cell 
lines (ATCC, TIB-152), a frequently used human T-cell leukemia cell line that allows efficient 
and reproducible transfection with expression vectors. For PBMC isolation, the whole blood of 
healthy volunteers was collected via venipuncture, diluted with PBS, carefully loaded on Biocoll 
solution (BioChrom, L6113), and centrifuged at 800 g for 20 min without brake. PBMC were 
enriched by selecting the interphase of the Biocoll gradient and were then washed two times with 
ice-cold PBS and resuspended in medium. Both cell types were maintained in RPMI (Gibco) 
supplemented with 10% FCS and 100 units/ml penicillin and streptomycin. For all treatments, 
cells were left after seeding to rest overnight and the next day were incubated overnight with 
vehicle (0.05% DMSO), 100 nM DEX (Sigma, D4902), and/or 100 nM SAFit1. FKBP5 
overexpression in Jurkat cells was performed using a previously described FKBP51-
FLAG(Wochnik et al, 2005). 
 
Western Blot Analysis 
Protein extracts were obtained by lysing cells in 62.5 mM Tris, 2% SDS, and 10% sucrose, 
supplemented with protease (Sigma, P2714) and phosphatase (Roche, 04906837001) inhibitors. 
Samples were sonicated and heated at 95°C for 5 min. Proteins were separated by SDS-PAGE 
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and electro-transferred onto nitrocellulose membranes. Blots were placed in Tris-buffered saline, 
supplemented with 0.05% Tween (Sigma, P2287) and 5% non-fat milk for 1 h at room 
temperature and then incubated with primary antibody (diluted in TBS/0.05% Tween) overnight 
at 4°C. The following primary antibodies were used: FLAG (1:7,000, Rockland, 600-401-383), 
FKBP5 (1:1,000, Bethyl, A301-430A; 1:1000, Cell Signaling, #8245), IKKα (1:1000, Cell 
Signaling, # 2682), pIKKα
S176
 (1:1000, Cell Signaling, #2078), NIK (1:1000, Cell Signaling, 
#4994), and Actin (1:5,000, Santa Cruz, sc-1616). Subsequently, the blots were washed and 
probed with the respective horseradish-peroxidase or fluorophore-conjugated secondary antibody 
for 2 h at room temperature. The immuno-reactive bands were visualized either by using ECL 
detection reagent (Millipore, WBKL0500) or directly by excitation of the respective fluorophore. 
Recording of the band intensities was performed with the ChemiDoc MP system from Bio-Rad. 
 
Co-immunoprecipitation experiments (CoIPs) 
CoIPs of endogenous or FLAG-tagged FKBP5 with endogenous IKKα and NIK were performed 
in Jurkat cells and PBMC using previously described methods(Gassen et al, 2014). 5 x 10
6
 cells 
were electroporated with 2 µg of the respective expression plasmids using the Amaxa 
Nucleofector Device and the Cell Line Nucleofector Kit V (Lonza, Basel, Switzerland). After 3 
days of cultivation in medium, cells were lysed in CoIP buffer containing 20 mM Tris-HCl (pH 
8.0), 100 mM NaCl, 1 mM EDTA, and 0.5% Igepal, complemented with protease inhibitor 
cocktail. This was followed by incubation on an overhead shaker for 20 min at 4°C. The lysate 
was cleared by centrifugation, the protein concentration was determined, and 1.2 mg of lysate 
was incubated with 2.5 µg of FLAG antibody overnight at 4°C. 20 µl of BSA-blocked Protein G 
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Dynabeads (Invitrogen, 100-03D) were added to the lysate-antibody mix, followed by 3 h of 
incubation at 4°C. The beads were washed three times with  PBS,  and  protein-antibody 
complexes were eluted with 100 µl of 1 x FLAG-peptide solution (Sigma, 100–200 µg/ml, 
F3290) in CoIP buffer for 30 min at 4°C. 5–15 µg of the cell lysates or 2.5 µl of the 
immunoprecipitates was separated by SDS-PAGE.  
 
Quantification of Protein Data 
All protein data were normalized to Actin, which was detected on the same blot in the same lane 
(multiplexing). In the case of IKKα phosphorylation and to rule out confounding by changes in 
total IKKα levels, we normalized pIKKα by calculating its ratio to total IKKα. We obtained 
indistinguishable results when normalizing pIKKα to Actin.  
 
Dual-luciferase reporter gene assays 
1 x 10
6
 Jurkat cells were transfected with NF- κB luciferase reporter (1µg, Promega, E8491) and 
Renilla control plasmids (300ng, Promega, E6921), as well as with either FKBP5-FLAG (1µg) 
or control vector (pRK5; 1µg), using the Amaxa Nucleofector Device. Immediately after 
transfection, cells were seeded on 96-well plates at a density of 20,000 cells/well and were left to 
rest overnight.  On the next day, cells were incubated for 2 hours with SAFit1 or vehicle and 
were then stimulated overnight with Phorbol-12-myristate-13-acetate (PMA; 25ng/ml, Sigma, 
P1585) and ionomycin (375ng/ml, Sigma, I0634). Cells were then lysed in lysis buffer 
(Promega, E1941) and stored in -80°C until the plate was read with the TriStar² S LB 942 
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microplate reader (Berthold, Bad Wildbad, Germany) following a previously described 
protocol(Hampf and Gossen, 2006). To control for differences in transfection efficiency, the NF- 
κB-driven reporter gene activity was calculated as the ratio of Photinus to Renilla luciferase 
signals. 
 
Enzyme-linked immunosorbent assay (ELISA) for human interleukin-8 (IL-8) 
1 x 10
6
 Jurkat cells were transfected with either FKBP5-FLAG (1µg) or control vector (1µg), 
were seeded in 24-well plates at a density of 500,000 cells/well and, after overnight rest, were 
stimulated with PMA (25ng/ml) and ionomycin (375ng/ml). Supernatants were collected the next 
day, cleared by centrifugation at 125g, and stored at -80°C until IL-8 measurement with ELISA, 
which was performed with a commercially available kit (Merck Millipore, EZHIL8). 
 
Statistical analysis 
All statistical analyses involving DNA methylation used M-values, which have shown superior 
statistical performance as compared to Beta-values(Du et al, 2010). To average the methylation 
levels of the two age-regulated FKBP5 CpGs, we calculated the mean of the respective Beta-
values and then transformed each mean to the corresponding M-values as previously 
described(Du et al, 2010). All p values reporting the statistical significance of DNA methylation 
analyses originate from tests using M values; however, to more intuitively depict methylation 
results, all figures show Beta-values for DNA methylation. 
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Linear regression models examined the effect of age and stress-related phenotypes on DNA 
methylation, while including as covariates all the potential confounders that were available in the 
respective cohorts. Covariates used in each cohort were as follows: age, sex, blood cell 
proportions, the first two genome-wide SNP-based principal components, smoking status, and 
substance use in the GTP; age, sex, blood cell proportions, smoking status, and the first two 
genome-wide SNP-based principal components in the KORA; age, sex, case/control status, blood 
cell proportions, and the first two genome-wide SNP-based principal components in the MPIP; 
and age, smoking status, and blood cell proportions in the HBCS. Linear regression models 
examining FKBP5 expression as the dependent variable of interest in the GTP included as 
covariates age, sex, the first two SNP-based principal components, and blood cell proportions. 
These models tested methylation of the age-regulated FKBP5 CpGs (M-values), age, stress-
related phenotypes, and cortisol as the independent variables of interest. Lastly, linear regression 
models examined the association of history for MI with lower methylation of the age-regulated 
CpGs, while controlling for age, sex, and smoking status in the KORA, and while controlling for 
age and sex in the MPIP. For stratified analyses in the GTP, we performed median splits of the 
respective continuous variables. This was performed for methylation levels of the age-regulated 
FKBP5 CpGs to distinguish subjects with higher vs. lower methylation, for CTQ scores to 
stratify individuals in high- vs. low-trauma groups, for chronological age to stratify younger vs. 
older individuals, and for FKBP5 mRNA levels to distinguish subjects with higher vs. lower 
FKBP5 expression. All p values reporting the statistical significance of regression models are 
after correction for relevant covariates as described above. 
Experimental data were tested using student’s t-test when comparing two groups and with 
two-way analysis of variance (ANOVA) when examining two factors of interest. Significant 
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interactions between factors in the two-way ANOVA were followed with Bonferroni-corrected 
pairwise comparisons. 
Experimental data were analyzed in Sigma Plot version 13.0. All other statistical tests 
were performed in R version 3.1.0 (http://www.r-project.org/)(Team, 2014). The level of 
statistical significance was set a priori at 0.05 (5 × 10
−2
). All reported p values are two-tailed and 
nominal, unless corrected for multiple testing as indicated and reported in the manuscript.  
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Overarching discussion 
Psychological stress is associated with accelerated cellular aging and increased risk for diseases 
of the aging, but the underlying molecular mechanisms are poorly understood. The present work 
examined large human cohorts with genome-wide DNA methylation and gene expression data 
from peripheral blood, as well as with detailed information on stress-related phenotypes, 
including childhood and lifetime stress, major depression, and posttraumatic stress disorder. The 
converging findings presented here show that higher stress burden throughout life accelerates the 
epigenetic impact of advancing age both at the systems level and at selective, stress-responsive 
sites, as exemplified by the FKBP5 gene. Furthermore, by examining subjects exposed to 
glucocorticoid agonists, this work shows that age-related DNA methylation sites are susceptible 
to alterations in glucocorticoid signaling, which are frequently observed in stress-related 
phenotypes. By mechanistically dissecting the potential downstream effects of stress-induced 
epigenetic changes, the thesis illustrates that the age- and stress-related epigenetic upregulation 
of FKBP5 may be associated with functional effects on gene expression, alterations in biological 
pathways critical for immune function and epigenetic regulation, and heightened risk for aging-
related disease. These findings and their implications are discussed in more detail in the 
following sections. 
 
Higher stress burden accelerates the epigenetic effects of advancing age 
The work presented in this thesis shows that stress-related phenotypes accelerate the epigenetic 
changes that occur with advancing age. This was shown for the impact of cumulative lifetime 
stressors on epigenetic aging and for the effects of severe childhood trauma and depressive 
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phenotypes on the stress-responsive FKBP5 locus (Zannas et al, 2015a). Interestingly, lifetime 
stressful experiences had no effect on FKBP5 methylation and depressive symptoms did not 
influence epigenetic aging, overall suggesting that different stress-related phenotypes may 
influence different susceptibility sites across the epigenome. In both cases, childhood trauma 
moderated the subsequent impact of stress-related phenotypes. This moderation resulted in 
blunting of the epigenetic age acceleration associated with cumulative stress, but accentuation of 
the FKBP5 demethylation associated with childhood trauma and depression. Together these 
findings indicate that repetitive stressors may interact in complex ways, which either enhance or 
attenuate sensitivity of the epigenome depending on the context and type of subsequent stress 
exposure. Such development-specific effects are concordant with previous observations that 
childhood trauma specifically influences glucocorticoid-sensitive CpGs of the FKBP5 locus 
(Klengel et al, 2013). Moreover, the impact of lifetime stress on epigenetic aging became more 
apparent in older ages, suggesting that the epigenome becomes more sensitive to the “wear and 
tear” effects of stress as age advances. An intriguing possibility explaining this finding is that 
stressors synergize with other environmental factors and with the aging process itself to impact 
the aging epigenome (Gassen et al, 2016), possibly through converging effects at distinct 
components of the epigenetic machinery. 
 
Glucocorticoid signaling as mediator of stress-induced effects on the aging epigenome 
As discussed above, glucocorticoids could mediate the lasting effects of stress on the epigenome. 
In particular, stress-induced changes in DNA methylation are more likely to occur at susceptible 
CpGs, such as the ones located at or near GREs (Bose et al, 2010; Bose et al, 2015; Klengel et 
al, 2013; Thomassin et al, 2001; Wiench et al, 2011a; Wiench et al, 2011b; Yang et al, 2012). 
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Supporting the relevance of glucocorticoid signaling for the effects of stress on epigenetic aging, 
a large number of epigenetic clock CpGs (85 out of 353) were found to be located within 
functional GREs (Zannas et al, 2015a). Furthermore, in individuals exposed to the glucocorticoid 
receptor agonist dexamethasone (DEX), about one third of epigenetic clock CpGs (110 out of 
353) showed dynamic methylation changes, and more than 80% of the genes neighboring these 
CpGs underwent rapid changes in their expression levels. These findings show that the age-
regulated methylation sites that comprise the epigenetic clock are susceptible to glucocorticoids, 
thereby indicating that the effects of stress on epigenetic aging could be mediated by stress-
induced alterations in HPA axis regulation and glucocorticoid signaling, which may have lasting 
consequences on the methylation status of susceptible CpGs. 
 
Demethylation is more likely than hypermethylation at age- and stress-regulated CpGs 
A striking observation concerning both the CpGs that comprise the epigenetic clock and the age-
regulated sites of the FKBP5 locus is that the majority of these sites undergo demethylation in 
response to stress-related phenotypes and glucocorticoid exposure (Zannas et al, 2015a). This is 
in line with previous studies showing that stress-responsive sites, especially ones located at or 
near GREs, are likely to undergo demethylation upon glucocorticoid exposure (Bose et al, 2010; 
Bose et al, 2015; Klengel et al, 2013; Thomassin et al, 2001; Wiench et al, 2011a; Wiench et al, 
2011b; Yang et al, 2012). By contrast, no FKBP5 CpGs and a minority of epigenetic clock CpGs 
(12 out of 110) underwent hypermethylation upon glucocorticoid exposure (Zannas et al, 2015a), 
suggesting that differential mechanisms may underlie the effects of stress on these sites. The 
hyper- or hypo-methylating effects of stress could also depend on the specific developmental and 
genomic context. For instance, in utero stress exposure has been shown to induce both DNMT1 
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and TET1 in specific tissues (Benoit et al, 2015; Dong et al, 2015), indicating that certain 
stressful environments could simultaneously promote methylation and demethylation processes, 
thereby promoting a milieu of dynamic methylation changes that are in turn stabilized at select 
genomic regions through yet unknown mechanisms. 
 
FKBP5 as modulator of downstream epigenetic mechanisms 
Previous studies show that FKBP5 is a versatile protein that can influence diverse biological 
pathways (Avellino et al, 2005; Baughman et al, 1995; Bouwmeester et al, 2004; Daudt et al, 
2011; Erlejman et al, 2014; Gassen et al, 2014; Gassen, 2015; Giordano et al, 2006; Kim et al, 
2012; Li et al, 2002; Maiaru et al, 2016; Park et al, 2007; Romano et al, 2004; Romano et al, 
2010; Romano et al, 2015; Srivastava et al, 2015; Weiwad et al, 2006; Zannas et al, 2016). The 
work presented here expands the landscape of FKBP5-interacting pathways, by identifying the 
functional impact of FKBP5 on DNMT1, the methyltransferase that plays key roles in 
maintaining DNA methylation (Telese et al, 2013). More specifically, FKBP5 was shown to 
inhibit the activity of DNMT1 (Gassen et al, 2015), thereby decreasing methylation levels of the 
promoter of the gene that encodes the brain-derived neurotrophic factor (BDNF). Because 
FKBP5 is robustly induced by stress and mediates the effects of stress and glucocorticoids on 
downstream pathways, these findings suggest that FKBP5-mediated inhibition of DNMT1 could 
underlie the previously observed stress- and glucocorticoid-induced loss of DNA methylation 
(Bose et al, 2010; Bose et al, 2015; Klengel et al, 2013; Thomassin et al, 2001; Wiench et al, 
2011a; Wiench et al, 2011b; Yang et al, 2012; Zannas et al, 2015a). Interestingly, DNMT1 is 
downregulated with aging and upon glucocorticoid exposure (Li et al, 2010; Yang et al, 2012), 
whereas FKBP5 is epigenetically upregulated by aging and stress-related phenotypes.  Taken 
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together, these findings suggest that FKBP5 and DNMT1 form a feed-forward mechanism that 
could initiate and propagate the effects of stress on the aging epigenome.  
 
FKBP5 contributes to NF-κB-driven peripheral inflammation 
Unpublished work presented here (Zannas et al, unpublished) also shows that, in both humans 
and cells, FKBP5 promotes peripheral inflammation and secretion of the proinflammatory 
chemokine IL-8 (Roebuck, 1999). This is the first work to examine how upregulation of FKBP5 
influences IL-8 secretion by immune cells, and it builds on a previous study showing that 
downregulation of FKBP5 suppresses IL-8 production in other cell types (Srivastava et al, 2015). 
The FKBP5-mediated increase in IL-8 suggests that the proinflammatory effect of FKBP5 could 
in part be explained by the IL-8-driven recruitment of granulocytes in peripheral blood 
(Kobayashi, 2008). Supporting this possibility, FKBP5 mRNA positively correlated with the 
granulocyte to lymphocyte (G/L) ratio, suggesting that FKBP5 upregulation in peripheral blood 
is overall associated with a shift towards a proinflammatory blood cell composition. Because 
FKBP5 is the gene that is most robustly induced by glucocorticoids in human blood (Menke et 
al, 2012), individuals with epigenetic upregulation of FKBP5, such as older adults with higher 
levels of depressive symptoms and trauma exposure, could be more vulnerable to developing 
stress-induced inflammation.  
Several lines of evidence further suggested that the effects of FKBP5 on peripheral 
inflammation are driven by the NF-κB signaling pathway. Following an unbiased approach that 
used genome-wide gene expression data in human peripheral blood, the work presented here 
identified strong enrichment for NF-κB-related genes and profound changes in the NF-κB-
coexpression network (Zannas et al, unpublished). Furthermore, mechanistic dissection of the 
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NF-κB pathway in both peripheral blood monocytes (PBMC) and Jurkat T cells identified a 
novel interaction between FKBP5 and the NF-κB-inducing kinase (NIK). This effect 
strengthened the interaction between NIK and the NF-κB kinase subunit alpha (IKKα), 
promoting functional phosphorylation of IKKα at serine 176 and facilitating NF-κB activity. 
These findings extend previous studies showing that downregulation of FKBP5 inhibits NF-κB 
activity (Avellino et al, 2005; Bouwmeester et al, 2004; Daudt et al, 2011; Giordano et al, 2006; 
Kim et al, 2012; Park et al, 2007; Romano et al, 2004; Romano et al, 2010; Romano et al, 2015; 
Srivastava et al, 2015). Intriguingly, the induction of NF-κB conferred by FKBP5 upregulation 
was abolished when cells were concomitantly treated with FKBP5 antagonists (SAFit1). By 
contrast, as shown both here and in a previous study (Gaali et al, 2015), SAFit1 does not 
influence immune function under baseline FKBP5 levels. Therefore, it is likely that FKBP5 
antagonists could prevent some undesirable effects of stress on immune regulation, especially 
when targeted at individuals with upregulated FKBP5.  
 
Implications for aging-related disease phenotypes 
The findings presented in this thesis could have important implications for the pathogenesis of 
aging-related diseases, most notably cardiovascular disease. First, the DEX-regulated genes with 
TSS near epigenetic clock CpGs showed enriched association for aging-related disease 
phenotypes, coronary artery disease, arteriosclerosis, and leukemias (Zannas et al, 2015a). 
Second, demethylation of the age regulated FKBP5 CpGs, a signature of stress-related 
phenotypes, was associated with previous history of myocardial infarction in two independent 
cohorts (Zannas et al, unpublished). Third, higher G/L ratio and IL-8 levels, both of which were 
associated with FKBP5 upregulation (Zannas et al, unpublished), have been shown to predict 
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heightened cardiovascular risk and mortality (Bhat et al, 2013; Boekholdt et al, 2004; Cavusoglu 
et al, 2015). Taken together, these findings provide molecular insights into previous associations 
of stress-related phenotypes with heightened inflammation and cardiovascular risk (Chandola et 
al, 2006; Danese et al, 2012; Danese et al, 2009; Danese et al, 2008; Danese et al, 2007; Felitti 
et al, 1998; Rozanski et al, 1999; Ruo et al, 2003; Vaccarino et al, 2013). 
 
Concluding remark 
In conclusion, the findings of this cumulative thesis support a model whereby exposure to stress 
and stress-related phenotypes may have lasting effects on the aging epigenome. These effects can 
in turn dysregulate molecular effectors of stress and downstream biological pathways, potentially 
contributing to risk for the development of aging-related disease. These findings are 
schematically summarized below in Scheme. 
Beyond providing molecular insights into the mechanisms through which psychological 
stress contributes to disease risk, these findings could also have future implications for the 
prevention and treatment of stress-related diseases. In particular, although stress-induced 
epigenetic changes can be long-lasting and persistent, they may also be reversible. Such 
reversibility has been supported, for example, by studies in rodents showing that methyl-donor 
supplementation can reverse the DNA methylation changes and negative behavioral outcomes 
conferred by early life stress (Roth et al, 2009; Weaver et al, 2005). Potential reversibility has 
been also demonstrated for stress-related epigenetic aging (Brody et al, 2016a; Brody et al, 
2016b; Zannas, 2016). Nevertheless, stress-induced epigenetic signatures occur in a tissue-
specific manner and are in many cases essential for successful adaptation to stressful 
environments (Russo et al, 2012; Zannas et al, 2014). Therefore, an important task for future 
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research will be to determine which stress-related epigenetic signatures may serve as disease 
biomarkers and the circumstances and tissues in which the modulation of these signatures may 
be indicated and feasible. 
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Scheme. Simplified scheme summarizing the molecular (DNA methylation) interplay between 
psychological stress and aging. Stress triggers adrenal release of cortisol, which enters the cells 
and activates the ligand-dependent transcription factor, glucocorticoid receptor (GR). The 
activated GR then shuttles into the nucleus and can induce DNA methylation changes either by 
direct binding to glucocorticoid response elements (GRE) or, presumably, by tethering via other 
transcription factors (TF), which can bind to their respective response elements (RE). GR-
induced demethylation upregulates, among other gene targets, the stress-responsive FKBP5 
gene. FKBP5 is a versatile co-chaperone protein that influences multiple biological pathways. As 
shown in the present thesis, FKBP5 inhibits the activity of the maintenance DNA 
methyltransferase DNMT1, thereby forming a feed-forward mechanism that can propagate 
stress-induced demethylation. This is further accentuated with advancing age, which 
downregulates DNMT1 and upregulates FKBP5. Importantly, upregulated FKBP5 also 
facilitates NF-κB signaling, an effect that in cells is prevented by treatment with FKBP5 
antagonists (SAFit1). Overall, these effects lead to widespread DNA methylation changes, 
accelerated epigenetic aging, and heightened peripheral inflammation, potentially contributing to 
increased risk for aging-related diseases. 
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